official_title,study_first_posted_date,verification_date,start_date,start_month_year,nct_id,phase,last_known_status,study_type,enrollment,overall_status,facilitiesCount,multisite,funding,fundingComb,intervention_comb,interventionType,interventionTypeCombined,were_results_reported,pubCount,pubCountBool,diverse,diverseGroup,yearStart,numMissing,interventionDrugNonDrug,industryNonIndustry,raceSpecific
Interactive Web Program and Health Coaching for Prehypertensive Adults,12/22/2015,1/31/2017,11/30/2013,Nov-13,NCT02637063,Not Applicable,NA,Interventional,203,Completed,1,FALSE,Industry,Industry,"Behavioral, Behavioral, Other",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Utilizing a Mobile Health (mHealth) Application to Improve Hypertension Monitoring and Self-management in an Underserved Community: A Pilot Study,12/17/2015,4/30/2018,1/31/2016,Jan-16,NCT02632838,Not Applicable,NA,Interventional,30,Completed,1,FALSE,Other,Other,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Prospective Evaluation of the New Micropulse Transscleral Cyclophotocoagulation,12/10/2015,10/31/2017,2/28/2014,Feb-14,NCT02627352,Not Applicable,NA,Interventional,15,Completed,1,FALSE,Other,Other,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Monitoring and Managing Newly Healed Chronic Leg and Foot Ulcer Skin Temperature: A Cooling Intervention (MUSTCOOL) to Prevent Ulcer Recurrence,12/10/2015,12/31/2019,6/30/2015,Jun-15,NCT02626156,Phase 2,NA,Interventional,240,"Active, not recruiting",2,TRUE,Other,Other,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The KaHOLO Project: Preventing Cardiovascular Disease in Native Hawaiians,12/3/2015,7/31/2018,1/31/2016,Jan-16,NCT02620709,Not Applicable,NA,Interventional,275,"Active, not recruiting",1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors in Resistant Hypertension,12/7/2015,5/31/2017,11/30/2015,Nov-15,NCT02623036,Phase 1,Recruiting,Interventional,20,Unknown status,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,3,TRUE,Non-race specific,Non-race specific,2015,0,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Twitter & Cardiovascular Health,12/4/2015,2/28/2018,6/30/2016,Jun-16,NCT02622256,Not Applicable,NA,Interventional,611,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Self-Administered Mobile Phone-based Holistic Intervention for Promoting Healthy Habits and Weight Loss in People Who Are Overweight or Obese,12/3/2015,12/31/2015,11/30/2015,Nov-15,NCT02621008,Not Applicable,Recruiting,Interventional,500,Unknown status,1,FALSE,Industry,Industry,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Meditative Movement for COPD Symptoms in Non-Smoking Flight Attendants,11/23/2015,6/30/2019,3/31/2015,Mar-15,NCT02612389,Not Applicable,NA,Interventional,250,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NOVAâ„¢ PERG (Pattern Electroretinogram)and FERG (Flash Electroretinogram): Establishment of Reference Values for PERG and FERG Measurements,11/20/2015,11/30/2018,11/30/2014,Nov-14,NCT02609204,Not Applicable,NA,Interventional,51,Completed,1,FALSE,Other,Other,Diagnostic Test,other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effects of Isometric Exercises on Balance, Heart Rate, Pulse Ox and Blood Pressure",11/9/2015,2/28/2017,11/30/2015,Nov-15,NCT02599727,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Quality by Maintaining Accurate Problems in the Electronic Health Record,11/4/2015,12/31/2016,4/30/2016,Apr-16,NCT02596087,Not Applicable,"Active, not recruiting",Interventional,2386,Unknown status,4,TRUE,Other,Other,Other,other,other,FALSE,8,TRUE,Non-race specific,Non-race specific,2015,0,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Dietary Nitrate Supplementation and Physiological Function in Older Adults,11/1/2015,9/30/2019,10/31/2015,Oct-15,NCT02593305,Not Applicable,NA,Interventional,23,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Study On The Effect of Combined Use of a Connected Pillbox, Pre-filled Medication Trays, Automated Text Message/Phone Call Reminds, On Medication Adherence in Patients With Type II Diabetes Mellitus, Hypertension or Hyperlipidemia",10/30/2015,10/31/2017,2/28/2015,Feb-15,NCT02593032,Not Applicable,NA,Interventional,50,Completed,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study,10/29/2015,1/31/2017,8/31/2015,Aug-15,NCT02591628,Not Applicable,NA,Interventional,2027,Completed,2,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"STEPs to Blood Pressure Reduction. A Randomized Clinical Trial of the Stroke Transitions, Education, and Prevention Clinic Versus Usual Care for Post-Stroke Blood Pressure Reduction",10/29/2015,4/30/2018,11/30/2015,Nov-15,NCT02591394,Not Applicable,NA,Interventional,200,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF",10/28/2015,5/31/2019,11/30/2015,Nov-15,NCT02589977,Phase 4,NA,Interventional,60,Recruiting,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,2,TRUE,Non-race specific,Non-race specific,2015,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Improving Chronic Disease Management With Pieces (ICD-Pieces),10/27/2015,10/31/2019,4/30/2016,Apr-16,NCT02587936,Not Applicable,NA,Interventional,5925,Completed,4,TRUE,Industry,Industry,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Insulin Sensitivity in the Peri-Wound Microcirculation of Pressure Ulcers in SCI,10/23/2015,8/31/2018,2/1/2017,1-Feb-17,NCT02585765,Phase 2,NA,Interventional,0,Withdrawn,1,FALSE,U.S. Fed,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Health Promotion for HIV Positives: A Randomized Trial With HIV Positive Black Men,10/8/2015,2/28/2019,1/8/2015,8-Jan-15,NCT02572414,Not Applicable,NA,Interventional,302,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Stand & Move at Work: A Group Randomized Trial,10/2/2015,10/31/2019,1/15/2016,15-Jan-16,NCT02566317,Not Applicable,NA,Interventional,630,Completed,2,TRUE,Other,Other,"Device, Behavioral",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Cranberry Juice on Cardiovascular Risk Factors in a Placebo-controlled Crossover Trial,9/22/2015,12/31/2019,10/31/2015,Oct-15,NCT02556749,Not Applicable,NA,Interventional,47,Completed,1,FALSE,Industry,Industry,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Aqua Therapy to Lower Adverse and Negative Effects of Deep Vein ThrombosIs and Post Thrombotic Syndrome,9/18/2015,9/30/2015,9/30/2015,Sep-15,NCT02553720,Not Applicable,Recruiting,Interventional,100,Unknown status,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,4,TRUE,Non-race specific,Non-race specific,2015,0,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Carbidopa in Familial Dysautonomia: Phase-II Study, Investigational New Drug (IND) 117435, Date: 01/07/13",9/17/2015,9/30/2019,9/30/2015,Sep-15,NCT02553265,Phase 2,NA,Interventional,14,Completed,2,TRUE,Other,Other,"Drug, Other, Drug",Drug,Pharmaceutical,FALSE,6,TRUE,Non-race specific,Non-race specific,2015,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Physical Activity Behavior in Patients With High Cardio-metabolic Risk Using a Multi-modal mHealth Intervention: a 2-arm Randomized Controlled Trial,9/16/2015,8/31/2018,9/30/2015,Sep-15,NCT02551640,Not Applicable,NA,Interventional,300,"Active, not recruiting",2,TRUE,Industry,Industry,Other,other,other,FALSE,2,TRUE,Non-race specific,Non-race specific,2015,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Heat & Aerobic Training (HEAT) for Pre-Hypertensive Middle-Aged Adults,9/11/2015,4/30/2019,8/21/2015,21-Aug-15,NCT02546726,Not Applicable,NA,Interventional,41,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Nitrite Modulation of Hypertension, Platelet Activation, and Endothelial and Mitochondrial Function",8/7/2015,12/31/2019,3/31/2020,Mar-20,NCT02517697,Phase 2,NA,Interventional,40,Not yet recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX,8/7/2015,3/31/2018,1/31/2015,Jan-15,NCT02517671,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,U.S. Fed,Public,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial (OPEN-UP),8/3/2015,10/31/2019,1/31/2020,Jan-20,NCT02513914,Not Applicable,NA,Interventional,98,Not yet recruiting,1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure and Improving Endothelial Function of Pre-menopausal African American Women,8/3/2015,10/31/2019,12/1/2015,1-Dec-15,NCT02513823,Not Applicable,NA,Interventional,27,Terminated,1,FALSE,Other,Other,Dietary Supplement,other,other,TRUE,NA,FALSE,African American,Race-specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Study of a Tele-pharmacy Intervention for Chronic Diseases to Improve Treatment Adherence (STIC2IT),7/30/2015,3/31/2019,8/31/2015,Aug-15,NCT02512276,Not Applicable,NA,Interventional,4078,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Surrogate Markers of Portal Pressure and Changes in Portal Pressure in Patients With Compensated Cirrhosis Undergoing Anti-viral Therapy,7/24/2015,11/30/2019,4/30/2014,Apr-14,NCT02508298,Not Applicable,NA,Interventional,41,Completed,2,TRUE,U.S. Fed,Public,"Procedure, Drug, Device, Device",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients,7/24/2015,8/31/2019,8/31/2015,Aug-15,NCT02508129,Not Applicable,NA,Interventional,542,"Active, not recruiting",1,FALSE,NIH,Public,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
American Heart Association Strategically Focused Research Network: mHealth Intervention to Preserve and Promote Ideal Cardiovascular Health,7/14/2015,5/31/2019,5/31/2015,May-15,NCT02496728,Not Applicable,NA,Interventional,302,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension,7/2/2015,9/30/2019,4/6/2015,6-Apr-15,NCT02489045,Phase 4,NA,Interventional,178,Completed,2,TRUE,NIH,Public,Drug,Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2015,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Fentanyl Effect on Blood Pressure in Elderly Patients After Induction of General Anesthesia,7/2/2015,6/30/2019,2/19/2018,19-Feb-18,NCT02489019,Phase 2/Phase 3,NA,Interventional,105,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,5,TRUE,Non-race specific,Non-race specific,2015,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Prospective Randomized Controlled Trial to Determine Return on Investment in a Tablet/Smartphone-based Heart Failure Remote Monitoring Program,6/18/2015,3/31/2016,6/30/2015,Jun-15,NCT02475577,Not Applicable,Recruiting,Interventional,163,Unknown status,1,FALSE,Industry,Industry,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Health Evaluation in African Americans Using RAS Therapy,6/15/2015,5/31/2019,4/30/2015,Apr-15,NCT02471833,Phase 1,NA,Interventional,66,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,African American,Race-specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Group-based Chronic Kidney Disease Care,6/10/2015,3/31/2019,8/31/2014,Aug-14,NCT02467894,Not Applicable,NA,Interventional,60,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Macronutrient Effects on Alzheimer's Disease: HTN and IR (Hypertension and Insulin Resistance) (MEAL-2),6/4/2015,8/31/2018,3/31/2013,Mar-13,NCT02463084,Not Applicable,NA,Interventional,60,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis",6/4/2015,2/28/2018,6/30/2015,Jun-15,NCT02462967,Phase 2,NA,Interventional,162,Completed,46,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Promoting Self-Management in Low Income African Americans Living With Hypertension,5/29/2015,5/31/2016,7/31/2014,Jul-14,NCT02457871,Not Applicable,NA,Interventional,59,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages,5/27/2015,3/31/2017,5/31/2015,May-15,NCT02454660,Not Applicable,NA,Interventional,49,Completed,2,TRUE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,FALSE,12,TRUE,Non-race specific,Non-race specific,2015,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement,5/25/2015,3/31/2018,5/1/2015,1-May-15,NCT02452749,Not Applicable,NA,Interventional,30,Completed,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's Disease,5/22/2015,7/31/2017,5/31/2015,May-15,NCT02452125,Not Applicable,NA,Interventional,10,Completed,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Reducing Socioeconomic Disparities in Health at Pediatric Visits,5/21/2015,7/31/2019,9/30/2015,Sep-15,NCT02451059,Not Applicable,NA,Interventional,1205,"Active, not recruiting",6,TRUE,NIH,Public,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Furosemide for Prevention of Severe Postpartum Hypertension: a Randomized Controlled Trial,5/21/2015,10/31/2019,8/31/2015,Aug-15,NCT02450773,Phase 2,NA,Interventional,248,Recruiting,2,TRUE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,5/21/2015,4/30/2019,11/30/2015,Nov-15,NCT02450760,Not Applicable,NA,Interventional,36,"Active, not recruiting",1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,3,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effect of Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2",5/19/2015,5/31/2017,6/30/2012,Jun-12,NCT02447783,Not Applicable,NA,Interventional,75,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2015,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 1",5/19/2015,5/31/2017,5/31/2012,May-12,NCT02447770,Not Applicable,NA,Interventional,37,Completed,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2015,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Comparing the Effects of an Immunosuppressant (Mycophenolate Mofetil or MMF) on the Urinary Sodium Excretion Response to Mental Stress in a Crossover Design (MMF),5/4/2015,6/30/2019,4/22/2014,22-Apr-14,NCT02432339,Phase 1/Phase 2,NA,Interventional,50,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress in a Randomized Double Blind Placebo Controlled Design,5/1/2015,6/30/2019,4/30/2015,Apr-15,NCT02431936,Phase 2,NA,Interventional,50,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,African American,Race-specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Acid-Base Compensation in Chronic Kidney Disease: Measurement and Physiologic Impact,4/28/2015,4/30/2017,4/30/2015,Apr-15,NCT02427594,Phase 1,NA,Interventional,14,Completed,1,FALSE,NIH,Public,"Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effects of Gabapentin Enacarbil on Intensity of Cortical Arousal, Heart Rate, Blood Pressure and Anterior Tibialis EMG Responses Associated With PLMs During Sleep in Patients With RLS Using a Novel Computer Assisted Scoring System",4/23/2015,4/30/2015,6/30/2015,Jun-15,NCT02424695,Phase 4,Not yet recruiting,Interventional,20,Unknown status,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,5,TRUE,Non-race specific,Non-race specific,2015,0,Drug Intervention,Industry Sponsor,Non-Race Specific
Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue,4/17/2015,11/30/2018,8/7/2015,7-Aug-15,NCT02419508,Phase 4,NA,Interventional,290,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Worksite Screening for Cardiovascular Risk Factors Among Migrant Agricultural Workers,4/16/2015,11/30/2016,4/30/2015,Apr-15,NCT02418637,Not Applicable,NA,Interventional,40,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
STOP-DKD Automated Population Program (APP),4/16/2015,11/30/2016,3/31/2015,Mar-15,NCT02418091,Not Applicable,NA,Interventional,131,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension,4/9/2015,11/30/2018,6/30/2013,Jun-13,NCT02412761,Not Applicable,NA,Interventional,42,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2015,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Placental Role in Mediating Adverse Outcomes in Obstructive Sleep Apnea,4/9/2015,8/31/2018,6/30/2015,Jun-15,NCT02412696,Not Applicable,NA,Interventional,262,Recruiting,1,FALSE,Other,Other,"Device, Other",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Fresh Start Experiment,4/8/2015,5/31/2017,4/30/2015,Apr-15,NCT02411032,Not Applicable,NA,Interventional,13323,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Prediction and Pre-commitment Mailings for Medication Adherence,4/8/2015,9/30/2016,11/30/2014,Nov-14,NCT02411006,Not Applicable,NA,Interventional,47088,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects (Aim #2)",4/2/2015,12/31/2018,7/31/2009,Jul-09,NCT02406586,Not Applicable,NA,Interventional,36,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Non-invasive Cardiac Output Monitoring in Patients With Burn Injuries,3/31/2015,2/28/2018,1/31/2018,Jan-18,NCT02404597,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"An Evaluation of the Heart Rate, Blood Pressure and Repolarization Effects of an Energy Drink as Compared to Coffee",3/30/2015,10/31/2016,3/31/2014,Mar-14,NCT02401776,Not Applicable,NA,Interventional,30,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement, Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Destiffening and Hypotensive Effects of Whole Milk and Full-fat Dairy Products,3/25/2015,1/31/2018,3/31/2015,Mar-15,NCT02397902,Not Applicable,NA,Interventional,60,Completed,1,FALSE,Industry,Industry,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Respiratory Motor Control and Blood Pressure Regulation After Spinal Cord Injury,3/24/2015,4/30/2019,6/30/2016,Jun-16,NCT02396823,Not Applicable,NA,Interventional,60,"Active, not recruiting",1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Stop Retinal Ganglion Cell Dysfunction Study,3/17/2015,12/31/2019,9/30/2015,Sep-15,NCT02390284,Phase 3,NA,Interventional,500,Recruiting,1,FALSE,NIH,Public,"Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,3/12/2015,12/31/2018,2/6/2015,6-Feb-15,NCT02386540,Not Applicable,NA,Interventional,295,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,3,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effectiveness of Avapro in the Treatment of Salt Sensitivity in Both Normotensive and Untreated Hypertensive Obese African Americans: A Randomized Double Blind Placebo Controlled Trial,3/11/2015,6/30/2019,4/30/2014,Apr-14,NCT02386293,Phase 2,NA,Interventional,30,Recruiting,1,FALSE,Other,Other,"Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,African American,Race-specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluating CVD Medication Adherence Program in Low SES,3/3/2015,1/31/2016,1/31/2015,Jan-15,NCT02375737,Not Applicable,NA,Interventional,100,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease,2/26/2015,5/31/2019,4/30/2015,Apr-15,NCT02373241,Phase 2,NA,Interventional,40,Recruiting,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,8,TRUE,Non-race specific,Non-race specific,2015,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes,2/26/2015,2/28/2015,2/28/2015,Feb-15,NCT02372955,Phase 4,Recruiting,Interventional,21,Unknown status,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,2/25/2015,8/31/2019,5/1/2015,1-May-15,NCT02371317,Not Applicable,NA,Interventional,141,"Active, not recruiting",2,TRUE,Other,Other,"Behavioral, Behavioral, Other",Behavioral,Behavioral,FALSE,1,TRUE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Acute Effects of Nutrition Supplementation on Treatment Efficiency and Hemodynamics During Dialysis,2/25/2015,9/30/2017,2/28/2015,Feb-15,NCT02371018,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,2/13/2015,8/31/2017,1/31/2015,Jan-15,NCT02362737,Not Applicable,"Active, not recruiting",Interventional,332,Unknown status,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The Effects of Including Almonds in an Energy-restricted Diet on Weight, Abdominal Fat Loss, Blood Pressure, and Cognitive Function",2/11/2015,1/31/2018,10/31/2012,Oct-12,NCT02360787,Not Applicable,NA,Interventional,80,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Mechanisms of Refractory Hypertension (High and Low Salt Diet),2/6/2015,5/31/2019,2/28/2015,Feb-15,NCT02357017,Not Applicable,NA,Interventional,40,"Active, not recruiting",1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,2/6/2015,3/31/2019,2/28/2015,Feb-15,NCT02357004,Not Applicable,NA,Interventional,100,"Active, not recruiting",1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,3,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation,2/3/2015,1/31/2019,1/31/2015,Jan-15,NCT02353806,Phase 4,NA,Interventional,16,Completed,1,FALSE,NIH,Public,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Treating Resistant Hypertension Using Lifestyle Modification to Promote Health,1/21/2015,12/31/2019,6/30/2015,Jun-15,NCT02342808,Not Applicable,NA,Interventional,150,Recruiting,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,12/30/2014,3/31/2019,11/30/2014,Nov-14,NCT02327312,Not Applicable,NA,Interventional,1200,Recruiting,10,TRUE,Industry,Industry,"Device, Procedure, Device",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,3,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Barber-Pharmacist Coordination to Improve Blood Pressure Management in Black Men,12/22/2014,7/31/2018,2/17/2015,17-Feb-15,NCT02321618,Not Applicable,NA,Interventional,320,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Pregnant Women,12/18/2014,12/31/2018,6/30/2015,Jun-15,NCT02319174,Not Applicable,NA,Interventional,43,Completed,1,FALSE,Other,Other,Device,Device,Device,TRUE,6,TRUE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Nudging Doctors to Collaborate With Pharmacists to Improve Medication Adherence,12/3/2014,11/30/2014,3/31/2011,Mar-11,NCT02306122,Not Applicable,NA,Interventional,2697,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation,12/2/2014,2/28/2017,4/30/2015,Apr-15,NCT02305550,Not Applicable,NA,Interventional,12,Completed,1,FALSE,Other,Other,Device,Device,Device,FALSE,2,TRUE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Multi-Component Behavioral Intervention for Complex Patients With CVD Risk. The Changing Results: Engage and Activate to Enhance Wellness (CREATE Wellness) Study,11/27/2014,10/31/2018,1/31/2015,Jan-15,NCT02302612,Not Applicable,NA,Interventional,647,Completed,1,FALSE,NIH,Public,"Behavioral, Other",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,11/26/2014,2/28/2018,10/31/2014,Oct-14,NCT02301455,Not Applicable,NA,Interventional,104,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,3,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Pragmatic Multicenter Randomized Clinical Trial (RCT) of Antihypertensive Therapy for Mild Chronic Hypertension During Pregnancy: Chronic Hypertension and Pregnancy (CHAP) Project,11/24/2014,11/30/2019,6/30/2015,Jun-15,NCT02299414,Phase 4,NA,Interventional,2404,Recruiting,75,TRUE,NIH,Public,"Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study,11/24/2014,4/30/2019,10/31/2014,Oct-14,NCT02299388,Phase 4,NA,Interventional,11,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Online CBT-I for High Blood Pressure,11/24/2014,8/31/2016,8/31/2014,Aug-14,NCT02299193,Not Applicable,NA,Interventional,58,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pharmacogenetic Prediction of Metoprolol Effectiveness,11/18/2014,3/31/2018,9/30/2014,Sep-14,NCT02293096,Not Applicable,NA,Interventional,500,Recruiting,1,FALSE,NIH,Public,"Drug, Genetic, Procedure",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.",11/7/2014,9/30/2018,11/30/2014,Nov-14,NCT02285634,Not Applicable,NA,Interventional,68,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2014,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The SCCS Polypill Pilot Trial,10/30/2014,12/31/2019,12/31/2015,Dec-15,NCT02278471,Phase 2,NA,Interventional,303,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Adult Volunteers,10/17/2014,9/30/2018,1/31/2015,Jan-15,NCT02267577,Not Applicable,NA,Interventional,90,Completed,1,FALSE,Other,Other,"Device, Device",Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy,10/17/2014,6/30/2019,10/31/2014,Oct-14,NCT02266394,Phase 1,NA,Interventional,42,"Active, not recruiting",3,TRUE,Other,Other,"Drug, Procedure",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Impact of Patient Navigators on Health Education and Quality of Life in Formerly Incarcerated Patients,10/8/2014,8/31/2015,6/30/2014,Jun-14,NCT02259634,Not Applicable,NA,Interventional,144,Terminated,2,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease,10/8/2014,9/30/2014,10/31/2014,Oct-14,NCT02259049,Early Phase 1,NA,Interventional,6,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Tissue Sodium in Pre-hypertensive Patients,9/10/2014,4/30/2019,9/30/2014,Sep-14,NCT02236520,Phase 2,NA,Interventional,71,Completed,1,FALSE,Other,Other,"Drug, Drug, Dietary Supplement, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,African American,Race-specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Cardiovascular Disease Prevention Among African-Americans by FAITH! (Fostering African-American Improvement in Total Health),9/10/2014,12/31/2015,9/30/2014,Sep-14,NCT02235896,Not Applicable,NA,Interventional,37,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Genomic Medicine Pilot for Hypertension and Kidney Disease in Primary Care,9/9/2014,1/31/2018,11/30/2014,Nov-14,NCT02234063,Not Applicable,NA,Interventional,2052,Completed,2,TRUE,Other,Other,Other,other,other,FALSE,NA,FALSE,African American,Race-specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome,9/8/2014,9/30/2017,9/20/2013,20-Sep-13,NCT02233088,Not Applicable,"Active, not recruiting",Interventional,48,Unknown status,1,FALSE,NIH,Public,"Behavioral, Other, Other",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation,9/5/2014,12/31/2016,8/31/2014,Aug-14,NCT02232880,Phase 2,NA,Interventional,1,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Social Work Intervention Focused on Transitions Among At-Risk Older Adults,9/5/2014,12/31/2016,2/28/2011,Feb-11,NCT02232126,Not Applicable,NA,Interventional,181,Completed,2,TRUE,NIH,Public,Other,other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Biomarker Guided Therapies in Stage A/B Heart Failure,9/3/2014,10/31/2019,10/1/2014,1-Oct-14,NCT02230891,Phase 2,NA,Interventional,210,"Active, not recruiting",1,FALSE,U.S. Fed,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension",9/3/2014,10/31/2016,8/31/2014,Aug-14,NCT02230683,Phase 2,NA,Interventional,23,Completed,16,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Regular Apple Consumption Improves Cardiovascular Risk Factors and Glycemic Control in Overweight and Obese Prediabetics and Type 2 Diabetics,8/25/2014,12/31/2016,8/31/2014,Aug-14,NCT02224365,Phase 2,NA,Interventional,50,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study),8/20/2014,1/31/2020,2/28/2015,Feb-15,NCT02221830,Early Phase 1,NA,Interventional,124,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pulmonary Hemodynamic Effects of Stored Red Blood Cell Transfusion in Post-Operative Cardiac Surgical Patients: Influence of Breathing Nitric Oxide. A Randomized Controlled Trial in the Cardiac-Intensive Care Unit.,8/15/2014,3/31/2016,3/31/2016,Mar-16,NCT02217683,Phase 2,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2014,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
MEDication Focused Outpatient Care for Underutilization of Secondary Prevention,8/13/2014,2/28/2019,1/20/2015,20-Jan-15,NCT02215408,Not Applicable,NA,Interventional,402,Completed,18,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,2,TRUE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Dietary Approaches to Stopping Hypertension (DASH) Mobile App Pilot,8/12/2014,3/31/2017,7/31/2015,Jul-15,NCT02214459,Not Applicable,NA,Interventional,24,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients,8/11/2014,6/30/2019,7/15/2017,15-Jul-17,NCT02213575,Phase 1,NA,Interventional,9,Recruiting,1,FALSE,NIH,Public,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Phase I Study of Nicotinamide for Early Onset Preeclampsia,8/11/2014,3/31/2018,1/1/2014,1-Jan-14,NCT02213094,Phase 1,NA,Interventional,10,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,8/7/2014,10/31/2018,8/31/2014,Aug-14,NCT02210767,Not Applicable,NA,Interventional,46,Completed,1,FALSE,Other,Other,"Other, Other, Other",other,other,FALSE,7,TRUE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Early Identification and Action in CKD,8/5/2014,11/30/2016,9/30/2014,Sep-14,NCT02208674,Not Applicable,NA,Interventional,47,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Barber-Based Intervention for Hypertension in Black Men: Follow-Up Evaluation,7/23/2014,7/31/2014,8/31/2009,Aug-09,NCT02198144,Not Applicable,NA,Interventional,14,Completed,1,FALSE,NIH,Public,Other,other,other,FALSE,3,TRUE,African American,Race-specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Empagliflozin (10mg, 25mg) Administered Orally, Once Daily Over 24 Weeks in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus",7/8/2014,6/30/2018,7/25/2014,25-Jul-14,NCT02182830,Phase 3,NA,Interventional,166,Completed,92,TRUE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,African American,Race-specific,2014,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers,7/3/2014,12/31/2019,10/31/2014,Oct-14,NCT02181062,Not Applicable,NA,Interventional,240,Completed,4,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,22,TRUE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness",7/3/2014,3/31/2016,3/31/2014,Mar-14,NCT02180841,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Industry,Industry,"Dietary Supplement, Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
NA,7/1/2014,4/30/2018,6/30/2014,Jun-14,NCT02179008,Phase 2,NA,Interventional,184,Completed,14,TRUE,Industry,Industry,"Drug, Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,3,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension",6/30/2014,3/31/2019,6/30/2014,Jun-14,NCT02178098,Phase 2,NA,Interventional,143,Completed,35,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,4,TRUE,Non-race specific,Non-race specific,2014,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension,6/20/2014,11/30/2017,6/30/2014,Jun-14,NCT02168309,Not Applicable,NA,Interventional,50,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study,6/19/2014,9/30/2014,6/30/2011,Jun-11,NCT02167464,Not Applicable,NA,Interventional,70,Completed,8,TRUE,Other,Other,"Drug, Other, Drug",Drug,Pharmaceutical,FALSE,2,TRUE,Non-race specific,Non-race specific,2014,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Mechanisms of Arterial Hypotension in Chronic Spinal Cord Injury,6/3/2014,4/30/2019,6/30/2011,Jun-11,NCT02154412,Not Applicable,NA,Interventional,24,"Active, not recruiting",1,FALSE,Other,Other,Other,other,other,FALSE,12,TRUE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Tart Cherry Improves Cardiovascular Risk Factors Associated With Metabolic Syndrome,6/3/2014,12/31/2016,4/30/2014,Apr-14,NCT02154100,Phase 2,NA,Interventional,26,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Using Social Comparison To Improve Medication Adherence In Statin Users With Diabetes,5/28/2014,7/31/2017,1/31/2014,Jan-14,NCT02148523,Not Applicable,NA,Interventional,201,Completed,1,FALSE,Industry,Industry,"Behavioral, Behavioral, Device",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Metabolic and Molecular Effects of a Mediterranean Diet and Intermittent Fasting,5/28/2014,10/31/2018,6/30/2014,Jun-14,NCT02148458,Not Applicable,NA,Interventional,53,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Heart Health 4 Moms: Engaging Women With a Recent History of Preeclampsia to Reduce Their Cardiovascular Disease Risk,5/28/2014,7/31/2017,9/21/2015,21-Sep-15,NCT02147626,Not Applicable,NA,Interventional,151,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The Effect of Whole-body Vibration Training Combined With L-cit Supplementation on Cardiovascular, Autonomic Function and Body Composition in Postmenopausal Women",5/21/2014,3/31/2015,3/31/2013,Mar-13,NCT02143817,Not Applicable,NA,Interventional,60,Completed,1,FALSE,Other,Other,"Dietary Supplement, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Treatment of Masked Hypertension,5/20/2014,12/31/2017,6/30/2014,Jun-14,NCT02142881,Phase 3,NA,Interventional,4,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Somali, Latino & Hmong Radio Stories About Children's Healthy Eating and Exercise: A SoLaHmo Pilot Study",5/15/2014,10/31/2019,9/30/2012,Sep-12,NCT02139787,Not Applicable,NA,Interventional,146,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health and Reduce the Risks of Preterm Delivery,5/13/2014,8/31/2014,12/31/2014,Dec-14,NCT02137408,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Dietary Supplement, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Cardiovascular Risk Clinic,5/13/2014,5/31/2014,4/30/2009,Apr-09,NCT02136758,Not Applicable,NA,Interventional,207,Terminated,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Angiotensin and Neuroimmune Activation in Hypertension,5/8/2014,5/31/2019,12/31/2016,Dec-16,NCT02133885,Phase 1/Phase 2,NA,Interventional,101,Recruiting,1,FALSE,NIH,Public,"Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Angiotensin and Neuroimmune Activation in Hypertension,5/8/2014,6/30/2019,10/31/2014,Oct-14,NCT02133872,Phase 1,NA,Interventional,101,Recruiting,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Contribution of Substance P to Blood Pressure Regulation in the Setting of Dipeptidyl Peptidase IV (DPP4) and Angiotensin-Converting Enzyme (ACE) Inhibition,5/5/2014,12/31/2019,6/30/2014,Jun-14,NCT02130687,Not Applicable,NA,Interventional,150,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study,4/23/2014,12/31/2016,5/31/2014,May-14,NCT02121041,Not Applicable,NA,Interventional,28,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of Pumpkin Seed Oil Supplementation on Blood Pressure in Premenopausal Women,4/21/2014,12/31/2014,4/30/2014,Apr-14,NCT02119429,Phase 2,NA,Interventional,50,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Endothelin Receptor Function and Acute Stress (End-Stress),4/16/2014,10/31/2019,6/30/2015,Jun-15,NCT02116335,Not Applicable,NA,Interventional,320,Recruiting,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Exercise as an Adjunct Therapy to Reduce Blood Pressure in Chronic Kidney Disease,4/14/2014,3/31/2017,7/31/2013,Jul-13,NCT02112825,Not Applicable,NA,Interventional,40,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Compatibility of Radiofrequency Detection Technology With Cardiac Internal Electronic Devices (RF Assure Study),4/11/2014,12/31/2019,3/31/2014,Mar-14,NCT02111980,Not Applicable,NA,Interventional,50,Completed,1,FALSE,Industry,Industry,Device,Device,Device,TRUE,5,TRUE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial,4/10/2014,2/28/2017,9/30/2014,Sep-14,NCT02110381,Not Applicable,NA,Interventional,32,Terminated,1,FALSE,Other,Other,"Device, Device",Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of L-Citrulline Supplementation on Vascular and Cardiac Autonomic Responses to Cold Pressor Test Concurrent With Postexercise Muscle Ischemia,4/4/2014,3/31/2015,3/31/2013,Mar-13,NCT02104375,Phase 1/Phase 2,NA,Interventional,16,Completed,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Role of Aldosterone on Sympathetic Nerve Activity and Insulin Sensitivity,4/2/2014,3/31/2019,11/30/2010,Nov-10,NCT02102243,Phase 4,NA,Interventional,2,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Drug, Procedure, Procedure, Procedure, Procedure",Procedure,Procedure,FALSE,4,TRUE,Non-race specific,Non-race specific,2014,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide,4/1/2014,12/31/2015,3/31/2014,Mar-14,NCT02100462,Phase 4,Recruiting,Interventional,30,Unknown status,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Daily Incorporation of Strawberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Prehypertension,3/31/2014,12/31/2016,2/28/2013,Feb-13,NCT02099578,Not Applicable,NA,Interventional,60,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Mobile Health Platform - Development and Feasibility Evaluation,3/31/2014,10/31/2014,3/31/2014,Mar-14,NCT02099513,Not Applicable,NA,Interventional,6,Completed,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,3/27/2014,12/31/2015,5/31/2014,May-14,NCT02097719,Phase 4,NA,Interventional,100,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,3,Drug Intervention,Industry Sponsor,Non-Race Specific
e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions,3/14/2014,8/31/2015,6/30/2013,Jun-13,NCT02087293,Not Applicable,"Active, not recruiting",Interventional,38400,Unknown status,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,4,TRUE,Non-race specific,Non-race specific,2014,0,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Assessment of Coronary Artery Disease in Asymptomatic Survivors of Allogeneic Hematopoietic Cell Transplantation (HCT): A Pilot Feasibility Study,3/4/2014,4/30/2015,2/28/2014,Feb-14,NCT02077218,Not Applicable,NA,Interventional,20,Completed,1,FALSE,NIH,Public,"Procedure, Other, Other, Other",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Achieving Blood Pressure Control Through Enhanced Discharge,2/21/2014,11/30/2016,10/31/2013,Oct-13,NCT02069015,Not Applicable,NA,Interventional,150,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,3,TRUE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Pilot Study to Assess the Feasibility, Safety and Tolerability of Sleeve Gastrectomy in Morbidly Obese Patients Undergoing Orthotopic Liver Transplantation",2/21/2014,9/30/2015,2/28/2014,Feb-14,NCT02068872,Phase 1,NA,Interventional,1,Completed,1,FALSE,Other,Other,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Phase 3 Study of Carvedilol vs Variceal Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding,2/19/2014,7/31/2018,7/31/2018,Jul-18,NCT02066649,Phase 3,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Procedure",Procedure,Procedure,FALSE,1,TRUE,Non-race specific,Non-race specific,2014,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Healthy Oils for Women: Reducing Visceral Adipose Tissue in Women With Metabolic Syndrome (HOW Study),2/14/2014,3/31/2016,2/28/2014,Feb-14,NCT02063165,Not Applicable,NA,Interventional,18,Completed,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Primary Medication Adherence Phase 2 Evaluation of a Decision Support Tool,2/12/2014,2/28/2015,2/28/2014,Feb-14,NCT02060981,Not Applicable,"Active, not recruiting",Interventional,140,Unknown status,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Intraosseous Pressure Monitoring in Intensive Care Unit Patients,2/11/2014,4/30/2018,12/31/2013,Dec-13,NCT02059928,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Industry,Industry,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Efficacy and Safety of the Dietary Approaches to Stop Hypertension (DASH) Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study,2/11/2014,10/31/2014,2/28/2014,Feb-14,NCT02059811,Not Applicable,NA,Interventional,42,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Can a Targeted Screen-and-treat Program for Chronic Kidney Disease Improve Blood Pressure (BP) Management Among Persons at High Risk for Complications ?,2/11/2014,12/31/2019,9/30/2015,Sep-15,NCT02059408,Not Applicable,NA,Interventional,1819,Completed,1,FALSE,Other,Other,"Other, Other",other,other,TRUE,4,TRUE,Non-race specific,Non-race specific,2014,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)",2/11/2014,7/31/2017,7/11/2014,11-Jul-14,NCT02059135,Phase 3,NA,Interventional,120,Completed,23,TRUE,Industry,Industry,"Biological, Other",Biological,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Conditioned Pharmacotherapeutic Effects in Hypertension,2/6/2014,6/30/2019,3/31/2011,Mar-11,NCT02056626,Phase 4,NA,Interventional,44,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,3,TRUE,Non-race specific,Non-race specific,2014,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure,2/3/2014,8/31/2019,4/30/2014,Apr-14,NCT02053571,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Industry,Industry,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects",1/28/2014,3/31/2016,8/31/2013,Aug-13,NCT02047656,Phase 1,NA,Interventional,93,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Industry Sponsor,Non-Race Specific
3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts,1/27/2014,11/30/2016,7/31/2013,Jul-13,NCT02046473,Not Applicable,NA,Interventional,18,Completed,1,FALSE,Other,Other,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus,1/27/2014,4/30/2019,1/31/2012,Jan-12,NCT02046395,Phase 4,NA,Interventional,30,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The IMPULSE Pilot Study-- Investigating a Novel Synergy: Applying Ischemic Conditioning to Modulate the Altered Physiology From Contemporary continUous Flow Left Ventricular Assist Devices, to Reduce Stroke and Other Adverse Effects",1/24/2014,4/30/2017,8/31/2014,Aug-14,NCT02044471,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Industry,Industry,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"University of Alabama at Birmingham CORT Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure",1/16/2014,9/30/2019,7/31/2014,Jul-14,NCT02038179,Phase 2/Phase 3,NA,Interventional,99,Completed,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Supplementation With Omega-3: Mechanism of Action,1/15/2014,2/28/2017,4/30/2013,Apr-13,NCT02036307,Phase 2,NA,Interventional,13,Terminated,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effectiveness of Telehome Monitoring on Quality of Life and Health Resources Utilization Among People With Chronic Disease Residing in Rural Maryland,1/14/2014,1/31/2014,2/28/2011,Feb-11,NCT02035566,Not Applicable,NA,Interventional,23,Completed,2,TRUE,NIH,Public,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Understanding the Exercise-Hypertension Paradox: Implication for Rehabilitation,1/13/2014,1/31/2020,2/1/2014,1-Feb-14,NCT02034422,Not Applicable,NA,Interventional,72,Recruiting,1,FALSE,U.S. Fed,Public,"Dietary Supplement, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone,1/8/2014,6/30/2017,7/31/2013,Jul-13,NCT02030314,Phase 4,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Can Point-of-care Testing (POCT) and Assistance From Comprehensive Medication Management (CMM) Pharmacists Improve Early Detection and Management of Metabolic Syndrome in Patients Treated With Antipsychotic Medications?,1/8/2014,4/30/2018,2/28/2010,Feb-10,NCT02029989,Not Applicable,NA,Interventional,121,Completed,3,TRUE,Other,Other,"Device, Device, Device, Device, Device, Behavioral",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): A Randomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery.,1/6/2014,4/30/2016,2/29/2012,Feb-12,NCT02027272,Not Applicable,NA,Interventional,1,Terminated,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia,1/1/2014,1/31/2020,9/30/2012,Sep-12,NCT02025426,Phase 4,NA,Interventional,12,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The Effect of Riociguat on Gas Exchange, Exercise Performance, and Pulmonary Artery Pressure During Acute Altitude Exposure",12/31/2013,3/31/2017,1/31/2014,Jan-14,NCT02024386,Phase 4,NA,Interventional,28,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,31,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Using Social Support To Improve Medication Adherence In Statin Users With Diabetes,12/23/2013,8/31/2017,1/31/2014,Jan-14,NCT02018809,Not Applicable,NA,Interventional,200,Completed,1,FALSE,Industry,Industry,"Behavioral, Device",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors,12/13/2013,7/31/2019,12/31/2013,Dec-13,NCT02011685,Not Applicable,NA,Interventional,450,"Active, not recruiting",1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluation of Clinical Benefits of B-Flow With the LOGIQ E9 Ultrasound System,12/11/2013,4/30/2018,10/31/2013,Oct-13,NCT02008097,Not Applicable,NA,Interventional,180,Completed,1,FALSE,Industry,Industry,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
ACTH Treatment of APOL1- Associated Nephropathy,12/10/2013,4/30/2016,1/31/2014,Jan-14,NCT02006849,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II,12/6/2013,2/28/2017,4/30/2009,Apr-09,NCT02003469,Not Applicable,NA,Interventional,67,Completed,1,FALSE,Other,Other,Device,Device,Device,FALSE,2,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism,12/4/2013,5/31/2018,11/27/2013,27-Nov-13,NCT02001051,Phase 2,NA,Interventional,4,Terminated,1,FALSE,NIH,Public,"Procedure, Other",Procedure,Procedure,TRUE,3,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension,11/27/2013,1/31/2019,7/31/2013,Jul-13,NCT01996449,Not Applicable,NA,Interventional,3,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Procedure, Procedure, Procedure, Procedure, Procedure, Procedure",Procedure,Procedure,FALSE,7,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Ola Hou i ka Hula: A Pilot Study to Investigate Hula and Hypertension Control,11/27/2013,11/30/2013,3/31/2012,Mar-12,NCT01995812,Not Applicable,NA,Interventional,59,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Automatic Medication Increase Protocol in the Treatment of Elevated Blood Pressure,11/25/2013,1/31/2017,11/30/2013,Nov-13,NCT01994408,Phase 1/Phase 2,NA,Interventional,3,Terminated,1,FALSE,Other,Other,Other,other,other,FALSE,4,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX),11/14/2013,1/31/2020,8/31/2014,Aug-14,NCT01984164,Phase 2,NA,Interventional,176,Completed,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care,11/14/2013,8/31/2019,3/19/2014,19-Mar-14,NCT01983813,Not Applicable,NA,Interventional,302,Completed,12,TRUE,Other,Other,"Other, Other",other,other,FALSE,8,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Vascular Dysfunction in Human Obesity Hypertension: Integrative Role of Sympathetic and Renin-Angiotensin Systems,11/14/2013,8/31/2019,10/31/2013,Oct-13,NCT01983462,Phase 2,NA,Interventional,126,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,11/7/2012,4/30/2019,1/31/2012,Jan-12,NCT01722604,Phase 3,NA,Interventional,258,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,3,Drug Intervention,Industry Sponsor,Non-Race Specific
BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects,11/7/2013,2/28/2018,11/30/2013,Nov-13,NCT01977859,Phase 1,NA,Interventional,4,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,18,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Testing Enrollment Methods on Participation in Behavioral Economic Interventions for Diabetes Care: A Randomized Controlled Pilot Study,11/6/2013,12/31/2015,12/31/2013,Dec-13,NCT01977495,Not Applicable,NA,Interventional,136,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Scripps Wired for Health Study,11/3/2013,5/31/2015,11/30/2012,Nov-12,NCT01975428,Not Applicable,NA,Interventional,161,Completed,1,FALSE,Other,Other,"Device, Device, Device, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project,10/31/2013,10/31/2013,7/31/2010,Jul-10,NCT01973556,Not Applicable,NA,Interventional,75,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Renal Denervation Using the SYMPLICITY Renal Denervation System in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4,10/30/2013,4/30/2017,10/31/2013,Oct-13,NCT01972139,Not Applicable,NA,Interventional,44,Completed,3,TRUE,Industry,Industry,"Device, Other, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Is a Smartphone Application Effective as an Oral Medication Adherence Aid,10/24/2013,11/30/2017,10/30/2013,30-Oct-13,NCT01968876,Early Phase 1,NA,Interventional,68,Terminated,3,TRUE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
RENAL ARTERY IRRADIATION FOR SYMPATHETIC RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION,10/24/2013,12/31/2019,8/31/2013,Aug-13,NCT01968785,Not Applicable,NA,Interventional,2,Completed,1,FALSE,Other,Other,"Radiation, Radiation",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evening Dosing of Antihypertensive Medications in Chronic Kidney Disease Patients - A Pilot Study,10/18/2013,12/31/2017,11/30/2013,Nov-13,NCT01965847,Not Applicable,NA,Interventional,79,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,1,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Targeting Wave Reflections to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function in Hypertension",10/11/2013,10/31/2014,8/31/2013,Aug-13,NCT01961453,Phase 2,NA,Interventional,0,Withdrawn,1,FALSE,U.S. Fed,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,2,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Nebivolol on Left Ventricular and Left Atrial Morphodynamics in Adults With Hypertension and Isolated Diastolic Dysfunction,10/11/2013,10/31/2017,3/31/2012,Mar-12,NCT01961323,Phase 4,NA,Interventional,70,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension,10/11/2013,3/31/2019,10/31/2013,Oct-13,NCT01960946,Not Applicable,NA,Interventional,59,"Active, not recruiting",1,FALSE,NIH,Public,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Targeted Treatment of Obstructive Sleep Apnea to Reduce Cardiovascular Disparity,10/10/2013,9/30/2019,1/5/2015,5-Jan-15,NCT01960465,Not Applicable,NA,Interventional,220,Completed,1,FALSE,U.S. Fed,Public,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Whey Protein With and Without Exercise Training Enhances Total and Regional Body Composition, Insulin, Leptin, and Blood Pressure in Overweight and Obese Adults - The P+RISE Study",10/10/2013,10/31/2013,1/31/2011,Jan-11,NCT01960335,Not Applicable,NA,Interventional,79,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement, Other",other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage (PITCH-ER),10/10/2013,9/30/2017,10/31/2013,Oct-13,NCT01960153,Phase 3,NA,Interventional,0,Withdrawn,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of Whey Protein Supplementation on Cerebrovascular and Cognitive Function in Older Adults,10/8/2013,10/31/2017,10/31/2013,Oct-13,NCT01956994,Not Applicable,NA,Interventional,99,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Combined Atrial Fibrillation Ablation and Renal Artery Denervation for the Maintenance of Sinus Rhythm and Management of Resistant Hypertension,9/30/2013,2/28/2019,3/31/2019,Mar-19,NCT01952925,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Concomitant Renal Denervation Therapy in Hypertensive Patients Undergoing Atrial Fibrillation Ablation - A Feasibility Study,9/30/2013,3/31/2017,9/30/2013,Sep-13,NCT01952743,Not Applicable,NA,Interventional,3,Terminated,1,FALSE,Other,Other,"Procedure, Procedure",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care Delivery System,9/27/2013,9/30/2013,10/31/2011,Oct-11,NCT01952119,Not Applicable,NA,Interventional,182,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy,9/27/2013,8/31/2014,9/30/2013,Sep-13,NCT01951950,Phase 1,NA,Interventional,40,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,5,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Sympathetic Regulation in Intradialytic Hypertension,9/20/2013,10/31/2019,9/30/2013,Sep-13,NCT01947673,Not Applicable,NA,Interventional,100,Recruiting,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2),9/16/2013,6/30/2018,9/18/2012,18-Sep-12,NCT01942395,Not Applicable,NA,Interventional,18,Terminated,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,4,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Nebivolol in Chronic Obstructive Pulmonary Disease,9/11/2013,1/31/2016,1/31/2012,Jan-12,NCT01939990,Phase 2/Phase 3,NA,Interventional,0,Withdrawn,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Open Label Study to Assess the Efficacy, Safety and Dosing of Clevidipine in Pediatric Patients Undergoing Surgery",9/10/2013,5/31/2017,3/31/2014,Mar-14,NCT01938547,Phase 4,NA,Interventional,100,Suspended,2,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Study of the Effects of an Oral Nitric Oxide Supplement on Functional Capacity and Blood Pressure in Healthy Adults With Prehypertension,9/10/2013,9/30/2013,1/31/2013,Jan-13,NCT01937754,Phase 1/Phase 2,"Active, not recruiting",Interventional,30,Unknown status,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Randomized Controlled Trial to Test a Synchronized Prescription Refill Program to Improve Medication Adherence,9/4/2013,12/31/2015,9/30/2013,Sep-13,NCT01934608,Not Applicable,NA,Interventional,691,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Pharmacokinetic Substudy of Subjects Transitioning From Twice Daily to Three Times Daily Dosing of UT-15C SR (Treprostinil Diethanolamine) in the TDE-PH-304 Protocol,9/4/2013,9/30/2016,8/31/2013,Aug-13,NCT01934582,Phase 3,NA,Interventional,13,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction,8/30/2013,2/29/2016,8/31/2013,Aug-13,NCT01932606,Phase 2,NA,Interventional,28,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Pumpkin Seeds on the Dietary Fatty Acid Intake and Blood Pressure in Women,8/27/2013,5/31/2017,8/31/2013,Aug-13,NCT01928966,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease,8/16/2013,10/31/2019,5/31/2013,May-13,NCT01924312,Not Applicable,NA,Interventional,80,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Is Reduced Blood Pressure a Consequence of Improved Sleep in Veterans With PTSD?,8/12/2013,8/31/2014,8/31/2013,Aug-13,NCT01920451,Not Applicable,NA,Interventional,19,Terminated,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Center for Stroke Disparities Solution (CSDS) Project II: Community Transitions Intervention (CTI),8/8/2013,9/30/2019,9/30/2012,Sep-12,NCT01918891,Not Applicable,NA,Interventional,495,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants,8/5/2013,2/28/2018,9/30/2013,Sep-13,NCT01915706,Not Applicable,NA,Interventional,81,Completed,1,FALSE,Other,Other,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,7/30/2013,8/31/2015,1/31/2012,Jan-12,NCT01910857,Not Applicable,NA,Interventional,60,Completed,2,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2013,3,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy,7/29/2013,7/31/2013,4/30/2010,Apr-10,NCT01910532,Phase 4,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Multi-center, Randomized, Single-blind, Sham Controlled Clinical Investigation of Renal Denervation for Uncontrolled Hypertension",7/19/2013,1/31/2019,10/31/2013,Oct-13,NCT01903187,Not Applicable,NA,Interventional,4,Terminated,3,TRUE,Industry,Industry,"Device, Procedure",Procedure,Procedure,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Family and Community Intervention to Address Hypertension Disparities,7/18/2013,9/30/2016,9/30/2013,Sep-13,NCT01902719,Not Applicable,NA,Interventional,159,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Community Health Worker Support to Help Patients Control Chronic Disease,7/16/2013,5/31/2017,7/31/2013,Jul-13,NCT01900470,Not Applicable,NA,Interventional,302,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Randomized Controlled Trial of Spironolactone Versus Standard of Care Blood Pressure Treatment on the Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension,7/12/2013,12/31/2013,1/31/2009,Jan-09,NCT01897727,Not Applicable,NA,Interventional,41,Completed,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Cluster Randomized Trial of the Implementation of the NHLBI Expert Panel Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,7/9/2013,8/31/2014,11/30/2011,Nov-11,NCT01893593,Phase 4,NA,Interventional,32,Completed,2,TRUE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Discovering Healthcare Innovations to Address Disparities in Stroke,7/4/2013,10/31/2016,6/30/2013,Jun-13,NCT01892592,Not Applicable,NA,Interventional,3698,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effect of Early iNO on Oxidative Stress, Vascular Tone and Inflammation in Term and Late-Preterm Infants With Hypoxic Respiratory Failure",7/3/2013,1/31/2020,5/31/2016,May-16,NCT01891500,Phase 4,NA,Interventional,0,Withdrawn,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of a Grape Seed Extract (GSE) on Insulin Resistance,6/28/2013,6/30/2017,11/30/2012,Nov-12,NCT01889368,Not Applicable,NA,Interventional,19,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Reducing Health Disparities in Appalachians With Multiple Cardiovascular Disease Risk Factors,6/21/2013,3/31/2017,8/1/2013,1-Aug-13,NCT01884246,Not Applicable,NA,Interventional,330,Completed,1,FALSE,Other,Other,"Behavioral, Other",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Bioavailability of Potassium From Potatoes and Potassium Gluconate,6/19/2013,5/31/2018,3/1/2013,1-Mar-13,NCT01881295,Not Applicable,NA,Interventional,45,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement, Dietary Supplement, Dietary Supplement, Dietary Supplement, Dietary Supplement, Dietary Supplement, Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
One-Day Acceptance and Commitment Training Intervention in Primary Care Patients,6/18/2013,5/31/2017,8/31/2012,Aug-12,NCT01879800,Not Applicable,NA,Interventional,44,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Stroke Therapy, Education, Prevention: Telemedicine Outpatient Initiative Trial",6/11/2013,10/31/2019,11/30/2012,Nov-12,NCT01875328,Not Applicable,NA,Interventional,64,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Promoting Self-Management in Stroke Survivors Using Health IT,6/11/2013,6/30/2016,10/31/2012,Oct-12,NCT01875094,Phase 1/Phase 2,NA,Interventional,56,Completed,1,FALSE,U.S. Fed,Public,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust With Moderate Exercise in Healthy Adults,6/11/2013,6/30/2013,8/31/2010,Aug-10,NCT01874834,Not Applicable,NA,Interventional,15,Completed,1,FALSE,U.S. Fed,Public,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomeraâ„¢ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension",6/10/2013,4/30/2014,6/30/2013,Jun-13,NCT01873885,Phase 1,NA,Interventional,20,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Industry Sponsor,Non-Race Specific
NA,5/29/2013,1/31/2015,6/30/2013,Jun-13,NCT01863953,Phase 2,NA,Interventional,112,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,3,Drug Intervention,Industry Sponsor,Non-Race Specific
Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement: Continuous Intracranial Pressure Monitoring Subprotocol,5/29/2013,8/31/2017,9/30/2014,Sep-14,NCT01863381,Not Applicable,NA,Interventional,5,Terminated,1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Adherence Enhancement for Renal Transplant Patients,5/21/2013,6/30/2016,9/30/2011,Sep-11,NCT01859273,Not Applicable,NA,Interventional,18,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,7,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Resveratrol and Cardiovascular Health in the Elderly: The Reache Trial,4/29/2013,7/5/2019,2/9/2013,9-Feb-13,NCT01842399,Phase 1/Phase 2,NA,Interventional,300,Recruiting,1,FALSE,NIH,Public,"Dietary Supplement, Drug",Drug,Pharmaceutical,FALSE,3,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin.,4/29/2013,9/30/2013,4/30/2013,Apr-13,NCT01842113,Phase 4,NA,Interventional,4,Terminated,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke,4/29/2013,4/30/2013,1/31/2012,Jan-12,NCT01841840,Not Applicable,NA,Interventional,11,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Phase I Study of Autologous Mesenchymal Stem Cells in the Treatment of Atherosclerotic Renal Artery Stenosis,4/25/2013,8/31/2017,4/30/2013,Apr-13,NCT01840540,Phase 1,NA,Interventional,6,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Optimization of Pre-surgical Testing With an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events in Orthopedic Surgery,4/22/2013,4/30/2019,2/28/2014,Feb-14,NCT01837069,Phase 4,NA,Interventional,198,Terminated,1,FALSE,Other,Other,"Drug, Drug, Drug, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Intense vs. Standard Hypertension Management on Nighttime Blood Pressure,4/18/2013,1/31/2019,6/30/2013,Jun-13,NCT01835249,Not Applicable,NA,Interventional,897,Completed,10,TRUE,U.S. Fed,Public,"Other, Other",other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of PVC Suppression on Blood Pressure Control in Patients With Frequent PVCs,4/16/2013,1/31/2019,2/28/2013,Feb-13,NCT01833455,Phase 2,NA,Interventional,8,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
CALM-FIM_US -Controlling and Lowering Blood Pressure With the MobiusHDâ„¢ - A Prospective Multicenter Safety Study,4/15/2013,10/31/2019,5/31/2013,May-13,NCT01831895,Not Applicable,NA,Interventional,20,"Active, not recruiting",7,TRUE,Industry,Industry,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
NA,4/12/2013,4/30/2015,7/31/2013,Jul-13,NCT01830140,Phase 3,NA,Interventional,466,Completed,2,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,3,Drug Intervention,Industry Sponsor,Non-Race Specific
Simultaneous Risk Factor Control Using Telehealth to SlOw Progression of Diabetic Kidney Disease (STOP-DKD),4/11/2013,2/28/2019,5/31/2014,May-14,NCT01829256,Not Applicable,NA,Interventional,285,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Medication Adherence in Hypertensive Patients,4/8/2013,1/31/2014,1/31/2014,Jan-14,NCT01826435,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function in Hypertensive Patients: A Pilot Study,4/2/2013,3/31/2015,3/31/2013,Mar-13,NCT01822860,Phase 4,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Field Administration of Stroke Therapy-Blood Pressure Lowering Pilot Trial,3/14/2013,6/30/2015,4/30/2013,Apr-13,NCT01811693,Phase 2,Recruiting,Interventional,45,Unknown status,2,TRUE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,3/7/2013,3/31/2013,4/30/2012,Apr-12,NCT01806324,Phase 1,NA,Interventional,30,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,3,Drug Intervention,Industry Sponsor,Non-Race Specific
ENaC as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes,3/5/2013,5/31/2018,3/31/2013,Mar-13,NCT01804777,Early Phase 1,NA,Interventional,9,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.",3/4/2013,11/30/2017,2/28/2013,Feb-13,NCT01803711,Phase 2/Phase 3,NA,Interventional,6,Terminated,1,FALSE,Other,Other,"Drug, Dietary Supplement, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression,2/18/2013,8/31/2016,5/31/2013,May-13,NCT01794455,Phase 4,NA,Interventional,1,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Alternative Instruction in Six Minute Walk Test (6MWT),2/12/2013,8/31/2017,6/30/2010,Jun-10,NCT01789996,Not Applicable,NA,Interventional,45,Completed,1,FALSE,NIH,Public,"Procedure, Procedure",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pilot Study: Lipoic Acid and Omega-3 Fatty Acid for Alzheimer's Disease Prevention,1/31/2013,2/28/2017,4/30/2013,Apr-13,NCT01780974,Phase 1/Phase 2,NA,Interventional,42,Completed,2,TRUE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Azilsartan on Aldosterone in Postmenopausal Females,1/24/2013,10/31/2017,1/31/2013,Jan-13,NCT01774591,Not Applicable,NA,Interventional,21,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Industry Sponsor,Non-Race Specific
An Exploratory Study to Evaluate the Ability of the Citrus Polyphenol Hesperidin to Improve Insulin Sensitivity in Healthy Subjects and to Ameliorate Insulin Resistance in Obese Subjects,1/23/2013,11/30/2019,6/30/2015,Jun-15,NCT01773486,Phase 2,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2013,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving the Willpower-based Self-care for Hypertension,1/18/2013,7/31/2015,8/31/2012,Aug-12,NCT01770756,Not Applicable,"Active, not recruiting",Interventional,40,Unknown status,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Fluid-Weight, Volume, Sodium, Blood Pressure Management in Hemodialysis by Limiting Intradialytic and Inter-dialytic Exposure to Sodium and Protocol-based Challenge of Post-dialysis Target Weight: A Pilot and Feasibility Trial",1/11/2013,7/31/2016,9/30/2012,Sep-12,NCT01766882,Not Applicable,NA,Interventional,50,Completed,2,TRUE,Other,Other,"Behavioral, Other",Behavioral,Behavioral,FALSE,16,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Gonadal Steroid Regulation of the Natriuretic Peptide System,1/9/2013,10/31/2017,6/30/2014,Jun-14,NCT01763541,Early Phase 1,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NSAID Effects on Clinical and Imaging Breast Biomarkers,1/7/2013,11/30/2018,12/31/2012,Dec-12,NCT01761877,Phase 2,NA,Interventional,80,"Active, not recruiting",2,TRUE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Electronic Health Record-Based Clinical Decision Support to Improve Blood Pressure Management in Adolescents,1/4/2013,6/30/2017,4/30/2014,Apr-14,NCT01760239,Not Applicable,NA,Interventional,31579,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,TRUE,1,TRUE,Non-race specific,Non-race specific,2013,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 2a, Randomized, Placebo-controlled, Single Center Trial to Evaluate the Impact of Intravenous Bendaviaâ„¢ (MTP-131) on Ischemia Reperfusion Injury in Atherosclerotic Renal Artery Stenosis in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)",12/24/2012,6/30/2016,12/31/2012,Dec-12,NCT01755858,Phase 1/Phase 2,NA,Interventional,17,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Phase 1, Double-blind, Randomized, 2-Way Crossover, Placebo-controlled Study to Investigate the Effect of AMG 151 on 24-hour Ambulatory Blood Pressure and Glucose Levels in Subjects With Type 2 Diabetes Mellitus",12/24/2012,4/30/2013,11/30/2012,Nov-12,NCT01755442,Phase 1,NA,Interventional,5,Terminated,1,FALSE,Industry,Industry,"Other, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
The Effect of Medication Reminder Technology on Medication Adherence and Hypertension,12/24/2012,8/31/2015,6/30/2013,Jun-13,NCT01755312,Not Applicable,NA,Interventional,28,Terminated,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,12/17/2012,5/31/2016,8/31/2012,Aug-12,NCT01750294,Phase 4,NA,Interventional,14,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,3,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Creating an Active Collaborative Network of Comparative Effectiveness Researchers: A Randomized Study of Initial Diuretic Therapy for Hypertension.,12/12/2012,8/31/2017,8/31/2016,Aug-16,NCT01748123,Phase 4,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Evaluate Changes in Medication Adherence and Patient Perspective of Polyglot Systems, Inc's Meducation Technology",12/6/2012,10/31/2015,2/28/2013,Feb-13,NCT01744392,Not Applicable,NA,Interventional,23,Completed,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function in Obese Postmenopausal Women,12/5/2012,12/31/2012,9/30/2011,Sep-11,NCT01741779,Not Applicable,NA,Interventional,60,Completed,1,FALSE,Industry,Industry,"Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"The Effects of 8 Weeks of Stretching Training on Arterial Stiffness, Wave Reflection, Endothelial Function and Cardiac Autonomic Control.",12/5/2012,12/31/2012,5/31/2011,May-11,NCT01741766,Not Applicable,NA,Interventional,30,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Pilot Study of the DASH Diet in Not-Well-Controlled Adult Asthma,11/14/2012,9/30/2014,1/31/2013,Jan-13,NCT01725945,Not Applicable,NA,Interventional,90,Completed,2,TRUE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Peer-Led, Medical Disease Self-Management Program for Mental Health Consumers",11/14/2012,9/30/2019,6/30/2011,Jun-11,NCT01725815,Not Applicable,NA,Interventional,400,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Liraglutide in the Treatment of Type 1 Diabetes Mellitus,11/6/2012,3/31/2015,11/30/2012,Nov-12,NCT01722266,Phase 3,NA,Interventional,72,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,12,TRUE,Non-race specific,Non-race specific,2012,1,Drug Intervention,Industry Sponsor,Non-Race Specific
A Pilot Study to Assess Whether the Combination of Phentermine and B12 Has a Significant Effect on Weight Loss Among an Obese Study Population,11/1/2012,8/31/2015,9/30/2012,Sep-12,NCT01719185,Early Phase 1,NA,Interventional,22,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pravastatin for the Prevention of Preeclampsia in High-Risk Women: A Phase I Pilot Study,10/30/2012,2/28/2019,8/31/2012,Aug-12,NCT01717586,Phase 1,NA,Interventional,48,"Active, not recruiting",3,TRUE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2012,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Combined Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplantation and for Left Ventricular Assist Device Placement,10/30/2012,10/31/2017,10/31/2012,Oct-12,NCT01717209,Phase 4,NA,Interventional,14,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,4,TRUE,Non-race specific,Non-race specific,2012,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization",10/26/2012,11/30/2015,8/31/2011,Aug-11,NCT01714609,Phase 2,NA,Interventional,10,Completed,6,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Using an Internet Survey to Improve Patient Adherence in Chronic Disease,10/10/2012,1/31/2020,10/31/2012,Oct-12,NCT01702883,Not Applicable,NA,Interventional,186,"Active, not recruiting",1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluation of Lysine-Specific Demethylase 1 As An Epigenetic Regulator of Salt Sensitive Hypertension,10/8/2012,7/31/2017,7/31/2012,Jul-12,NCT01702688,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study,10/5/2012,12/31/2017,1/31/2010,Jan-10,NCT01701622,Not Applicable,NA,Interventional,1,Terminated,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults (S31),9/28/2012,8/31/2015,4/30/2012,Apr-12,NCT01696097,Not Applicable,NA,Interventional,19,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effects of Milk Protein Concentrate on Blood Pressure, Inflammation, Muscle Health During Weight Loss in Overweight/Obese Adults",9/25/2012,11/30/2015,1/31/2012,Jan-12,NCT01692860,Not Applicable,NA,Interventional,48,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Five Plus Nuts and Beans Trial,9/21/2012,8/31/2016,4/30/2012,Apr-12,NCT01689844,Not Applicable,NA,Interventional,123,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Daily Incorporation of Blueberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension.,9/18/2012,1/31/2015,1/31/2012,Jan-12,NCT01686282,Phase 2,NA,Interventional,48,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension,9/11/2012,3/31/2017,10/31/2012,Oct-12,NCT01682837,Phase 2,NA,Interventional,35,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2012,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Financial Incentives for Medication Adherence,9/3/2012,1/31/2015,9/30/2012,Sep-12,NCT01678183,Not Applicable,NA,Interventional,74,Completed,1,FALSE,Industry,Industry,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Dietary Nitrates for Heart Failure,9/10/2012,4/30/2019,1/31/2012,Jan-12,NCT01682356,Phase 1/Phase 2,NA,Interventional,126,Enrolling by invitation,2,TRUE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,9,TRUE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Insights for Community Health,9/10/2012,10/31/2015,9/30/2012,Sep-12,NCT01681862,Not Applicable,NA,Interventional,55,Completed,2,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Open-Label Study of Oral Nitrite in Adults With Metabolic Syndrome and Hypertension,9/10/2012,3/31/2019,10/31/2012,Oct-12,NCT01681810,Phase 2,NA,Interventional,20,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
BAROSTIM NEO Hypertension Pivotal Trial,9/5/2012,9/30/2019,4/12/2013,12-Apr-13,NCT01679132,Not Applicable,NA,Interventional,10,Suspended,11,TRUE,Industry,Industry,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"A Randomized, Unblinded, Single Research Site, Comparator Study of Raisins Versus Alternative Snacks on Glycemic Control and Other Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus",9/3/2012,3/31/2014,6/30/2012,Jun-12,NCT01677936,Phase 4,NA,Interventional,51,Completed,1,FALSE,Other,Other,"Other, Other",other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Program for Research on the Outcomes of VA Education: Controlled Study of Panel Management and Microsystem Education Interventions to Improve Outcomes in Hypertension and Smoking Cessation,9/3/2012,5/31/2018,9/1/2009,1-Sep-09,NCT01677533,Not Applicable,NA,Interventional,5000,Completed,2,TRUE,U.S. Fed,Public,"Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease,8/30/2012,4/30/2014,9/30/2012,Sep-12,NCT01676103,Phase 1/Phase 2,NA,Interventional,40,Completed,1,FALSE,Other,Other,"Dietary Supplement, Other",other,other,FALSE,15,TRUE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
ARTISAN: iCASTâ„¢ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients With Resistant Hypertension,8/28/2012,7/31/2019,10/31/2012,Oct-12,NCT01673373,Not Applicable,NA,Interventional,68,"Active, not recruiting",12,TRUE,Industry,Industry,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension,8/27/2012,12/31/2014,7/31/2012,Jul-12,NCT01672840,Not Applicable,NA,Interventional,120,Completed,2,TRUE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pharmacokinetics of Sildenafil in Premature Infants,8/21/2012,11/30/2016,2/28/2013,Feb-13,NCT01670136,Phase 1,NA,Interventional,34,Completed,9,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension,8/7/2012,8/31/2015,10/31/2012,Oct-12,NCT01658657,Not Applicable,NA,Interventional,17,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Prevalence, Awareness and Management of Hypertension in Acute Care Personnel",8/2/2012,5/31/2013,8/31/2012,Aug-12,NCT01655654,Not Applicable,"Active, not recruiting",Interventional,160,Unknown status,1,FALSE,Other,Other,"Behavioral, Behavioral, Other",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Low Systolic Blood Pressure,8/1/2012,1/31/2018,7/31/2012,Jul-12,NCT01654835,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and Hypertension,7/31/2012,7/31/2019,11/30/2011,Nov-11,NCT01653678,Not Applicable,NA,Interventional,25875,"Active, not recruiting",1,FALSE,NIH,Public,"Dietary Supplement, Drug, Dietary Supplement, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evive Health Randomized Controlled Trials,7/30/2012,9/30/2017,8/31/2014,Aug-14,NCT01653197,Not Applicable,NA,Interventional,29,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Micro-Clinic Obesity and Metabolic Risk Prevention Program: A Randomized-Control Trial of a Social-Network Based Intervention,7/26/2012,3/31/2016,6/30/2011,Jun-11,NCT01651065,Not Applicable,NA,Interventional,919,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People,7/26/2012,4/30/2019,12/31/2011,Dec-11,NCT01650402,Not Applicable,NA,Interventional,199,Completed,1,FALSE,NIH,Public,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Integrative Stress Reduction for Maternal-Child Health,7/20/2012,12/31/2014,1/31/2011,Jan-11,NCT01646463,Phase 1/Phase 2,"Active, not recruiting",Interventional,49,Unknown status,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Non-invasive Diagnosis of Portal Hypertension by Acoustic Radiation Force Impulse (ARFI) Imaging of the Liver and Spleen in Patients With Chronic Liver Disease,7/19/2012,9/30/2018,7/31/2012,Jul-12,NCT01644656,Not Applicable,NA,Interventional,500,Completed,2,TRUE,U.S. Fed,Public,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Tailored Approaches to Improve Medication Adherence,7/18/2012,9/30/2019,4/30/2013,Apr-13,NCT01643473,Not Applicable,NA,Interventional,42,Completed,1,FALSE,Industry,Industry,"Behavioral, Other",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets,7/17/2012,12/31/2016,6/30/2012,Jun-12,NCT01642355,Not Applicable,NA,Interventional,400,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,1,TRUE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea,7/11/2012,6/30/2017,6/30/2012,Jun-12,NCT01637623,Phase 2,NA,Interventional,90,Completed,4,TRUE,NIH,Public,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Influence of Hormone Replacement on Neural Cardiovascular Control in Postmenopausal Women,7/4/2012,6/30/2017,9/30/2011,Sep-11,NCT01633814,Not Applicable,NA,Interventional,4,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Impact of Renal SympAthetic DenerVation on Chronic HypErtension,6/26/2012,1/31/2018,10/31/2011,Oct-11,NCT01628198,Not Applicable,NA,Interventional,38,Terminated,1,FALSE,Other,Other,Device,Device,Device,TRUE,28,TRUE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Arthritis Foundation Exercise Program & ""10 Keys"" to Healthy Aging",6/11/2012,12/31/2014,3/31/2012,Mar-12,NCT01616433,Phase 2,NA,Interventional,462,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability,6/8/2012,3/31/2018,9/30/2013,Sep-13,NCT01615484,Not Applicable,NA,Interventional,24,Completed,2,TRUE,Industry,Industry,"Procedure, Device",Procedure,Procedure,TRUE,10,TRUE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
A Pilot Study to Improve Patient-Doctor Communication,5/28/2012,5/31/2012,11/30/2010,Nov-10,NCT01606930,Not Applicable,NA,Interventional,106,Completed,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Modernized Approach to Prenatal Care in Low Risk Women,5/28/2012,2/28/2017,7/31/2012,Jul-12,NCT01606774,Not Applicable,NA,Interventional,4,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?,5/24/2012,5/31/2014,6/30/2012,Jun-12,NCT01605370,Phase 4,NA,Interventional,1,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Increasing Medication Adherence Through Physician Incentives and Messaging,5/22/2012,10/31/2015,6/30/2012,Jun-12,NCT01603329,Not Applicable,NA,Interventional,734,Completed,1,FALSE,Industry,Industry,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Working With Veterans Organizations to Encourage Use of My HealtheVet,5/14/2012,2/28/2014,6/30/2012,Jun-12,NCT01597843,Not Applicable,NA,Interventional,282,Completed,1,FALSE,U.S. Fed,Public,Other,other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Nebivolol and Endothelial Regulation of Fibrinolysis,5/10/2012,6/30/2019,2/29/2012,Feb-12,NCT01595516,Phase 4,NA,Interventional,44,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug, Other, Other, Other",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Running Against Prehypertension Trial (RAPT): A Pilot Randomized Controlled Trial,4/30/2012,8/31/2013,3/31/2012,Mar-12,NCT01587183,Not Applicable,NA,Interventional,22,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Medication Metronome Project,4/27/2012,12/31/2015,5/31/2012,May-12,NCT01586897,Not Applicable,NA,Interventional,52,Completed,1,FALSE,U.S. Fed,Public,"Device, Other",Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,4/17/2012,12/31/2012,12/31/2011,Dec-11,NCT01579136,Not Applicable,NA,Interventional,26,Terminated,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,3,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
EHR-based Health Literacy Strategy to Promote Medication Therapy Management,4/17/2012,6/30/2019,4/30/2012,Apr-12,NCT01578577,Not Applicable,NA,Interventional,920,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Hypotensive Effects of Conventional Dairy Products: Role of Arterial Stiffness,4/13/2012,2/28/2014,1/31/2012,Jan-12,NCT01577030,Not Applicable,NA,Interventional,49,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response to Pseudoephedrine Concurrent With Placebo or TR 701 FA,4/13/2012,8/31/2018,4/23/2012,23-Apr-12,NCT01577459,Phase 1,NA,Interventional,18,Completed,1,FALSE,Industry,Industry,"Drug, Other",Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2012,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Multi-Method Health System QI Intervention to Reduce Hypertension Disparities,3/29/2012,1/31/2018,4/30/2011,Apr-11,NCT01566864,Not Applicable,NA,Interventional,66570,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults,3/29/2012,12/31/2015,2/28/2009,Feb-09,NCT01566084,Not Applicable,NA,Interventional,17,Completed,1,FALSE,NIH,Public,"Drug, Other",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized Multiple Baseline Intervention Study of Metabolic Syndrome, Mental Health, and Spiritual Well-Being of United Methodist Clergy in North Carolina",3/28/2012,2/28/2017,10/31/2010,Oct-10,NCT01564719,Not Applicable,NA,Interventional,1114,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,11,TRUE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension",3/19/2012,8/31/2015,2/29/2012,Feb-12,NCT01556997,Phase 3,NA,Interventional,837,Completed,48,TRUE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Effects of GSH and N-Acetylcysteine on Inflammatory Markers Among Adults With CVD Risk,3/12/2012,5/31/2017,6/30/2011,Jun-11,NCT01550432,Not Applicable,NA,Interventional,78,Completed,1,FALSE,NIH,Public,"Dietary Supplement, Dietary Supplement, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Early Prediction and Aspirin for Prevention of Preeclampsia,3/7/2012,5/31/2018,3/31/2012,Mar-12,NCT01547390,Not Applicable,NA,Interventional,104,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
B40 Non-Invasive Blood Pressure Equivalency Study,3/7/2012,5/31/2013,3/31/2012,Mar-12,NCT01546285,Not Applicable,NA,Interventional,66,Completed,1,FALSE,Industry,Industry,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"A Randomized Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Double and Triple Low Combination of Mean Arterial Pressure, and Either End-tidal Anesthetic Concentration or Bispectral Index.",3/7/2012,5/31/2014,1/31/2011,Jan-11,NCT01545596,Not Applicable,NA,Interventional,20237,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effectiveness of Yoga on Ambulatory Blood Pressure in Patients With Pre- and Stage I Hypertension,3/2/2012,1/31/2013,9/30/2011,Sep-11,NCT01542359,Not Applicable,NA,Interventional,90,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 1, Blinded, Placebo-Controlled, Crossover TR-701 FA Study of Blood Pressure Response Post-Tyramine Challenge",2/27/2012,5/31/2016,2/29/2012,Feb-12,NCT01539473,Phase 1,NA,Interventional,30,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers,2/10/2012,11/30/2013,2/29/2012,Feb-12,NCT01530464,Phase 1,NA,Interventional,18,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Stored Red Blood Cell Transfusion in Overweight Subjects With Endothelial Dysfunction: Influence of Inhaled Nitric Oxide (iNO),2/8/2012,4/30/2017,3/31/2012,Mar-12,NCT01529502,Phase 2,NA,Interventional,14,Completed,1,FALSE,Other,Other,"Procedure, Procedure, Drug",Procedure,Procedure,TRUE,6,TRUE,Non-race specific,Non-race specific,2012,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Prospective, Randomized, Comparative Effectiveness Trial of the ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations",2/8/2012,12/31/2016,7/31/2012,Jul-12,NCT01528293,Not Applicable,NA,Interventional,2,Terminated,1,FALSE,Other,Other,"Device, Other",Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,2/2/2012,10/31/2013,1/31/2012,Jan-12,NCT01525173,Phase 4,NA,Interventional,137,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,3,Drug Intervention,Industry Sponsor,Non-Race Specific
"Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Adult Subjects With Stage 1 or Stage 2 Essential Hypertension",2/1/2012,1/31/2013,1/31/2012,Jan-12,NCT01523067,Phase 1,NA,Interventional,68,Completed,5,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease",2/1/2012,1/31/2020,5/31/2010,May-10,NCT01522950,Phase 2,NA,Interventional,76,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Title: Comparative Effectiveness of Pedometer-Based Walking Interventions: WalkMore,1/27/2012,5/31/2015,5/31/2012,May-12,NCT01519583,Not Applicable,"Active, not recruiting",Interventional,120,Unknown status,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Preeclampsia: A Marker for Future Cardiovascular Risk in Women,1/26/2012,1/31/2019,5/31/2012,May-12,NCT01519297,Not Applicable,NA,Interventional,150,Suspended,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Novel Peptides in Resistant Human Hypertension,1/23/2012,3/31/2018,4/30/2012,Apr-12,NCT01514357,Phase 1/Phase 2,NA,Interventional,12,Terminated,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Targeting Obesity and Blood Pressure in Urban Youth(Consortium Title: Childhood Obesity Prevention and Treatment Research [COPTR] and Site Project Name IMPACT (Ideas Moving Parents and Adolescents to Change Together).,1/23/2012,2/28/2019,2/1/2011,1-Feb-11,NCT01514279,Not Applicable,NA,Interventional,360,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,1,TRUE,Non-race specific,Non-race specific,2012,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Diesel Exhaust Exposures on Vascular Function in Humans: The Role of Sympathetic Activation,1/12/2012,7/31/2015,1/31/2012,Jan-12,NCT01508637,Not Applicable,Recruiting,Interventional,24,Unknown status,1,FALSE,NIH,Public,"Other, Other, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension",1/11/2012,3/31/2014,1/31/2012,Jan-12,NCT01508026,Phase 3,NA,Interventional,4161,Completed,413,TRUE,Industry,Industry,"Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2012,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Effects of Nebivolol Versus Metoprolol on Blood Flow Responses to Exercise and Angiotensin II in Hypertensive Patients,1/2/2012,5/31/2018,4/30/2009,Apr-09,NCT01502787,Phase 4,NA,Interventional,46,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Procedure, Procedure, Procedure, Procedure, Drug",Procedure,Procedure,TRUE,18,TRUE,Non-race specific,Non-race specific,2012,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Effects of Nebivolol on Microvascular Perfusion in the Skeletal Muscles During Exercise in Hypertensive Patients,12/30/2011,5/31/2018,8/31/2010,Aug-10,NCT01501929,Phase 4,NA,Interventional,32,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Procedure, Procedure, Procedure",Procedure,Procedure,TRUE,23,TRUE,Non-race specific,Non-race specific,2011,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of Nebivolol Compared With Metoprolol in Hypertensive Patients With Peripheral Arterial Disease,12/26/2011,12/31/2014,8/31/2011,Aug-11,NCT01499134,Phase 3,NA,Interventional,17,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
The Effect of a Scratch Off Prompt on Health Engagement,7/25/2011,9/30/2015,7/31/2014,Jul-14,NCT01401621,Not Applicable,NA,Interventional,84953,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension",12/21/2011,7/31/2015,2/29/2012,Feb-12,NCT01496469,Phase 2,NA,Interventional,121,Completed,46,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Randomized, Double-Blind, Phase 3b Proof-of-Concept Study to Evaluate the Efficacy and Safety of TAK-491 Compared to Placebo When Used in Combination With Metformin in Subjects With Hypertension and Type 2 Diabetes",12/21/2011,4/30/2015,1/31/2012,Jan-12,NCT01496430,Phase 3,NA,Interventional,105,Terminated,68,TRUE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
NA,12/20/2011,5/31/2019,12/31/2011,Dec-11,NCT01495312,Not Applicable,NA,Interventional,0,Withdrawn,2,TRUE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,3,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients,12/14/2011,6/30/2015,6/30/2012,Jun-12,NCT01491919,Phase 1,NA,Interventional,26,Completed,7,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,33,TRUE,Non-race specific,Non-race specific,2011,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Accuracy Study of a Non-Invasive Forearm Blood Pressure Cuff in Comparison to an Invasive Radial Arterial Blood Pressure,12/5/2011,5/31/2019,12/31/2011,Dec-11,NCT01485120,Not Applicable,NA,Interventional,34,Completed,1,FALSE,Industry,Industry,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
SNIPE:SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement,11/30/2011,8/31/2016,11/30/2011,Nov-11,NCT01482325,Not Applicable,NA,Interventional,31,Terminated,2,TRUE,Industry,Industry,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"L-Arginine, Vascular Response and Mechanisms",11/30/2011,7/31/2016,4/30/2012,Apr-12,NCT01482247,Phase 2,NA,Interventional,25,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection.,11/29/2011,1/31/2013,12/31/2011,Dec-11,NCT01480531,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,14,TRUE,Non-race specific,Non-race specific,2011,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension (VDATH),11/16/2011,11/30/2011,7/31/2011,Jul-11,NCT01472796,Phase 4,Recruiting,Interventional,92,Unknown status,1,FALSE,Industry,Industry,"Dietary Supplement, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,African American,Race-specific,2011,1,Drug Intervention,Industry Sponsor,Non-Race Specific
"Treatment of Uric Acid With the Xanthine Oxidase Inhibitor Febuxostat: Effects on Blood Pressure, Metabolic Markers, and Aortic Stiffness in Prehypertensive",11/16/2011,11/30/2019,10/31/2011,Oct-11,NCT01472692,Phase 4,NA,Interventional,47,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pilot Randomized Clinical Trial of Inhaled PGE1 in Neonates With Sub-Optimal Response to Inhaled Nitric Oxide,11/8/2011,4/30/2019,11/30/2011,Nov-11,NCT01467076,Phase 2,NA,Interventional,7,Terminated,11,TRUE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Text Messaging to Improve Hypertension Medication Adherence in African Americans,11/4/2011,12/31/2014,3/31/2011,Mar-11,NCT01465217,Not Applicable,NA,Interventional,58,Completed,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Controlled, Trial to Assess the Effects of Low-fat Dairy Intake on Endothelial Function and Blood Pressure in Subjects With Pre-hypertension or Stage 1 Hypertension",11/1/2011,5/31/2012,8/31/2011,Aug-11,NCT01463085,Not Applicable,"Active, not recruiting",Interventional,65,Unknown status,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The Effects L-citrulline Supplementation on Arterial Stiffness, Wave Reflection, and Cardiac Autonomic Responses to Cold Exposure With Isometric Exercise",10/31/2011,8/31/2014,5/31/2011,May-11,NCT01462591,Phase 1/Phase 2,NA,Interventional,16,Completed,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Acute Carotid Sinus Endovascular Stimulation II Study,10/24/2011,10/31/2012,10/31/2011,Oct-11,NCT01458483,Phase 1,NA,Interventional,9,Completed,1,FALSE,Industry,Industry,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Efficiency of Daily Grapefruit Exposure in Reducing Body Weight and Inflammatory Markers,10/17/2011,10/31/2011,8/31/2009,Aug-09,NCT01452841,Not Applicable,NA,Interventional,85,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients,10/4/2011,1/31/2019,10/25/2011,25-Oct-11,NCT01446003,Phase 1,NA,Interventional,31,Completed,2,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
The Impact of Nebivolol Versus Metoprolol on Quality of Life Measures and Cost-effectiveness in Stable Renal Transplant Recipients,9/27/2011,3/31/2017,2/29/2012,Feb-12,NCT01441570,Not Applicable,NA,Interventional,11,Terminated,2,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension During Orif of Tibia Fracture Under General Anesthesia,9/27/2011,3/31/2015,1/31/2012,Jan-12,NCT01441531,Early Phase 1,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Telehealth & Remote Measurement Technologies to Improve Medication Adherence in Hypertension,9/23/2011,2/28/2017,9/30/2011,Sep-11,NCT01439256,Not Applicable,NA,Interventional,207,Completed,1,FALSE,Other,Other,"Behavioral, Other",Behavioral,Behavioral,FALSE,4,TRUE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Diagnostic Labeling: Effect on White Coat Hypertension,9/15/2011,7/31/2017,7/13/2009,13-Jul-09,NCT01434953,Not Applicable,NA,Interventional,100,Terminated,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Double Blind, Active Comparator, Parallel-group Study to Determine Whether the Combination of Valsartan and Aliskiren Provides Cardioprotection in African American Patients With Hypertension and Elements of the Metabolic Syndrome",9/12/2011,11/30/2013,2/28/2011,Feb-11,NCT01432106,Phase 1,NA,Interventional,0,Withdrawn,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,African American,Race-specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
BRIGHTEN Heart: Reducing Disparities in Late Life Depression and Metabolic Syndrome,9/5/2011,5/31/2015,3/31/2011,Mar-11,NCT01428791,Not Applicable,"Active, not recruiting",Interventional,250,Unknown status,2,TRUE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Caveolin-1 and Vascular Dysfunction,8/31/2011,7/31/2018,10/1/2010,1-Oct-10,NCT01426529,Phase 1,NA,Interventional,120,"Active, not recruiting",1,FALSE,NIH,Public,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Heart Healthy Lenoir: Improving Care for Patients With High Blood Pressure,8/30/2011,11/30/2014,9/30/2011,Sep-11,NCT01425515,Not Applicable,NA,Interventional,535,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,1,TRUE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Blood Pressure in Dialysis Patients (BID Study),8/23/2011,1/31/2017,10/31/2011,Oct-11,NCT01421771,Not Applicable,NA,Interventional,126,Completed,21,TRUE,Other,Other,"Drug, Other, Dietary Supplement",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3),8/17/2011,4/30/2017,9/30/2011,Sep-11,NCT01418261,Not Applicable,NA,Interventional,535,Completed,79,TRUE,Industry,Industry,"Device, Diagnostic Test",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE): A Double Blind Placebo Controlled Trial,8/16/2011,5/31/2017,10/31/2009,Oct-09,NCT01417104,Phase 2/Phase 3,NA,Interventional,71,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes,8/15/2011,9/30/2015,8/31/2011,Aug-11,NCT01416766,Not Applicable,NA,Interventional,196,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years) Who Have Stage 1 or 2 Essential Hypertension",8/12/2011,3/31/2013,8/31/2011,Aug-11,NCT01415531,Phase 4,NA,Interventional,641,Completed,75,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Multicenter, Open-Label, Single-Arm, Free Tablet Combination, Long-Term Study to Evaluate the Safety of Nebivolol in Combination With Valsartan in Patients With Stage 1 or Stage 2 Essential Hypertension",8/12/2011,5/31/2013,8/31/2011,Aug-11,NCT01415505,Phase 3,NA,Interventional,812,Completed,135,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1,8/10/2011,10/31/2015,11/30/2011,Nov-11,NCT01413542,Not Applicable,NA,Interventional,44,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy,8/2/2011,7/31/2019,1/31/2012,Jan-12,NCT01407809,Phase 1,NA,Interventional,20,"Active, not recruiting",1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention,7/29/2011,11/30/2015,3/31/2011,Mar-11,NCT01405638,Not Applicable,NA,Interventional,451,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effects of a Modified Lower Carbohydrate, Higher Fat DASH Diet Plan on Plasma Lipids, Lipoprotein Particle Size, and Blood Pressure in Healthy Adults",7/28/2011,3/31/2015,7/31/2011,Jul-11,NCT01404897,Not Applicable,NA,Interventional,36,Completed,1,FALSE,Industry,Industry,"Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Monetary Incentives and Intrinsic Motivation to Sustain Hypertension Control Pilot Study,7/26/2011,3/31/2015,8/31/2011,Aug-11,NCT01402453,Not Applicable,NA,Interventional,207,Completed,2,TRUE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of Short-term Aerobic Training on Arterial Stiffness and Blood in Chronic Kidney Disease (CKD) Patients,7/21/2011,1/31/2014,9/30/2009,Sep-09,NCT01399489,Not Applicable,NA,Interventional,51,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,7/21/2011,12/31/2013,7/31/2010,Jul-10,NCT01399138,Not Applicable,"Active, not recruiting",Interventional,50,Unknown status,1,FALSE,U.S. Fed,Public,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A 12 Week, Phase II Trial of the Safety, Pharmacokinetics, and Efficacy of INV-144 Compared With Losartan Potassium in Patients With Hypertension and Type 2 Diabetes Mellitus With Nephropathy",7/20/2011,8/31/2012,6/30/2011,Jun-11,NCT01398423,Phase 2,NA,Interventional,88,Completed,19,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Nebivolol and the Endothelin (ET)-1 System,7/15/2011,12/31/2018,5/31/2011,May-11,NCT01395329,Phase 4,NA,Interventional,42,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug, Other, Other, Other, Other, Other",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Effects of Dietary Flavanols on Cutaneous, Peripheral, and Cerebral Vascular Function in Young and Old Humans",7/15/2011,7/31/2015,9/30/2011,Sep-11,NCT01395277,Not Applicable,NA,Interventional,30,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Randomized Trial of Titrated Disease Management for Patients With Hypertension,7/11/2011,9/30/2018,7/27/2012,27-Jul-12,NCT01390272,Not Applicable,NA,Interventional,385,Completed,1,FALSE,U.S. Fed,Public,"Behavioral, Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,TRUE,2,TRUE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Promoting Health Literacy of African Americans With High Blood Pressure,7/7/2011,12/31/2017,10/31/2011,Oct-11,NCT01389037,Not Applicable,NA,Interventional,198,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pilot Study of Home Blood Pressure Control Program (eBP Control),7/6/2011,3/31/2016,9/30/2010,Sep-10,NCT01387945,Not Applicable,NA,Interventional,28,Completed,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Stroke Health and Risk Education (SHARE),6/22/2011,4/30/2015,5/31/2011,May-11,NCT01378780,Not Applicable,NA,Interventional,760,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension",6/14/2011,11/30/2012,5/31/2011,May-11,NCT01373086,Phase 2,NA,Interventional,19,Terminated,11,TRUE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Effects of Low-intensity Resistance Exercise Training and Diet on Central Hemodynamics and Arterial Stiffness in Obese Middle-aged Women With High Blood Pressure,6/10/2011,8/31/2014,12/31/2010,Dec-10,NCT01371370,Not Applicable,NA,Interventional,41,Completed,1,FALSE,Industry,Industry,"Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Treatment Trial of Droxidopa and Pyridostigmine to Improve Orthostatic Hypotension Without Aggravating Supine Hypertension,6/10/2011,8/31/2019,11/30/2011,Nov-11,NCT01370512,Phase 2,NA,Interventional,45,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Glycooxidative Stress on Human Aging- Study #3,6/1/2011,5/31/2015,12/31/2010,Dec-10,NCT01363141,Not Applicable,NA,Interventional,383,Completed,1,FALSE,NIH,Public,"Other, Other",other,other,FALSE,7,TRUE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Adjunct Vitamin D Therapy as a Means to Reduce the Disparity in Subclinical Target Organ Cardiac Damage Among Vulnerable Hypertensive Patients,5/25/2011,12/31/2015,8/31/2011,Aug-11,NCT01360476,Not Applicable,NA,Interventional,354,Completed,1,FALSE,NIH,Public,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,African American,Race-specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction,5/17/2011,4/30/2019,4/30/2011,Apr-11,NCT01354613,Not Applicable,NA,Interventional,14,Completed,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of a Coloring Prompt on Health Engagement,5/11/2011,5/31/2017,5/31/2011,May-11,NCT01352390,Not Applicable,NA,Interventional,8711,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Does Reversal of Visceral Obesity by Drug Therapy Improve Vascular Function?,5/11/2011,1/31/2020,3/31/2011,Mar-11,NCT01351753,Phase 2,NA,Interventional,136,Suspended,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects,5/6/2011,4/30/2017,6/30/2011,Jun-11,NCT01349114,Phase 4,NA,Interventional,21,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
A Double-Blind Study to Evaluate the Pharmacodynamic Interaction Between 10 mg Vardenafil ODT (Orally Disintegrating Tablet) and Procardia XLÂ® (Nifedipine GITS) in Elderly Male Patients With Both Hypertension and Erectile Dysfunction,5/6/2011,5/31/2014,5/31/2011,May-11,NCT01348880,Phase 1,NA,Interventional,42,Completed,2,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Study of Safety and IOP Lowering Efficacy of Transdermal Brimonidine Therapy,5/2/2011,4/30/2011,4/30/2011,Apr-11,NCT01345448,Phase 2,Recruiting,Interventional,22,Unknown status,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Physical Fitness, Cardiovascular and Brain Health",4/25/2011,4/30/2014,3/31/2011,Mar-11,NCT01341145,Not Applicable,NA,Interventional,41,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in VHA,4/20/2011,3/31/2016,4/30/2012,Apr-12,NCT01339390,Not Applicable,NA,Interventional,3169,Completed,1,FALSE,U.S. Fed,Public,"Behavioral, Behavioral",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract,4/8/2011,12/31/2011,5/31/2010,May-10,NCT01331486,Phase 1,NA,Interventional,24,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)",4/5/2011,7/31/2015,3/31/2011,Mar-11,NCT01328769,Phase 4,NA,Interventional,49,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Comparison of Standard Cardiopulmonary Resuscitation Alone Versus Active Compression Decompression Cardiopulmonary Resuscitation Plus an Impedance Threshold Device Versus Standard Cardiopulmonary Resuscitation Plus an Intrathoracic Pressure Regulator on Arterial Blood Pressures During Out-of-Hospital Cardiac Arrest,3/30/2011,7/31/2016,3/31/2011,Mar-11,NCT01325870,Not Applicable,NA,Interventional,48,Completed,1,FALSE,Industry,Industry,"Device, Device, Procedure, Device",Procedure,Procedure,TRUE,30,TRUE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Pharmacokinetic and Pharmacodynamic Effect of LY2189265 on Lisinopril in Subjects With Hypertension and Metoprolol in Healthy Subjects,3/29/2011,10/31/2014,3/31/2011,Mar-11,NCT01324388,Phase 1,NA,Interventional,51,Completed,3,TRUE,Industry,Industry,"Biological, Drug, Drug, Drug",Biological,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE),3/22/2011,5/31/2017,3/31/2011,Mar-11,NCT01320722,Phase 3,NA,Interventional,242,Completed,1,FALSE,NIH,Public,"Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,3/21/2011,1/31/2015,6/30/2011,Jun-11,NCT01319045,Not Applicable,NA,Interventional,5,Terminated,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,13,TRUE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Dopamine Versus Vasopressin for Cardiovascular Support in Extremely Low Birth Weight Infants: A Randomized, Blinded Pilot Study",3/18/2011,1/31/2019,3/31/2011,Mar-11,NCT01318278,Not Applicable,NA,Interventional,70,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"""Reversibility of Cardiovascular Injury With Continuous Positive Airway Pressure (CPAP) Use: Mechanisms Involved""",3/17/2011,9/30/2015,3/31/2011,Mar-11,NCT01317329,Not Applicable,NA,Interventional,90,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Does Home Telemonitoring Increase the Number of Diabetic Patients at Goal Blood Pressure in a Primary Care Practice?,2/21/2011,3/31/2014,3/31/2011,Mar-11,NCT01300338,Not Applicable,NA,Interventional,50,Completed,1,FALSE,Other,Other,"Device, Device",Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Antihypertensive Medication Adherence,2/15/2011,4/30/2019,2/28/2011,Feb-11,NCT01296594,Not Applicable,NA,Interventional,30,Completed,1,FALSE,NIH,Public,"Other, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure,2/9/2011,8/31/2018,3/31/2011,Mar-11,NCT01292694,Phase 1,NA,Interventional,12,Terminated,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,2/8/2011,11/30/2013,4/30/2011,Apr-11,NCT01291108,Phase 2,NA,Interventional,125,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,3,Drug Intervention,Industry Sponsor,Non-Race Specific
Real-Time MRI Right Heart Catheterization Using Passive Catheters,2/1/2011,3/21/2019,2/23/2011,23-Feb-11,NCT01287026,Phase 1/Phase 2,NA,Interventional,150,Completed,1,FALSE,NIH,Public,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Tailored Communication to Reduce Cardiovascular Risk,1/31/2011,1/31/2015,1/31/2011,Jan-11,NCT01286311,Not Applicable,NA,Interventional,464,Completed,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Safety and Efficacy of Intravenous Norepinephrine for Orthostatic Hypotension,1/28/2011,9/30/2014,1/31/2011,Jan-11,NCT01285908,Phase 1/Phase 2,NA,Interventional,6,Completed,1,FALSE,NIH,Public,Drug,Drug,Pharmaceutical,TRUE,4,TRUE,Non-race specific,Non-race specific,2011,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Financial Incentives for Home-based Health Management: A Pilot Randomized Trial,1/25/2011,8/31/2016,2/28/2011,Feb-11,NCT01282957,Not Applicable,NA,Interventional,75,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,3,TRUE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease,1/21/2011,1/31/2020,1/31/2011,Jan-11,NCT01280994,Phase 1,NA,Interventional,445,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,13,TRUE,Non-race specific,Non-race specific,2011,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Promoting Physical Activity in Older Adults With Comorbidity,1/21/2011,1/31/2018,1/31/2012,Jan-12,NCT01280903,Not Applicable,NA,Interventional,182,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Using Stories to Address Disparities in Hypertension,1/13/2011,10/31/2016,1/31/2013,Jan-13,NCT01276197,Not Applicable,NA,Interventional,618,Completed,4,TRUE,U.S. Fed,Public,"Other, Other",other,other,TRUE,3,TRUE,Non-race specific,Non-race specific,2011,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Double Blind Pilot Study Evaluating CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression in Caucasian Hypertensive Patients Treated With Eplerenone",1/12/2011,6/30/2015,12/31/2011,Dec-11,NCT01275352,Phase 4,NA,Interventional,0,Withdrawn,2,TRUE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study,1/12/2011,4/30/2019,12/31/2012,Dec-12,NCT01275339,Phase 4,NA,Interventional,10,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study,1/7/2011,9/30/2018,1/31/2011,Jan-11,NCT01272388,Phase 4,NA,Interventional,1,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2011,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
24-hour IOP-lowering Effect of 0.01% Bimatoprost,1/7/2011,5/31/2014,1/31/2011,Jan-11,NCT01271686,Phase 4,NA,Interventional,16,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2011,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan",1/6/2011,5/31/2011,4/30/2010,Apr-10,NCT01271374,Phase 4,"Active, not recruiting",Interventional,80,Unknown status,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,African American,Race-specific,2011,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Project Wellness: Increasing HIV Testing Among West African Immigrants,1/5/2011,5/31/2015,4/30/2012,Apr-12,NCT01270061,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2011,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Transition From Parenteral Prostanoids to Inhaled Treprostinil,12/31/2010,8/31/2017,8/31/2010,Aug-10,NCT01268553,Phase 4,NA,Interventional,6,Completed,3,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress",12/28/2010,12/31/2017,12/31/2010,Dec-10,NCT01267227,Phase 2/Phase 3,NA,Interventional,80,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,7,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Relaxation Response Training to Treat Hypertension: Effects on Blood Pressure, Biomarkers, and Endothelial Function",12/21/2010,4/30/2016,4/30/2009,Apr-09,NCT01263743,Not Applicable,NA,Interventional,58,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors,12/20/2010,3/31/2018,12/31/2010,Dec-10,NCT01263223,Phase 1,NA,Interventional,24,Completed,2,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of LY2216684 on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Albuterol or Propranolol,12/20/2010,1/31/2019,12/31/2010,Dec-10,NCT01263197,Phase 1,NA,Interventional,48,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Exercise Intervention in Pregnancy for Reduction of Blood Pressure in Obese Gravidas,12/17/2010,1/31/2015,11/30/2010,Nov-10,NCT01261884,Not Applicable,NA,Interventional,66,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The QutenzaÂ® Patch for Disabling Treprostinil Infusion Site Pain,12/15/2010,3/31/2016,11/30/2010,Nov-10,NCT01260454,Phase 2,NA,Interventional,6,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Randomized, Unblinded, Single Research Site, Comparator Study of Raisins Versus Alternative Snacks on Cardiovascular Risk Factors In Generally Healthy Subjects",12/15/2010,4/30/2014,12/31/2010,Dec-10,NCT01260272,Not Applicable,NA,Interventional,49,Completed,1,FALSE,Other,Other,"Other, Other",other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Series of Single Patient Trials Comparing the Efficacy Between the Most Commonly Prescribed Thiazide Diuretic in the US, Hydrochlorothiazide, and Lisinopril for the Treatment of Stage 1 Hypertension.",12/13/2010,5/31/2015,11/30/2010,Nov-10,NCT01258764,Not Applicable,NA,Interventional,2,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Uncontrolled Hypertension: The Role of Medication Adherence and Clinical Inertia,12/9/2010,2/28/2017,1/31/2011,Jan-11,NCT01257347,Not Applicable,NA,Interventional,124,Completed,1,FALSE,NIH,Public,"Behavioral, Device",Behavioral,Behavioral,TRUE,6,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The Effect of a Behavioral Weight Loss Program With Nutrisystem Meal Provision on Change in Weight, Fasting Blood Glucose, Cholesterol, and Blood Pressure Over 12 Weeks.",12/2/2010,6/30/2011,1/31/2011,Jan-11,NCT01252303,Not Applicable,NA,Interventional,50,Completed,1,FALSE,Industry,Industry,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"Does Administration of Etomidate and Propofol if the Anesthetic Induction of the Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngosacopy, When Compared to Propofol or Etomidate Alone?",11/25/2010,7/31/2012,7/31/2012,Jul-12,NCT01248234,Phase 3,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Pilot Study of the Effect of Intradialytic Vasopressin Infusion on Chronic Blood Pressure Control in Hypertensive Patients With End Stage Renal Disease: A Program to Develop a Decisive, Randomized Controlled Trial",11/24/2010,10/31/2019,10/31/2010,Oct-10,NCT01247090,Phase 2,NA,Interventional,12,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Feasibility of Mid-frequency Ventilation in Newborn Infants With Respiratory Distress Syndrome (RDS): Crossover Pilot Trial,11/17/2010,5/31/2014,10/31/2011,Oct-11,NCT01242462,Phase 1/Phase 2,NA,Interventional,12,Completed,1,FALSE,Other,Other,"Procedure, Other",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability,11/16/2010,7/31/2018,12/31/2010,Dec-10,NCT01241942,Not Applicable,NA,Interventional,11,Terminated,1,FALSE,Industry,Industry,"Device, Other",Device,Device,FALSE,9,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Daylight: The Effect of Vitamin D Supplementation on Blood Pressure in Vitamin D Deficient Individuals With Pre-Hypertension,11/15/2010,3/31/2017,12/31/2010,Dec-10,NCT01240512,Not Applicable,NA,Interventional,534,Completed,3,TRUE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation,11/7/2010,5/31/2018,5/31/2011,May-11,NCT01235910,Phase 4,NA,Interventional,1,Terminated,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study,11/5/2010,11/30/2014,9/30/2011,Sep-11,NCT01235377,Phase 4,NA,Interventional,20,Completed,5,TRUE,U.S. Fed,Public,Other,other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension,11/4/2010,7/31/2018,2/28/2011,Feb-11,NCT01234922,Phase 2,NA,Interventional,6,Terminated,1,FALSE,Other,Other,"Drug, Drug, Other, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Primary Care of Patients With Mental Disorders,10/25/2010,2/29/2016,4/30/2010,Apr-10,NCT01228032,Phase 3,NA,Interventional,447,Completed,1,FALSE,NIH,Public,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial,10/19/2010,12/31/2019,3/31/2010,Mar-10,NCT01224210,Not Applicable,NA,Interventional,30,"Active, not recruiting",6,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
NA,10/13/2010,10/31/2014,4/30/2011,Apr-11,NCT01220336,Not Applicable,NA,Interventional,441,Completed,2,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,3,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,10/7/2010,7/31/2015,10/31/2010,Oct-10,NCT01215786,Phase 1,NA,Interventional,50,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,3,Drug Intervention,Industry Sponsor,Non-Race Specific
"20% Mannitol vs 3% Hypertonic Saline in the Treatment of Intracranial Hypertension in Patients With Traumatic Brain Injury: A Double-blinded, Randomized Trial",10/5/2010,4/30/2013,10/31/2010,Oct-10,NCT01215019,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass(CPB) in Cardiac Surgery: a Randomized, Controlled Trial",10/1/2010,2/28/2019,12/31/2010,Dec-10,NCT01212874,Not Applicable,NA,Interventional,70,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Advanced Echocardiographic Evaluation of Nebivolol,9/21/2010,2/28/2018,9/30/2010,Sep-10,NCT01206439,Phase 4,NA,Interventional,2,Terminated,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Systolic Blood Pressure Intervention Trial,9/21/2010,10/31/2018,10/31/2010,Oct-10,NCT01206062,Not Applicable,NA,Interventional,9361,"Active, not recruiting",1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,TRUE,3,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
IRB-HSR# 14296 The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Systemic Blood Pressure in Patient Undergoing CABG Surgery,9/20/2010,8/31/2011,5/31/2009,May-09,NCT01205594,Phase 2,NA,Interventional,20,Completed,1,FALSE,Other,Other,Device,Device,Device,FALSE,8,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pharmacogenomic Evaluation of Antihypertensive Responses 2,9/16/2010,4/30/2018,8/31/2010,Aug-10,NCT01203852,Phase 4,NA,Interventional,839,Completed,3,TRUE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effects of the Novel Beta-adrenergic Antagonist Nebivolol (Bystolic) on Prehypertensive Subjects at Genetic Risk of Hypertension: Implications for Inflammation, Endothelial Dysfunction, and Oxidative Stress.",9/15/2010,7/31/2019,7/31/2010,Jul-10,NCT01202175,Phase 4,NA,Interventional,50,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Phase II, Dose Escalation, Single Center Study on the Effects of Early Propranolol on Heart Rate, Blood Pressure, and Cerebral Perfusion Pressure in Subjects Who Present With Moderate to Severe Traumatic Brain Injury.",9/15/2010,5/31/2016,6/30/2010,Jun-10,NCT01202110,Phase 2,NA,Interventional,10,Terminated,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Enhanced Spanish Drug Label Design to Promote Patient Understanding and Use,9/14/2010,11/30/2014,10/31/2010,Oct-10,NCT01200849,Not Applicable,NA,Interventional,420,Completed,1,FALSE,U.S. Fed,Public,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Metabolic Impact of Fructose Restriction in Obese Children,9/13/2010,5/31/2018,7/31/2010,Jul-10,NCT01200043,Not Applicable,NA,Interventional,54,Completed,1,FALSE,NIH,Public,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Comparative Clinical Trial to Assess the Accuracy of the TensorTip, a Novel Non Invasive Device for the Measurement of Physiological and Blood Chemistry Parameters",9/8/2010,7/31/2018,8/31/2010,Aug-10,NCT01196533,Not Applicable,NA,Interventional,94,Completed,1,FALSE,Industry,Industry,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
GRAPe Seed Extract and Ventriculovascular Investigation in Normal Ejection-Fraction Heart Failure,8/19/2010,6/30/2017,10/31/2010,Oct-10,NCT01185067,Phase 1,NA,Interventional,15,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,4,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Oral L-citrulline/L-arginine in Watermelon on Central Blood Pressure and Arterial Stiffness in Individuals With Obesity-related High Blood Pressure,8/19/2010,3/31/2012,8/31/2010,Aug-10,NCT01185041,Phase 1/Phase 2,NA,Interventional,20,Completed,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Comparative Bioavailability Study of UT-15C SR (Treprostinil Diethanolamine, Sustained Release) Oral Tablets and UT-15C (Treprostinil Diethanolamine) Administered as an Oral Solution in Healthy Volunteers",7/29/2010,7/31/2010,8/31/2010,Aug-10,NCT01172496,Phase 1,NA,Interventional,24,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
NA,7/27/2010,4/30/2019,12/31/2009,Dec-09,NCT01170884,Phase 4,NA,Interventional,121,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of Sodium Concentration of Priming and Rinsing Fluids on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients: a Prospective Pilot Study,7/23/2010,4/30/2017,7/31/2010,Jul-10,NCT01168947,Not Applicable,NA,Interventional,17,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Virtual Hypertension Clinic (VHC) Study,7/22/2010,10/31/2016,11/30/2009,Nov-09,NCT01167920,Not Applicable,NA,Interventional,74,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,11,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Evaluation of the Comparative Bioavailability of a Single Oral Dose of 1mg UT-15C (Treprostinil Diethanolamine) SR Tablets Manufactured by Two Independent Facilities Administered to Healthy Volunteers in the Fed State,7/19/2010,4/30/2011,7/31/2010,Jul-10,NCT01165476,Phase 1,NA,Interventional,64,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"An Open Label, Non-Randomized Pilot Study to Evaluate the Safety and Performance of the GeNO Nitrosyl Delivery System in Subjects Being Evaluated for Orthotopic Heart Transplantation (OHT), or Left Ventricular Assist Device (LVAD) Implantation",7/19/2010,8/31/2014,9/30/2010,Sep-10,NCT01165047,Phase 2,NA,Interventional,10,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Baerveldt Plate Area Comparison (BPAC),7/9/2010,4/30/2018,6/30/2010,Jun-10,NCT01159314,Not Applicable,NA,Interventional,69,Terminated,5,TRUE,Other,Other,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients",7/5/2010,2/29/2016,7/31/2010,Jul-10,NCT01157234,Phase 4,NA,Interventional,32,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,18,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Care Guides: Can Trained Laypersons Help Manage Chronic Disease? A Randomized Trial.,7/5/2010,4/30/2019,7/31/2010,Jul-10,NCT01156974,Phase 2,NA,Interventional,2135,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,3,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Louisiana State University Health Care Services Division Tele-Health Projects: Weight Loss in Chronic Disease Patient Population,7/1/2010,4/30/2011,1/31/2010,Jan-10,NCT01155050,Not Applicable,NA,Interventional,240,Completed,3,TRUE,Other,Other,"Device, Behavioral, Device",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
MIPARC - Multilevel Intervention for Physical Activity in Retirement Communities,7/1/2010,8/31/2017,1/31/2011,Jan-11,NCT01155011,Not Applicable,NA,Interventional,307,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,TRUE,7,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"An Evaluation of the Pharmacokinetic Linearity and Comparative Bioavailability of a Single Oral Dose of 0.5 mg, 1 mg and 2.5 mg UT-15C (Treprostinil Diethanolamine) SR Tablets in Healthy Volunteers in the Fed State",6/30/2010,8/31/2010,7/31/2010,Jul-10,NCT01153386,Phase 1,NA,Interventional,36,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Health Promotion Outreach To Overcome Clinical Inertia In The Treatment Of Patients With Poorly-Controlled Hypertension,6/16/2010,8/31/2018,11/30/2009,Nov-09,NCT01145391,Not Applicable,NA,Interventional,591,Completed,1,FALSE,Industry,Industry,Other,other,other,TRUE,1,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Cardiovascular Intervention Improvement Telemedicine Study,6/11/2010,4/30/2016,11/30/2011,Nov-11,NCT01142908,Not Applicable,NA,Interventional,428,Completed,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,TRUE,4,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Controlling Hypertension Outcomes by Improved Communication & Engagement (CHOICE),6/2/2010,6/30/2017,9/1/2009,1-Sep-09,NCT01134887,Not Applicable,NA,Interventional,26,Completed,2,TRUE,U.S. Fed,Public,"Other, Behavioral, Other, Behavioral, Other",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Evaluation of the Pharmacokinetics and Safety of a Single Dose of UT-15C SR (Treprostinil Diethanolamine) in Subjects With Renal Impairment.,5/27/2010,5/31/2012,5/31/2010,May-10,NCT01131845,Phase 1,NA,Interventional,16,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Evaluation of Integrating Self Blood Pressure Monitoring Into Urban Primary Care Practices to Improve Ethnic/ Racial Disparities in Hypertension,5/14/2010,8/31/2012,5/31/2010,May-10,NCT01123577,Not Applicable,NA,Interventional,899,Completed,4,TRUE,Other,Other,Other,other,other,FALSE,4,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Obesity, Hypertension in African American Women, Neuro-metabolic Mechanism",5/13/2010,1/31/2017,1/31/2010,Jan-10,NCT01122407,Phase 1,NA,Interventional,34,Completed,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,African American,Race-specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Reducing Risk of Recurrences: Issues in Maintenance and Stability in Stroke (CDA 08-009),5/13/2010,8/31/2016,1/31/2010,Jan-10,NCT01122394,Not Applicable,NA,Interventional,140,Completed,1,FALSE,U.S. Fed,Public,"Behavioral, Behavioral",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study,5/11/2010,5/31/2013,4/30/2010,Apr-10,NCT01120613,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,13,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Patient Understanding of Preeclampsia,5/7/2010,7/31/2011,4/30/2010,Apr-10,NCT01119183,Not Applicable,NA,Interventional,120,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,5/3/2010,5/31/2011,4/30/2010,Apr-10,NCT01114893,Phase 2,NA,Interventional,60,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,3,Drug Intervention,Industry Sponsor,Non-Race Specific
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study,5/3/2010,1/31/2016,6/30/2010,Jun-10,NCT01114373,Phase 2,NA,Interventional,40,Completed,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,African American,Race-specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Melatonin and Nighttime Blood Pressure in African Americans- 8 mg Study,5/3/2010,11/30/2015,3/31/2010,Mar-10,NCT01114360,Phase 2,NA,Interventional,37,Completed,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,African American,Race-specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure,4/27/2010,3/31/2013,4/30/2010,Apr-10,NCT01111682,Phase 3,NA,Interventional,5,Terminated,1,FALSE,U.S. Fed,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,5,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,4/26/2010,7/31/2014,6/30/2010,Jun-10,NCT01110499,Phase 2,NA,Interventional,163,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,3,Drug Intervention,Industry Sponsor,Non-Race Specific
Yoga as a Complex Intervention for Vets With Stroke,4/23/2010,11/30/2015,7/31/2010,Jul-10,NCT01109602,Phase 1/Phase 2,NA,Interventional,47,Completed,1,FALSE,U.S. Fed,Public,Other,other,other,TRUE,1,TRUE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).,4/22/2010,3/31/2017,1/31/2012,Jan-12,NCT01108744,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,7,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Double-Blind, Placebo-Controlled, Crossover Evaluation of a Grape Seed Extract and Quercetin Supplement (Provex CV) to Reduce Markers of Inflammatory Cytokines and Blood Pressure in Subjects With Metabolic Syndrome",4/19/2010,1/31/2015,3/31/2010,Mar-10,NCT01106170,Phase 1,NA,Interventional,20,Completed,1,FALSE,Other,Other,"Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Making Accurate Problem Lists in the EHR,4/19/2010,1/31/2015,5/31/2010,May-10,NCT01105923,Not Applicable,"Active, not recruiting",Interventional,140,Unknown status,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Enhanced Medication Monitoring Program,4/16/2010,11/30/2011,9/30/2011,Sep-11,NCT01105104,Phase 1,Recruiting,Interventional,150,Unknown status,1,FALSE,Industry,Industry,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
NA,4/8/2010,4/30/2019,5/1/2010,1-May-10,NCT01099774,Phase 3,NA,Interventional,597,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Phase II: Healthy Bodies, Hearts After Menopause",4/6/2010,5/31/2014,6/30/2009,Jun-09,NCT01099007,Phase 1,NA,Interventional,99,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Randomized Evaluation of the Effects of Valsartan and Aliskiren in Combination Versus Tekturna Alone on Hemostatic Biomarkers in Patients With Newly Diagnosed Mild to Moderate Hypertension and Type 2 Diabetes Mellitus,3/30/2010,3/31/2010,3/31/2010,Mar-10,NCT01095822,Phase 4,"Active, not recruiting",Interventional,50,Unknown status,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Industry Sponsor,Non-Race Specific
An Open Label Pilot Study Evaluating Preliminary Safety and Performance of the GeNO Nitrosyl Delivery System,3/25/2010,4/30/2013,10/31/2010,Oct-10,NCT01092559,Phase 2,NA,Interventional,10,Completed,3,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Community-based Approaches to Treating Hypertension and Colon Cancer Prevention,3/24/2010,4/30/2015,5/31/2010,May-10,NCT01092078,Not Applicable,NA,Interventional,740,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,1,TRUE,African American,Race-specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluating the Impact of Computerized Decision Support on Racial/Ethnic Disparities in Hypertension Outcomes,3/10/2010,6/30/2011,10/31/2010,Oct-10,NCT01083940,Early Phase 1,"Active, not recruiting",Interventional,3600,Unknown status,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Comparative Blood Pressure Effects of Nebivolol Versus Lisinopril in Patients With New Onset or Exacerbated Hypertension Induced by Bevacizumab: a Crossover Study,2/25/2010,4/30/2012,2/28/2010,Feb-10,NCT01076140,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients; Role of Natriuresis,2/24/2010,2/28/2019,9/30/2009,Sep-09,NCT01074918,Phase 1/Phase 2,NA,Interventional,0,Withdrawn,2,TRUE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The Pharmacodynamics, Safety, and Pharmacokinetics of Sedation With Dexmedetomidine in Children Undergoing Hemodynamic Cardiac Catheterization With Special Reference to the Pulmonary Vascular Bed",2/22/2010,4/30/2019,3/31/2010,Mar-10,NCT01072643,Phase 2/Phase 3,NA,Interventional,4,Terminated,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Practice-based Trial of Blood Pressure Control in African Americans,2/17/2010,11/30/2013,2/28/2010,Feb-10,NCT01070056,Phase 3,NA,Interventional,194,Completed,4,TRUE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Vitamin D Deficiency Augments Renin-Angiotensin System Activity in Obesity,2/15/2010,3/31/2017,2/28/2010,Feb-10,NCT01068418,Not Applicable,NA,Interventional,26,Completed,1,FALSE,Other,Other,Dietary Supplement,other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Faith-based Approaches in the Treatment of Hypertension (FAITH),2/9/2010,2/29/2016,11/30/2010,Nov-10,NCT01065831,Not Applicable,NA,Interventional,373,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Comparison of Ketofol (Ketamine and Propofol Admixture) vs. Propofol as Induction Agents on Hemodynamic Parameters,2/9/2010,3/31/2013,12/31/2010,Dec-10,NCT01065350,Not Applicable,NA,Interventional,85,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Open-Label, Dose Escalation Study of Bevacizumab With Ambulatory Blood Pressure Monitoring in Previously Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer",2/5/2010,10/31/2019,3/31/2010,Mar-10,NCT01063283,Not Applicable,NA,Interventional,20,Completed,3,TRUE,Industry,Industry,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis,2/1/2010,4/30/2018,1/31/2010,Jan-10,NCT01060020,Phase 4,NA,Interventional,20,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of 5 mg or 20 mg Nebivolol Once Daily on Blood Pressure in Patients With Systolic Stage 2 Hypertension",1/27/2010,12/31/2011,3/31/2010,Mar-10,NCT01057251,Phase 4,NA,Interventional,433,Completed,36,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function,1/26/2010,3/31/2017,11/30/2009,Nov-09,NCT01056718,Not Applicable,NA,Interventional,53,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention,1/20/2010,11/30/2017,6/30/2009,Jun-09,NCT01052220,Not Applicable,NA,Interventional,118,Completed,2,TRUE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Impact of Nebivolol on Central Aortic Pressure,1/20/2010,7/31/2011,12/31/2009,Dec-09,NCT01051947,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension,1/14/2010,3/31/2017,12/31/2009,Dec-09,NCT01049009,Phase 4,NA,Interventional,91,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,African American,Race-specific,2010,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes (Triabetes) - Alliance of Randomized Trials of Medicine vs. Metabolic Surgery in Type 2 Diabetes ARMMST2D),1/13/2010,7/31/2019,9/30/2009,Sep-09,NCT01047735,Not Applicable,NA,Interventional,60,"Active, not recruiting",1,FALSE,NIH,Public,"Procedure, Procedure, Behavioral",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity,1/8/2010,4/30/2015,1/31/2010,Jan-10,NCT01044693,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,6,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Industry Sponsor,Non-Race Specific
The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Investigator Initiated Trial,1/5/2010,3/31/2018,5/31/2010,May-10,NCT01042574,Phase 4,NA,Interventional,0,Withdrawn,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2010,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells in Subjects With Hypertension,12/31/2009,12/31/2014,12/31/2009,Dec-09,NCT01041287,Phase 4,NA,Interventional,96,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Improving Care Transitions for Complex Patients Through Decision Support,12/24/2009,2/28/2014,12/31/2009,Dec-09,NCT01039324,Not Applicable,NA,Interventional,8422,Completed,1,FALSE,Other,Other,"Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Melatonin Supplementation and the Metabolic Syndrome: A Phase II Crossover Design Clinical Trial,12/24/2009,2/28/2015,7/31/2009,Jul-09,NCT01038921,Phase 2,NA,Interventional,39,Completed,2,TRUE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension,12/23/2009,7/31/2012,1/31/2010,Jan-10,NCT01037920,Not Applicable,NA,Interventional,179,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of a Novel Behavioral Intervention on Blood Pressure Control in Hypertension Patients,12/18/2009,11/30/2013,5/31/2010,May-10,NCT01035554,Phase 2/Phase 3,NA,Interventional,203,Completed,1,FALSE,NIH,Public,"Other, Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT),12/16/2009,8/31/2018,11/30/2009,Nov-09,NCT01033370,Phase 4,NA,Interventional,5,Terminated,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,10,TRUE,Non-race specific,Non-race specific,2009,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of Treatment of Orthostatic Hypotension on a Rehabilitation Unit,12/14/2009,7/31/2018,10/31/2011,Oct-11,NCT01030874,Not Applicable,NA,Interventional,356,Completed,1,FALSE,U.S. Fed,Public,"Other, Dietary Supplement, Other, Other, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Use of PAP in Women With Pre-eclampsia,12/10/2009,9/30/2017,5/31/2009,May-09,NCT01029691,Not Applicable,NA,Interventional,125,Completed,1,FALSE,NIH,Public,Device,Device,Device,TRUE,1,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Prospective, Single-center Investigation of the Safety and Performance of the Endo GIAâ„¢ Stapler With Endo GIAâ„¢ Sulu With Tri-Stapleâ„¢ Technology in a Gastric Bypass Procedure",12/4/2009,1/31/2014,1/31/2010,Jan-10,NCT01026103,Not Applicable,NA,Interventional,28,Completed,1,FALSE,Industry,Industry,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hypertension (TRIUMPH),12/3/2009,2/28/2017,1/31/2010,Jan-10,NCT01024933,Not Applicable,NA,Interventional,238,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Upper Cervical Manipulation for Patients With Stage 1 Hypertension,11/25/2009,1/31/2018,10/31/2010,Oct-10,NCT01020435,Not Applicable,NA,Interventional,51,Completed,1,FALSE,Other,Other,"Other, Other",other,other,TRUE,4,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,11/19/2009,2/28/2015,10/31/2009,Oct-09,NCT01016691,Phase 2,NA,Interventional,47,Completed,5,TRUE,Industry,Industry,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,3,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Multi-center, Randomized, Controlled and Prospective Pilot Study on the Effects of Intensified Sodium Management on Hospitalization in Chronic Hemodialysis Patients.",11/18/2009,9/30/2015,11/30/2009,Nov-09,NCT01015313,Not Applicable,NA,Interventional,0,Withdrawn,3,TRUE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Treating to Target for Patients With Hypertension,11/16/2009,11/30/2012,1/31/2009,Jan-09,NCT01013857,Not Applicable,NA,Interventional,240,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Music as an Auxiliary Analgesic and Anxiolytic During First Trimester Abortion,11/13/2009,11/30/2012,9/30/2009,Sep-09,NCT01013363,Not Applicable,NA,Interventional,106,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients,11/5/2009,5/31/2019,11/30/2009,Nov-09,NCT01007994,Phase 2/Phase 3,NA,Interventional,33,"Active, not recruiting",2,TRUE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Interaction Study to Evaluate the Effect of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin and Ramipril (Cardiovascular Fixed Dose Combination Pill) on Blood Pressure",10/30/2009,6/30/2012,10/31/2009,Oct-09,NCT01005290,Phase 2,NA,Interventional,38,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
NA,10/26/2009,8/31/2013,11/30/2009,Nov-09,NCT01001195,Phase 2,NA,Interventional,165,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,3,Drug Intervention,Industry Sponsor,Non-Race Specific
"A 25 Week, Open Label Study to Determine the Effects of Nebivolol When Added to Hydrochlorothiazide on Diastolic Function and Arterial Stiffness in African Americans With Hypertension",10/22/2009,5/31/2011,10/31/2009,Oct-09,NCT00999752,Not Applicable,NA,Interventional,40,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,African American,Race-specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Nebivolol Vs. Metoprolol: Comparative Effects on Fatigue and Quality of Life,10/21/2009,10/31/2018,10/31/2009,Oct-09,NCT00999102,Phase 4,NA,Interventional,37,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function,10/14/2009,3/31/2019,10/31/2009,Oct-09,NCT00995072,Not Applicable,NA,Interventional,29,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Prospective, Randomized, Open-label Clinical Trial to Evaluate the Effect of Tekturna (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension",10/14/2009,9/30/2017,8/31/2009,Aug-09,NCT00994253,Phase 4,NA,Interventional,0,Withdrawn,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Technologies for Enhancing Access and Health Management,9/30/2009,5/31/2010,10/31/2009,Oct-09,NCT00987025,Not Applicable,"Active, not recruiting",Interventional,144,Unknown status,4,TRUE,Industry,Industry,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Improving Quality Through Decision Support for Evidence-Based Pharmacotherapy,9/17/2009,12/31/2012,9/30/2009,Sep-09,NCT00979225,Not Applicable,NA,Interventional,5000,Completed,1,FALSE,U.S. Fed,Public,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Steroids And Laser Trabeculoplasty (SALT) Trial: Effect of Anti-Inflammatory Treatment on the Efficacy of SLT,9/22/2009,7/31/2019,9/30/2009,Sep-09,NCT00981435,Phase 4,NA,Interventional,97,Completed,2,TRUE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's,9/21/2009,3/31/2017,4/30/2009,Apr-09,NCT00980785,Phase 4,NA,Interventional,14,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effect of Grape Seed Extract Delivered in a Beverage on Blood Pressure in Individuals With Pre-hypertension.",9/18/2009,3/31/2018,11/15/2009,15-Nov-09,NCT00979732,Not Applicable,NA,Interventional,72,"Active, not recruiting",1,FALSE,Industry,Industry,"Dietary Supplement, Dietary Supplement",other,other,FALSE,3,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"Clevidipine in Aneurysmal Subarachnoid Hemorrhage, A Pilot Study",9/17/2009,9/30/2009,9/30/2009,Sep-09,NCT00978822,Phase 2,Recruiting,Interventional,20,Unknown status,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,1,Drug Intervention,Industry Sponsor,Non-Race Specific
"Vitamin D Deficiency, Renin Inhibitor Response, and Vitamin D Supplementation in Patients With Hypertension",9/11/2009,2/28/2018,8/31/2009,Aug-09,NCT00974922,Phase 4,NA,Interventional,40,Terminated,1,FALSE,Industry,Industry,"Drug, Dietary Supplement, Dietary Supplement",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Phase 2, Randomized Clinical Trial of the Safety and Efficacy of Brain Tissue Oxygen Monitoring in the Management of Severe Traumatic Brain Injury.",9/10/2009,9/30/2019,10/31/2009,Oct-09,NCT00974259,Phase 2,NA,Interventional,122,Completed,10,TRUE,NIH,Public,"Device, Device",Device,Device,TRUE,1,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Treating Sleep Disorder Breathing Therapy in Patients With Resistant Hypertension,9/9/2009,1/31/2012,5/31/2009,May-09,NCT00973531,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Enhanced Prescription Drug Label to Improve Patient Understanding and Use,9/9/2009,9/30/2014,5/31/2009,May-09,NCT00973180,Not Applicable,NA,Interventional,850,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Lifestyle Modification and Blood Pressure Study,8/25/2009,2/28/2017,8/31/2009,Aug-09,NCT00964847,Phase 2,NA,Interventional,147,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,3,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Translating the Dietary Approaches to Stop Hypertension (DASH)Diet Into an Urban, African-American Community in Winston-Salem, North Carolina",8/25/2009,7/31/2018,1/31/2010,Jan-10,NCT00964483,Not Applicable,NA,Interventional,25,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Evaluation of Single Dose UT-15C SR (Treprostinil Diethanolamine) Pharmacokinetics Following Repeated Dosing With the Proton Pump Inhibitor Esomeprazole in Healthy Adult Volunteers,8/20/2009,3/31/2010,9/30/2009,Sep-09,NCT00963027,Phase 1,NA,Interventional,30,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of Different Meal Types on the Pharmacokinetics of a Single 1 mg Oral Dose of UT-15C (Treprostinil Diethanolamine) Sustained Release Tablets in Healthy Volunteers,8/20/2009,3/31/2010,9/30/2009,Sep-09,NCT00963001,Phase 1,NA,Interventional,32,Completed,1,FALSE,Industry,Industry,"Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Assessment of Inspiratory Breathing Devices to Improve Orthostatic Tolerance in Neurogenic Orthostatic Hypotension,8/20/2009,4/30/2019,12/31/2010,Dec-10,NCT00962884,Not Applicable,NA,Interventional,30,"Active, not recruiting",1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,3,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults",8/10/2009,8/31/2017,6/30/2010,Jun-10,NCT00955903,Phase 3,NA,Interventional,167,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Double-blind, Placebo-controlled Cross-over Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure",8/10/2009,10/31/2017,7/31/2009,31-Jul-09,NCT00955396,Phase 1,NA,Interventional,60,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Role of EECP Therapy in Patients With Resistant Hypertension,8/6/2009,1/31/2012,5/31/2009,May-09,NCT00953797,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Clinical Proteomics and Protein Therapeutics in Human Hypertension (BNP in Human Hypertension - Phase 1),8/6/2009,10/31/2011,2/28/2009,Feb-09,NCT00953472,Phase 1,NA,Interventional,8,Terminated,1,FALSE,Other,Other,"Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Mechanism of the Anti-remodeling Activity of the Over-the-counter Dietary Supplement, Pycnogenol, on Age-dependent Process of Cardiac Fibrosis in Aged Hypertensive Subjects With Echocardiographic Evidence of Grade I/II Diastolic Dysfunction",8/6/2009,12/31/2013,7/31/2009,Jul-09,NCT00952627,Phase 2,NA,Interventional,9,Terminated,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients,8/4/2009,1/31/2015,7/31/2009,Jul-09,NCT00952081,Phase 4,NA,Interventional,22,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects",7/30/2009,3/31/2011,8/31/2009,Aug-09,NCT00949884,Phase 4,NA,Interventional,941,Completed,20,TRUE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Potassium Intake in Patients With Chronic Kidney Disease,7/30/2009,9/30/2012,7/31/2009,Jul-09,NCT00949585,Not Applicable,NA,Interventional,29,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,7/28/2009,9/30/2016,7/31/2010,Jul-10,NCT00947661,Phase 3,NA,Interventional,578,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,3,Drug Intervention,Industry Sponsor,Non-Race Specific
NA,7/24/2009,5/31/2016,11/30/2010,Nov-10,NCT00945958,Phase 3,NA,Interventional,161,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,3,Drug Intervention,Industry Sponsor,Non-Race Specific
"An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension",7/21/2009,5/31/2011,6/30/2009,Jun-09,NCT00942994,Phase 4,NA,Interventional,412,Completed,5,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2009,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet on Ventriculovascular Function in Heart Failure With Preserved Systolic Function,7/15/2009,10/31/2019,7/31/2009,Jul-09,NCT00939640,Not Applicable,NA,Interventional,14,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,TRUE,11,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation,7/9/2009,9/30/2014,9/30/2009,Sep-09,NCT00935766,Phase 3,NA,Interventional,76,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Effect of Nurse-Based, Protocol-Driven, Case-Management Utilizing Home Telemonitoring and Home HbA1c Measurement on Diabetes and Blood Pressure Outcomes",7/9/2009,9/30/2011,6/30/2009,Jun-09,NCT00935441,Not Applicable,NA,Interventional,460,Completed,1,FALSE,U.S. Fed,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Collaborative Model to Improve BP Control and Minimize Racial Disparities-CCC,7/8/2009,7/31/2014,1/31/2010,Jan-10,NCT00935077,Phase 3,NA,Interventional,1441,Completed,28,TRUE,Other,Other,"Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension",7/2/2009,3/31/2011,7/31/2009,Jul-09,NCT00931710,Phase 4,NA,Interventional,488,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus",6/25/2009,12/31/2012,5/31/2009,May-09,NCT00927394,Phase 4,NA,Interventional,1143,Completed,4,TRUE,Industry,Industry,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 Âµg Ethinylestradiol and 100 Âµg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women",6/16/2009,1/31/2014,6/30/2009,Jun-09,NCT00920985,Phase 3,NA,Interventional,346,Completed,28,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Mechanisms of the Relaxation Response in Elderly Hypertensives,6/4/2009,2/28/2010,3/31/2009,Mar-09,NCT00913991,Phase 1,NA,Interventional,69,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Interactive Spaced Education to Optimize Hypertension Management,5/19/2009,2/28/2019,2/28/2010,Feb-10,NCT00904007,Not Applicable,NA,Interventional,111,Completed,1,FALSE,U.S. Fed,Public,Other,other,other,TRUE,1,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Personalized Physician Learning Intervention to Improve Hypertension Care,5/15/2009,6/30/2014,3/31/2010,Mar-10,NCT00903071,Not Applicable,NA,Interventional,130,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Double-blind, Randomized, Placebo-controlled, Sequential Group Pilot Study to Assess Safety, Tolerability, and Effectiveness of TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension",5/12/2009,9/30/2013,5/31/2009,May-09,NCT00899977,Phase 1/Phase 2,NA,Interventional,1,Terminated,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"The Relationship Between Serine Threonine Kinase 39 (STK39) Genotypes, Salt Sensitivity, Thiazide Diuretics-induced Blood Pressure Response",5/11/2009,5/31/2018,10/31/2009,Oct-09,NCT00896389,Phase 4,NA,Interventional,124,Completed,1,FALSE,NIH,Public,"Procedure, Drug",Procedure,Procedure,TRUE,3,TRUE,Non-race specific,Non-race specific,2009,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Contingency Management for Initiating Smoking Abstinence in Patients With Hypertension,4/9/2009,4/30/2017,4/30/2009,Apr-09,NCT00879177,Phase 4,NA,Interventional,203,Completed,1,FALSE,NIH,Public,"Drug, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 4, Placebo Controlled, Single-blind, Cross-over Safety Study to Evaluate the Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR) as Measured by Right Heart Catheterization",4/9/2009,7/31/2012,3/31/2009,Mar-09,NCT00878878,Phase 4,NA,Interventional,30,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Early Blood Pressure Management in Extremely Preterm Infants Feasibility Pilot Study,4/2/2009,5/31/2017,7/31/2009,Jul-09,NCT00874393,Phase 1,NA,Interventional,10,Completed,17,TRUE,NIH,Public,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2009,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of a PPAR Alpha Agonist on CYP Monooxygenase Activity in Humans,3/31/2009,6/30/2013,9/30/2009,Sep-09,NCT00872599,Phase 4,NA,Interventional,75,Completed,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2009,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"DHA, Inflammation, and Insulin Sensitivity",3/19/2009,7/31/2009,4/30/2009,Apr-09,NCT00865683,Phase 1,Recruiting,Interventional,90,Unknown status,1,FALSE,NIH,Public,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African American Patients With Stage 2 Hypertension",3/2/2009,4/30/2012,2/28/2009,Feb-09,NCT00853957,Phase 4,NA,Interventional,443,Completed,9,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,African American,Race-specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease,2/27/2009,12/31/2009,4/30/2009,Apr-09,NCT00852787,Phase 4,"Active, not recruiting",Interventional,30,Unknown status,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,3,TRUE,Non-race specific,Non-race specific,2009,0,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study,2/24/2009,3/31/2013,1/31/2009,Jan-09,NCT00849810,Not Applicable,NA,Interventional,1,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism,2/20/2009,6/30/2011,2/28/2009,Feb-09,NCT00848731,Phase 1,NA,Interventional,25,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance",2/19/2009,11/30/2009,1/31/2009,Jan-09,NCT00847899,Phase 2,NA,Interventional,150,Completed,30,TRUE,Industry,Industry,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Safety and Efficacy of L-NAME and Midodrine to Increase MAP in Persons With Tetraplegia,2/3/2009,3/31/2014,5/31/2010,May-10,NCT00835224,Phase 2,NA,Interventional,34,Completed,1,FALSE,U.S. Fed,Public,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2009,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetics,1/27/2009,1/31/2016,1/31/2009,Jan-09,NCT00829296,Phase 2/Phase 3,NA,Interventional,70,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients",1/23/2009,1/31/2014,6/30/2009,Jun-09,NCT00827775,Phase 4,NA,Interventional,59,Completed,3,TRUE,NIH,Public,Drug,Drug,Pharmaceutical,FALSE,3,TRUE,Non-race specific,Non-race specific,2009,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Flavanol-Rich Cocoa, Vascular Responses and Mechanisms",1/21/2009,4/30/2014,1/31/2009,Jan-09,NCT00825695,Not Applicable,NA,Interventional,60,Completed,1,FALSE,Industry,Industry,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"Pilot Trial To Study Blood Pressure, Weight and Hydration State in Patients Undergoing A Treatment Regimen of Daily Ultrafiltration and Twice-weekly Hemodialysis As Compared to Conventional Three Times Per Week Hemodialysis",1/21/2009,4/30/2014,7/31/2009,Jul-09,NCT00825318,Not Applicable,NA,Interventional,13,Completed,3,TRUE,Other,Other,Procedure,Procedure,Procedure,TRUE,1,TRUE,Non-race specific,Non-race specific,2009,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Investigation of Reduction of Blood Pressure and Metabolic Rate in Obese Hypertensive Patients Using Eplerenone: Implications for Treatment of Hypertension and Heart Failure,1/19/2009,3/31/2014,1/31/2009,Jan-09,NCT00825188,Not Applicable,NA,Interventional,10,Terminated,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome,1/9/2009,1/31/2020,1/31/2009,Jan-09,NCT00819403,Phase 4,NA,Interventional,15,Completed,3,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2009,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients With Moderate-to-Severe Chronic Kidney Disease and Uncontrolled Hypertension",7/2/2018,1/31/2020,4/25/2018,25-Apr-18,NCT03574363,Phase 2,NA,Interventional,240,Recruiting,2,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine Systemâ„¢ Kit, in Subjects With Hypertension",9/22/2016,1/31/2020,7/22/2019,22-Jul-19,NCT02910414,Phase 3,NA,Interventional,300,Recruiting,3,TRUE,Industry,Industry,"Drug, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Industry Sponsor,Non-Race Specific
A Mobile Personal Health Record for Behavioral Health Homes,7/1/2013,1/31/2020,11/30/2014,Nov-14,NCT01890226,Not Applicable,NA,Interventional,311,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2013,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pilot for a Community Pharmacy Service Model: Impact of a Pharmacist Monitored Patient Blood Pressure Readings,10/27/2017,1/31/2020,1/15/2018,15-Jan-18,NCT03323840,Not Applicable,NA,Interventional,50,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1,11/13/2018,1/31/2020,11/15/2018,15-Nov-18,NCT03738878,Phase 4,NA,Interventional,32,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Remote Blood Pressure Monitoring in the Postpartum (PP) Period,11/2/2018,2/29/2020,11/9/2018,9-Nov-18,NCT03728790,Not Applicable,NA,Interventional,213,"Active, not recruiting",1,FALSE,Industry,Industry,Device,Device,Device,FALSE,20,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Spinal Cord Stimulation to Inhibit Afferent Feedback During Exercise in Heart Failure,1/20/2016,2/29/2020,1/31/2016,Jan-16,NCT02659202,Not Applicable,NA,Interventional,40,Recruiting,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduceâ„¢ Catheter and Vessixâ„¢ Generator for the Treatment of HyperTensioN: REINFORCE,3/19/2015,1/31/2020,4/30/2015,Apr-15,NCT02392351,Not Applicable,NA,Interventional,51,Completed,12,TRUE,Industry,Industry,"Device, Device",Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Exercise and Intensive Vascular Risk Reduction in Preventing Dementia,9/26/2016,2/29/2020,9/30/2016,Sep-16,NCT02913664,Phase 2/Phase 3,NA,Interventional,513,"Active, not recruiting",4,TRUE,Other,Other,"Drug, Behavioral, Other, Behavioral, Drug",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)",11/27/2017,10/31/2019,4/10/2018,10-Apr-18,NCT03354143,Phase 2,NA,Interventional,120,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Skin Surface Pressures Under Blood-Draw Tourniquets,6/14/2017,2/29/2020,12/31/2016,Dec-16,NCT03187041,Not Applicable,NA,Interventional,10,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,2,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Metabolic Effects of Angiotensin-(1-7),1/5/2016,2/29/2020,2/29/2016,Feb-16,NCT02646475,Phase 1,NA,Interventional,19,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure,10/29/2015,2/29/2020,2/29/2016,Feb-16,NCT02591173,Early Phase 1,NA,Interventional,22,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension,9/19/2014,2/29/2020,1/31/2015,Jan-15,NCT02245230,Phase 1,NA,Interventional,34,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Resistance Training and Cardiometabolic Health,10/30/2017,2/29/2020,9/21/2017,21-Sep-17,NCT03325933,Not Applicable,NA,Interventional,30,Recruiting,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,43,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Community-Based Dietary Approach for Hypertensive African Americans With Chronic Kidney Disease,10/3/2017,2/29/2020,12/4/2017,4-Dec-17,NCT03299816,Not Applicable,NA,Interventional,150,Recruiting,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Open-Labeled Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Metoprolol ER,4/15/2015,2/29/2020,8/31/2015,Aug-15,NCT02417246,Phase 4,NA,Interventional,61,Completed,2,TRUE,U.S. Fed,Public,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A More Engaging Visual Field Test to Increase Use and Reliability in Pediatrics,6/5/2014,2/29/2020,2/28/2015,Feb-15,NCT02157025,Not Applicable,NA,Interventional,20,Recruiting,1,FALSE,Other,Other,"Device, Other",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Peripheral Low Dose Systemic Thrombolysis Versus Catheter Directed Acoustic Pulse Thrombolysis for Treatment of Submassive Pulmonary Embolism,7/10/2018,2/29/2020,1/28/2019,28-Jan-19,NCT03581877,Phase 4,NA,Interventional,158,Recruiting,2,TRUE,Other,Other,"Drug, Device",Device,Device,FALSE,10,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Treatment of Supine Hypertension in Autonomic Failure With Continuous Positive Airway Pressure,10/17/2017,2/29/2020,9/21/2017,21-Sep-17,NCT03312556,Not Applicable,NA,Interventional,12,Recruiting,1,FALSE,Other,Other,"Device, Drug",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Overnight Trials to Compare the Effects of Controlled Heat Stress Versus Sham Control on Nocturnal Supine Hypertension in Autonomic Failure Patients,2/3/2017,2/29/2020,1/30/2017,30-Jan-17,NCT03042988,Not Applicable,NA,Interventional,20,Recruiting,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury,9/8/2016,2/29/2020,12/31/2016,Dec-16,NCT02893553,Phase 2,NA,Interventional,50,Recruiting,2,TRUE,U.S. Fed,Public,"Drug, Drug, Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2,4/4/2016,2/29/2020,4/30/2016,Apr-16,NCT02726711,Phase 1,NA,Interventional,2,"Active, not recruiting",1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
EMPower: Electronic Media Powering Positive Health Changes in Youth,5/14/2015,2/29/2020,7/31/2015,Jul-15,NCT02444689,Not Applicable,NA,Interventional,91,"Active, not recruiting",1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension,4/24/2015,2/29/2020,4/30/2015,Apr-15,NCT02425566,Phase 1,NA,Interventional,12,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Local Heat Stress in Autonomic Failure Patients With Supine Hypertension,4/15/2015,2/29/2020,4/30/2015,Apr-15,NCT02417415,Not Applicable,NA,Interventional,21,Enrolling by invitation,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2015,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Blood Pressure, Cerebral Blood Flow and Cognition in SCI",12/4/2014,2/29/2020,3/31/2014,Mar-14,NCT02307565,Phase 3,NA,Interventional,60,Completed,2,TRUE,U.S. Fed,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2014,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Role of Endothelin in the Supine Hypertension of Autonomic Failure,5/7/2010,2/29/2020,5/31/2010,May-10,NCT01119417,Phase 1,NA,Interventional,12,Enrolling by invitation,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2010,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study",8/10/2018,2/29/2020,9/19/2018,19-Sep-18,NCT03624517,Phase 4,NA,Interventional,160,Recruiting,8,TRUE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure",10/22/2018,2/29/2020,1/3/2019,3-Jan-19,NCT03714776,Phase 2,NA,Interventional,25,Completed,6,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Reach Out: Randomized Clinical Trial of Emergency Department-Initiated Hypertension Behavioral Intervention Connecting Multiple Health Systems,2/6/2018,2/29/2020,3/25/2019,25-Mar-19,NCT03422718,Not Applicable,NA,Interventional,1440,Recruiting,1,FALSE,NIH,Public,"Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Visualizing Vascular Mechanisms of Salt Sensitivity,10/4/2018,7/31/2019,2/1/2019,1-Feb-19,NCT03696433,Not Applicable,NA,Interventional,20,Recruiting,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,2,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Performance of CO2 Changes to Predict Fluid Responsiveness in Spontaneously Breathing Volunteers,12/28/2018,6/30/2019,5/1/2019,1-May-19,NCT03788707,Not Applicable,NA,Interventional,220,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
BP-CATCH: Boosting Primary Care Awareness and Treatment of Childhood Hypertension,12/21/2018,12/31/2019,9/1/2018,1-Sep-18,NCT03783650,Not Applicable,NA,Interventional,64,Enrolling by invitation,1,FALSE,U.S. Fed,Public,"Behavioral, Behavioral, Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Reducing Blood Viscosity and Suppressing Turbulence With Magneto-rheology to Lower Blood Pressure,12/20/2018,12/31/2018,8/10/2018,10-Aug-18,NCT03783117,Not Applicable,NA,Interventional,200,Recruiting,1,FALSE,Industry,Industry,Device,Device,Device,FALSE,2,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"A PHASE I, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE CARDIOVASCULAR AND METABOLIC PROPERTIES OF MANP IN SUBJECTS WITH HYPERTENSION AND METABOLIC SYNDROME ACCORDING TO RS5068 GENOTYPES",12/20/2018,4/30/2019,8/18/2017,18-Aug-17,NCT03781739,Phase 1,NA,Interventional,54,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Chickasaw Healthy Eating Environments Research Study,12/12/2018,3/31/2019,7/10/2018,10-Jul-18,NCT03774277,Not Applicable,NA,Interventional,600,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Salt-Sensitivity and Immunity Cell Activation,11/26/2018,4/30/2019,3/31/2020,Mar-20,NCT03753204,Phase 1/Phase 2,NA,Interventional,20,Not yet recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,2,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Acute Effects of Aerobic and Resistance Exercise on Maternal Glucose Metabolism and Vascular Function in Obese Pregnancy,11/23/2018,12/31/2019,11/20/2018,20-Nov-18,NCT03750695,Not Applicable,NA,Interventional,15,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Heart Health 4 New Moms: A Randomized Controlled Trial of a Lifestyle Intervention and Home Blood Pressure Monitoring Following Preeclampsia in Overweight and Obese Women,11/21/2018,1/31/2020,1/26/2019,26-Jan-19,NCT03749746,Not Applicable,NA,Interventional,90,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral, Other",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Targeting of UnControlled Hypertension in Emergency Department (TOUCHED),11/21/2018,11/30/2018,2/19/2019,19-Feb-19,NCT03749499,Not Applicable,NA,Interventional,770,Recruiting,1,FALSE,Other,Other,"Other, Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Team-Based and Technology-Driven Adherence Intervention to Improve Chronic Disease Outcomes,11/20/2018,12/31/2019,11/6/2019,6-Nov-19,NCT03748420,Not Applicable,NA,Interventional,3013,Recruiting,1,FALSE,NIH,Public,"Other, Behavioral",Behavioral,Behavioral,FALSE,12,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Longitudinal Evaluation of Disease Prevalence in Impoverished Communities of Lima, Peru",11/15/2018,11/30/2019,6/5/2017,5-Jun-17,NCT03742219,Not Applicable,NA,Interventional,1000,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluation of Personal Activity Intelligence (PAI) Score Pilot Study,11/14/2018,11/30/2019,10/2/2018,2-Oct-18,NCT03740074,Not Applicable,NA,Interventional,25,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Mindfulness and Behavioral Intervention for Reducing Hypertension Among Women of Childbearing Age,11/15/2018,11/30/2019,1/22/2019,22-Jan-19,NCT03741608,Not Applicable,NA,Interventional,60,Recruiting,4,TRUE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluation of a Lifestyle Medicine Practice,11/13/2018,11/30/2019,6/28/2018,28-Jun-18,NCT03739034,Not Applicable,NA,Interventional,2000,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Brain Connections, Self-care and Blood Pressure in Black and African Americans With Problems With Memory",11/9/2018,10/31/2019,8/23/2018,23-Aug-18,NCT03736434,Not Applicable,NA,Interventional,36,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia,11/8/2018,3/31/2019,1/15/2019,15-Jan-19,NCT03735433,Phase 4,NA,Interventional,400,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Dose Finding Trial for Angiotensin II in Hypertensive Adults on Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Anesthesia-Mediated Hypotension,11/7/2018,8/31/2019,10/3/2019,3-Oct-19,NCT03733145,Phase 1,NA,Interventional,60,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,6,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The MHERO Study (Michigan's Hypertension, Diabetes, and Obesity Education Research Online)",11/2/2018,11/30/2019,11/1/2018,1-Nov-18,NCT03729479,Phase 1/Phase 2,NA,Interventional,140,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Sleep and Cardiovascular Health in Adolescence,11/1/2018,2/28/2019,1/7/2019,7-Jan-19,NCT03727906,Not Applicable,NA,Interventional,110,Recruiting,1,FALSE,Industry,Industry,"Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Telemedicine and the Barbershop Model of Hypertension Care for Black Men,10/31/2018,1/31/2020,11/1/2018,1-Nov-18,NCT03726710,Phase 1,NA,Interventional,20,"Active, not recruiting",1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A COmmunity and Tech-Based ApproaCh for Hypertension Self-MANagement (COACHMAN),10/30/2018,1/31/2019,1/31/2019,31-Jan-19,NCT03724487,Not Applicable,NA,Interventional,40,Not yet recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of Technology-based Intervention and Positive Psychological Training on Cognitive Processing and Blood Pressure Control in African Americans,10/29/2018,10/31/2018,10/25/2018,25-Oct-18,NCT03722667,Not Applicable,NA,Interventional,20,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The Effects of Pumpkin Seed Oil Supplementation on Vascular Hemodynamics, Stiffness and Cardiac Autonomic Function in Postmenopausal Women.",10/23/2018,10/31/2018,9/1/2017,1-Sep-17,NCT03716960,Not Applicable,NA,Interventional,23,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Correlation Between Vasopressin and Renal Function Following a Controlled Intraabdominal Pressure Elevation,10/16/2018,11/30/2019,4/28/2017,28-Apr-17,NCT03707054,Not Applicable,NA,Interventional,16,"Active, not recruiting",1,FALSE,Other,Other,Diagnostic Test,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Remote Hypertension Management Using Home Blood Pressure Telemonitoring and a Standardized Treatment Protocol,10/9/2018,10/31/2018,9/17/2018,17-Sep-18,NCT03700775,Not Applicable,NA,Interventional,300,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Remote Dietary Counseling Using Web-based Tools to Promote Healthy Diet and Blood Pressure (Healthy BP),10/9/2018,10/31/2019,1/16/2019,16-Jan-19,NCT03700710,Not Applicable,NA,Interventional,200,Recruiting,2,TRUE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluating the Effects of a Sedentary Behavior Reduction Intervention on the Sedentary Time and Blood Pressure of Overweight/Obese Adults,10/9/2018,2/28/2019,8/1/2018,1-Aug-18,NCT03698903,Not Applicable,NA,Interventional,36,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Heart Inflammation and Mental Stress Study,10/3/2018,9/30/2019,8/19/2019,19-Aug-19,NCT03695146,Not Applicable,NA,Interventional,144,Recruiting,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pilot to Examine Risk and Feasibility of Remote Management of BP From Childhood Into Early Adulthood,10/2/2018,11/30/2019,7/20/2018,20-Jul-18,NCT03691701,Phase 2,NA,Interventional,60,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of 8 oz Fresh vs. Commercial Orange Juice on Blood Pressure In Normotensive Males Aged 18-59,10/1/2018,7/31/2019,10/1/2018,1-Oct-18,NCT03691194,Not Applicable,NA,Interventional,17,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Trial of Magnesium Supplementation and Blood Pressure Reduction Among Adults With Untreated High Blood Pressure,9/28/2018,9/30/2019,2/15/2019,15-Feb-19,NCT03688503,Not Applicable,NA,Interventional,59,"Active, not recruiting",1,FALSE,Industry,Industry,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients",9/27/2018,10/31/2019,8/5/2020,5-Aug-20,NCT03686657,Phase 1/Phase 2,NA,Interventional,115,Not yet recruiting,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Salt Sensitive Hypertension and Striatin,9/25/2018,1/31/2020,1/13/2020,13-Jan-20,NCT03683069,Not Applicable,NA,Interventional,250,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,16,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Prenatal Mindfulness Training for Pregnant Women at Risk for Hypertension,9/20/2018,8/31/2019,4/1/2019,1-Apr-19,NCT03679117,Not Applicable,NA,Interventional,20,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on REE, Cardiovascular, and Mood Responses",9/19/2018,3/31/2019,7/23/2018,23-Jul-18,NCT03678116,Not Applicable,NA,Interventional,14,Completed,1,FALSE,Other,Other,"Drug, Dietary Supplement, Dietary Supplement",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Stanford Clinics Physician Mindset Training,9/19/2018,9/30/2018,1/4/2018,4-Jan-18,NCT03677609,Not Applicable,NA,Interventional,3000,Enrolling by invitation,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia,9/12/2018,1/31/2020,7/22/2019,22-Jul-19,NCT03667326,Phase 2,NA,Interventional,90,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,2,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Dissemination of the Cardiovascular Risk Service,9/6/2018,9/30/2019,9/27/2018,27-Sep-18,NCT03660631,Not Applicable,NA,Interventional,700,Recruiting,12,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"LSFG-SKIN, Laser Speckle Flowgraphy",9/6/2018,9/30/2018,5/23/2017,23-May-17,NCT03660618,Not Applicable,NA,Interventional,100,Completed,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Fight Hypertension in the Digital Age,9/6/2018,9/30/2018,10/31/2018,Oct-18,NCT03659656,Not Applicable,NA,Interventional,80,Not yet recruiting,1,FALSE,Other,Other,"Behavioral, Device",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Open-label, Single-Dose, Two-Way Crossover Study to Assess the Relative Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet (NORVASCÂ® From Pfizer Inc.) in Healthy Subjects Followed by a Phase to Study Food Effect on the PK Profile of Levamlodipine",9/5/2018,9/30/2018,5/31/2018,31-May-18,NCT03657550,Phase 1,NA,Interventional,36,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Adoption and Effectiveness of a mHealth Intervention for Hypertension in Older Adults: a Pilot Clinical Trial,8/28/2018,10/31/2019,9/21/2018,21-Sep-18,NCT03650166,Not Applicable,NA,Interventional,62,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing",8/28/2018,10/31/2018,9/25/2018,25-Sep-18,NCT03649932,Phase 1,NA,Interventional,42,Recruiting,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,9,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Effect of Ozanimod on Blood Pressure and Heart Rate Response to Pseudoephedrine in Healthy Adult Subjects",8/23/2018,5/31/2019,7/11/2018,11-Jul-18,NCT03644576,Phase 1,NA,Interventional,54,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Heat Therapy and Cardiometabolic Health in Obese Women,8/23/2018,8/31/2018,9/8/2015,8-Sep-15,NCT03644524,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention,8/23/2018,10/31/2019,9/20/2019,20-Sep-19,NCT03643705,Not Applicable,NA,Interventional,300,Recruiting,3,TRUE,NIH,Public,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTET USA),8/21/2018,8/31/2019,8/30/2019,30-Aug-19,NCT03640312,Phase 2,NA,Interventional,365,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Double-blind, Randomized, Parallel 2- Arm Study to Compare the Efficacy of Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes Who Are Receiving Background Standard-of-care Cardio-metabolic Therapy With Metformin, an Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker, and a Statin.",8/21/2018,8/31/2018,9/1/2018,1-Sep-18,NCT03640221,Phase 4,NA,Interventional,0,Withdrawn,1,FALSE,Industry,Industry,"Drug, Drug, Device, Other, Other, Other, Other",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Psychological Stress, and Circadian Patterns of Sodium Excretion and Blood Pressure",8/17/2018,9/30/2019,11/16/2018,16-Nov-18,NCT03636490,Not Applicable,NA,Interventional,211,Recruiting,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Prospective, Randomized, Open-Label, Active-Comparator, Blinded-Endpoint, 12-week Forced-Titration Study of the Efficacy and Safety of Nebivolol Verses Metoprolol in Hypertensive Subjects Taking Amlodipine",8/17/2018,8/31/2018,8/30/2010,30-Aug-10,NCT03635125,Phase 4,NA,Interventional,40,Completed,1,FALSE,Other,Other,"Drug, Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Perioperative Blood Pressure Screening to Improve Long-term Cardiovascular Health,8/16/2018,1/31/2019,8/31/2018,31-Aug-18,NCT03634813,Phase 2,NA,Interventional,60,Recruiting,1,FALSE,Other,Other,"Device, Procedure",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc),8/14/2018,4/30/2019,7/31/2018,31-Jul-18,NCT03630211,Phase 2,NA,Interventional,8,Recruiting,3,TRUE,Other,Other,"Drug, Drug, Drug, Drug, Drug, Drug, Drug, Radiation",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Bingocize: A Novel Mobile Application to Help Maintain or Improve Older Adults' Health, Function, and Cognition",8/14/2018,10/31/2018,8/14/2018,14-Aug-18,NCT03629912,Not Applicable,NA,Interventional,160,Recruiting,4,TRUE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Accuracy of Non-invasive Non-oscillometric Blood Pressure Wristband,8/14/2018,4/30/2019,4/1/2019,1-Apr-19,NCT03629535,Not Applicable,NA,Interventional,15,Recruiting,1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Randomized, Active-Control Study to Determine the Effect of Mindfulness-Based Stress Reduction on Sympathetic Activity and Arterial Stiffness",8/13/2018,11/30/2018,9/4/2018,4-Sep-18,NCT03626363,Not Applicable,NA,Interventional,60,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Mechanical Ventilation Guided By Transpulmonary and Airway Driving Pressures in the Setting of Intra-abdominal Hypertension,8/10/2018,4/30/2019,3/13/2018,13-Mar-18,NCT03624491,Not Applicable,NA,Interventional,50,Enrolling by invitation,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study,8/6/2018,1/31/2020,11/1/2018,1-Nov-18,NCT03617302,Early Phase 1,NA,Interventional,18,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Innovation in Postpartum Care for Women With Hypertensive Disorders of Pregnancy: A Randomized Trial of Home- Versus Office-Based Blood Pressure Monitoring,8/3/2018,10/31/2019,9/1/2018,1-Sep-18,NCT03613714,Not Applicable,NA,Interventional,100,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Response of the Gut Microbiome and Circulating Metabolome to Diet Intervention in Young Children: Ancillary Study to the Keeping Ideal Cardiovascular Health Family Intervention Trial (KIDFIT),8/2/2018,10/31/2019,7/10/2018,10-Jul-18,NCT03612479,Not Applicable,NA,Interventional,112,Enrolling by invitation,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management,8/2/2018,10/31/2019,3/1/2019,1-Mar-19,NCT03612271,Not Applicable,NA,Interventional,450,Recruiting,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Role of Acumen Hypotension Prediction Index Software in Hypotension Management During Moderate to High-Risk Noncardiac Surgery: A Pilot Randomized Control Trial,8/1/2018,9/30/2019,7/12/2018,12-Jul-18,NCT03610165,Not Applicable,NA,Interventional,213,"Active, not recruiting",1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Cardiovascular Effects of Angiotensin 1-7 in Obesity Hypertension,7/27/2018,1/31/2020,4/1/2019,1-Apr-19,NCT03604289,Early Phase 1,NA,Interventional,24,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome,7/27/2018,7/31/2018,5/7/2018,7-May-18,NCT03604198,Phase 2,NA,Interventional,75,Recruiting,2,TRUE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Cardiovascular Effects of High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MCT),7/26/2018,4/30/2019,3/30/2017,30-Mar-17,NCT03602170,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Short Message Service System for Patients With Uncontrolled Hypertension,7/23/2018,11/30/2019,3/31/2020,Mar-20,NCT03596242,Not Applicable,NA,Interventional,20,Not yet recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Rice Vinegar as an Intervention to Lower Blood Pressure in Adults With Prehypertension and 10-year CVD Risk <10%,7/23/2018,7/31/2019,9/11/2018,11-Sep-18,NCT03596099,Not Applicable,NA,Interventional,130,"Active, not recruiting",2,TRUE,Industry,Industry,"Dietary Supplement, Dietary Supplement",other,other,FALSE,12,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily?,7/23/2018,3/31/2019,9/15/2018,15-Sep-18,NCT03595982,Phase 4,NA,Interventional,20,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,5,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Virtual Visits at Brigham and Women's Hospital: A Randomized Controlled Trial,7/19/2018,8/31/2019,4/13/2018,13-Apr-18,NCT03592355,Not Applicable,NA,Interventional,200,Enrolling by invitation,1,FALSE,Other,Other,Other,other,other,FALSE,3,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Modulating Celecoxib Induced Blood Pressure Changes by Timed Administration of Aspirin and the Human Chronobiome,7/18/2018,1/31/2020,11/30/2020,Nov-20,NCT03590821,Early Phase 1,NA,Interventional,60,Not yet recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Central & Peripheral Blood Flow Regulations in Individuals With Down Syndrome,7/18/2018,7/31/2019,3/1/2018,1-Mar-18,NCT03590665,Not Applicable,NA,Interventional,21,Terminated,1,FALSE,NIH,Public,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Assess the Accuracy of Transtek TMB-1591-A-002 Blood Pressure Monitor in Conformance With the ANSI/AAMI ISO 81060-2 Standard,7/17/2018,7/31/2018,5/30/2017,30-May-17,NCT03588559,Not Applicable,NA,Interventional,88,Completed,1,FALSE,Industry,Industry,Diagnostic Test,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Daily Intake of Cocoa Flavanols and Arterial Stiffness in Humans,7/16/2018,3/31/2019,3/23/2018,23-Mar-18,NCT03587883,Not Applicable,NA,Interventional,30,Recruiting,1,FALSE,Industry,Industry,"Other, Other, Other, Other",other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Adiposity and Endothelin Receptor Function,7/12/2018,10/31/2019,5/21/2018,21-May-18,NCT03583866,Early Phase 1,NA,Interventional,200,Recruiting,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Interactive Technology Enhanced Coaching Intervention for Black Women With Hypertension,7/5/2018,12/31/2019,1/28/2019,28-Jan-19,NCT03577990,Not Applicable,NA,Interventional,90,"Active, not recruiting",1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Treatment of Delayed Pulmonary Transition in Extremely Preterm Infants & Bronchopulmonary Dysplasia,7/3/2018,8/31/2019,7/15/2019,15-Jul-19,NCT03576885,Phase 1/Phase 2,NA,Interventional,138,Recruiting,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,30,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus,6/27/2018,7/31/2019,7/8/2019,8-Jul-19,NCT03570632,Phase 4,NA,Interventional,60,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Dietary Approaches to Stop Hypertension (DASH) Diet Effects on Serum Uric Acid (SUA) in Adults With Hyperuricemia and Gout,6/26/2018,11/30/2019,8/7/2018,7-Aug-18,NCT03569020,Not Applicable,NA,Interventional,43,Completed,2,TRUE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of Dietary Salt on Post-exercise Hypotension,6/21/2018,9/30/2019,5/1/2018,1-May-18,NCT03565653,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Acute Dietary Sodium on Cerebrovascular Reactivity and Blood Pressure Reactivity,6/20/2018,9/30/2019,5/1/2018,1-May-18,NCT03564262,Not Applicable,NA,Interventional,25,Recruiting,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Enhancing Systems of Care to Improve Hypertension Guideline Implementation to Communities With Health Disparities,6/20/2018,2/28/2019,2/28/2019,Feb-19,NCT03563872,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,African American,Race-specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of Acute Mild Dehydration on Blood Pressure Control,6/18/2018,9/30/2019,8/8/2017,8-Aug-17,NCT03560869,Not Applicable,NA,Interventional,19,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Sleep and Circadian Mechanisms Contributing to Disparity in Prevalence of Hypertension Between Black and White Americans,6/15/2018,10/31/2019,12/1/2018,1-Dec-18,NCT03558893,Not Applicable,NA,Interventional,52,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Vascular Responses to Sympathetic Activation and Altered Shear Rate: The Impact of Hypertension and Sodium Intake,6/15/2018,6/30/2019,5/15/2018,15-May-18,NCT03558022,Not Applicable,NA,Interventional,80,Recruiting,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Heat Therapy Versus Exercise Training in Hypertension,6/15/2018,11/30/2019,12/31/2019,Dec-19,NCT03557502,Not Applicable,NA,Interventional,50,Not yet recruiting,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Furosemide for Accelerated Recovery of Blood Pressure Postpartum,6/14/2018,6/30/2019,6/20/2018,20-Jun-18,NCT03556761,Phase 2,NA,Interventional,385,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Clinical Evaluation of the Serenity River Stent System to Treat Idiopathic Intracranial Hypertension,6/14/2018,11/30/2018,8/24/2018,24-Aug-18,NCT03556085,Not Applicable,NA,Interventional,39,Recruiting,3,TRUE,Industry,Industry,Device,Device,Device,FALSE,7,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of Occupational Therapy in Promoting Medication Adherence: A Randomized Control Trial,6/11/2018,6/30/2019,7/1/2018,1-Jul-18,NCT03551925,Not Applicable,NA,Interventional,32,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,1,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effects of Simulated Passive Jogging Device on Glucose Homeostasis, Muscle Strength and Endurance",6/8/2018,4/30/2019,6/5/2018,5-Jun-18,NCT03550105,Not Applicable,NA,Interventional,24,Completed,1,FALSE,Industry,Industry,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Taekwondo Training Reduces Blood Catecholamine Levels and Arterial Stiffness in Postmenopausal Women With Stage-2 Hypertension,6/1/2018,6/30/2019,5/1/2017,1-May-17,NCT03544307,Not Applicable,NA,Interventional,20,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome,5/31/2018,12/31/2019,9/19/2018,19-Sep-18,NCT03542240,Not Applicable,NA,Interventional,50,Recruiting,1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Impact of Blood Flow Restriction (BFR) on Exercise and Hemodynamic Responses,5/30/2018,7/31/2019,1/26/2018,26-Jan-18,NCT03540147,Not Applicable,NA,Interventional,38,Completed,1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,6,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Dietary Approaches to Stop Hypertension Eating Pattern on Cardiometabolic Markers in Advanced Heart Failure Patients,5/29/2018,11/30/2018,11/15/2018,15-Nov-18,NCT03538990,Not Applicable,NA,Interventional,36,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Safety and Efficacy of Splenic Artery Embolization to Treat Symptomatic Portal,5/22/2018,10/31/2019,11/1/2018,1-Nov-18,NCT03532750,Not Applicable,NA,Interventional,30,Recruiting,1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
MyLife: A Digital Health Coaching Program Encouraging Healthy Behaviors in Patients at Risk for Lifestyle-related Chronic Diseases,5/18/2018,12/31/2019,8/10/2018,10-Aug-18,NCT03529903,Not Applicable,NA,Interventional,100,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,7,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Dietary Approaches for Improving Cardiometabolic Health,5/17/2018,10/31/2018,1/15/2018,15-Jan-18,NCT03527290,Not Applicable,NA,Interventional,30,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects,5/14/2018,4/30/2019,3/18/2019,18-Mar-19,NCT03522935,Phase 1,NA,Interventional,30,Recruiting,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Feasibility of Home Telehealth Monitoring for Improvement in Management of Hypertension for Secondary Stroke Prevention,5/7/2018,5/31/2019,12/20/2016,20-Dec-16,NCT03517709,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Other, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Retail Outlet Health Kiosk Hypertension Trial,5/3/2018,5/31/2019,3/6/2019,6-Mar-19,NCT03515681,Not Applicable,NA,Interventional,140,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Using Lay Health Advisors to Help African Americans Address the Social Context of Hypertension Management,5/3/2018,2/28/2019,12/3/2018,3-Dec-18,NCT03515005,Not Applicable,NA,Interventional,312,Enrolling by invitation,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,18,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Respiratory Muscle Contribution to Blood Pressure During Exercise in Healthy Humans,5/2/2018,11/30/2019,8/1/2018,1-Aug-18,NCT03514823,Not Applicable,NA,Interventional,80,Recruiting,1,FALSE,NIH,Public,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin Tablets, 20 mg, for the Management of Essential Hypertension",5/2/2018,9/30/2019,10/18/2017,18-Oct-17,NCT03514641,Phase 2/Phase 3,NA,Interventional,678,Completed,87,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Autonomic Control of the Circulation and the Venous Distension Reflex,5/2/2018,7/31/2019,7/12/2017,12-Jul-17,NCT03513770,Early Phase 1,NA,Interventional,18,Recruiting,1,FALSE,Other,Other,"Other, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin Inhibition,4/26/2018,7/31/2019,6/1/2018,1-Jun-18,NCT03508739,Phase 3,NA,Interventional,25,Suspended,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Ethnic Differences in Anti-Hypertensive Medication Response Among Pregnant and Postpartum Patients,4/24/2018,6/30/2019,9/11/2017,11-Sep-17,NCT03506724,Phase 4,NA,Interventional,109,Completed,2,TRUE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Venous Distension Reflex and Orthostatic Hypertension,4/12/2018,4/30/2019,12/11/2017,11-Dec-17,NCT03496792,Not Applicable,NA,Interventional,30,Recruiting,1,FALSE,Other,Other,"Other, Other, Other, Other",other,other,FALSE,6,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Prospective, Double-blind, Randomized, Placebo-controlled Trial of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography",4/6/2018,4/30/2019,3/23/2018,23-Mar-18,NCT03490916,Phase 4,NA,Interventional,18,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy,4/3/2018,1/31/2020,7/20/2018,20-Jul-18,NCT03487185,Not Applicable,NA,Interventional,2700,Recruiting,12,TRUE,NIH,Public,"Device, Other",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Nitrate-rich Fruit and Vegetable Supplement and Blood Pressure in Normotensive Healthy Young Males: a Randomized, Double-blinded, Placebo-controlled Trial",4/3/2018,3/31/2018,11/16/2015,16-Nov-15,NCT03486145,Not Applicable,NA,Interventional,57,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Role of Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclamptic Pregnancy,3/29/2018,9/30/2019,8/26/2018,26-Aug-18,NCT03482440,Early Phase 1,NA,Interventional,32,Recruiting,2,TRUE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment,3/29/2018,2/28/2019,12/1/2018,1-Dec-18,NCT03482167,Phase 1/Phase 2,NA,Interventional,58,Recruiting,1,FALSE,NIH,Public,"Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Assessing the Effectiveness of a Multifaceted Implementation Strategy to Increase the Uptake of the USPSTF Hypertension Screening Recommendations in an Ambulatory Care Network: a Cluster Randomized Trial,3/29/2018,6/30/2019,4/2/2018,2-Apr-18,NCT03480217,Not Applicable,NA,Interventional,2000,Recruiting,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,FALSE,3,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"High-Resolution, Relational, Resonance-Based, Electroencephalic Mirroring (HIRREM) for Stage 1 Primary Hypertension",3/27/2018,8/31/2019,8/8/2018,8-Aug-18,NCT03479697,Not Applicable,NA,Interventional,24,Recruiting,1,FALSE,Other,Other,"Device, Other",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Targeting ADMA With Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients,3/20/2018,4/30/2018,4/1/2018,1-Apr-18,NCT03471117,Phase 4,NA,Interventional,28,Recruiting,2,TRUE,Other,Other,"Drug, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit in the Hypertensive Non-Diabetic Population,3/20/2018,7/31/2018,3/19/2018,19-Mar-18,NCT03470701,Not Applicable,NA,Interventional,999,Completed,1,FALSE,Industry,Industry,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Effects of Mental Stress and Diesel Exhaust on Cardiovascular Health,3/16/2018,11/30/2018,3/22/2018,22-Mar-18,NCT03467997,Not Applicable,NA,Interventional,22,Recruiting,1,FALSE,NIH,Public,"Behavioral, Other",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Physiological Study of the Efficacy and Mechanistic Effects of Alcohol Renal Denervation,3/14/2018,4/30/2019,3/1/2018,1-Mar-18,NCT03465917,Early Phase 1,NA,Interventional,5,"Active, not recruiting",1,FALSE,NIH,Public,Combination Product,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 1, Single-center, Open-label, Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder (TrIP) in Healthy Normal Volunteers",3/14/2018,10/31/2018,3/9/2018,9-Mar-18,NCT03464864,Phase 1,NA,Interventional,36,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Industry Sponsor,Non-Race Specific
A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension,3/9/2018,10/31/2018,4/2/2018,2-Apr-18,NCT03461003,Phase 4,NA,Interventional,80,Recruiting,1,FALSE,Other,Other,"Other, Other, Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Sildenafil in US Heart Failure Patients (SilHF-US),3/9/2018,3/31/2018,2/14/2018,14-Feb-18,NCT03460470,Phase 3,NA,Interventional,25,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,2,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Office Blood Pressure Measurement With an Automated Device,3/9/2018,9/30/2018,4/2/2018,2-Apr-18,NCT03460249,Not Applicable,NA,Interventional,30,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
BOLD: A Trial of Blood Pressure Lowering in Dialysis,3/9/2018,7/31/2019,3/23/2018,23-Mar-18,NCT03459807,Phase 2,NA,Interventional,50,Completed,2,TRUE,Other,Other,"Drug, Procedure",Procedure,Procedure,FALSE,18,TRUE,Non-race specific,Non-race specific,2018,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Nitric Oxide Bioavailability and Dynamics of Blood Flow and Vasodilation With Age,3/8/2018,1/31/2019,10/10/2017,10-Oct-17,NCT03459027,Not Applicable,NA,Interventional,10,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Patient Centered Health Technology Medication Adherence Program for African American Hypertensives,3/5/2018,3/31/2019,4/28/2017,28-Apr-17,NCT03454308,Not Applicable,NA,Interventional,192,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Leveraging Integrated Models of Care to Improve Patient-Centered Outcomes for Publicly-Insured Adults With Complex Health Care Needs,3/2/2018,9/30/2019,4/23/2018,23-Apr-18,NCT03451630,Not Applicable,NA,Interventional,1927,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Single-Arm, Single-Center, Pilot Study To Evaluate The Feasibility And Safety Of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation For Portal Hypertension Using A Radiofrequency Guidewire With Intravascular Ultrasound Guidance",3/1/2018,4/30/2019,10/25/2017,25-Oct-17,NCT03451149,Not Applicable,NA,Interventional,10,Completed,1,FALSE,Industry,Industry,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Cooking for Health Optimization With Patients,2/23/2018,11/30/2018,2/1/2018,1-Feb-18,NCT03443635,Phase 1/Phase 2,NA,Interventional,19500,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,2,TRUE,Non-race specific,Non-race specific,2018,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Assessing the Impact of Providing Pharmacists With Medical Records in a Patient-Centered, Community Pharmacy-Based, HIV Care Model",2/19/2018,6/30/2019,8/3/2018,3-Aug-18,NCT03437694,Not Applicable,NA,Interventional,200,Recruiting,2,TRUE,Other,Other,Other,other,other,FALSE,NA,FALSE,African American,Race-specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Ultrasound Elastography Assessment of Spleen and Liver Stiffness Before and After Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure,2/9/2018,11/30/2019,10/16/2017,16-Oct-17,NCT03427164,Not Applicable,NA,Interventional,100,Recruiting,1,FALSE,Other,Other,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Non-Invasive Determination of Nitric Oxide Release by Simulated Passive Jogging & Jumping Devices,2/8/2018,4/30/2019,3/1/2017,1-Mar-17,NCT03426774,Not Applicable,NA,Interventional,22,Completed,1,FALSE,Industry,Industry,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Vascular Effects of Dietary Salt in Humans With Salt-Resistant Blood Pressure: Dietary Counseling Study,2/7/2018,4/30/2019,1/21/2018,21-Jan-18,NCT03424993,Phase 4,NA,Interventional,125,Recruiting,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Phase II Study of Nicotinamide in Early Onset Preeclampsia,2/1/2018,2/28/2019,11/1/2017,1-Nov-17,NCT03419364,Phase 2,NA,Interventional,25,Recruiting,1,FALSE,NIH,Public,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Remote Monitoring and Enhanced Social Support for Hypertension Management,1/31/2018,1/31/2020,5/20/2018,20-May-18,NCT03416283,Not Applicable,NA,Interventional,250,"Active, not recruiting",1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Multi-center ESG Randomized Interventional Trial (MERIT-Trial),1/23/2018,9/30/2019,12/20/2017,20-Dec-17,NCT03406975,Not Applicable,NA,Interventional,200,"Active, not recruiting",9,TRUE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Automated Clinical-Decision Support to Improve Hypertension Care Among Overweight Children in Primary Care,1/19/2018,2/28/2019,8/21/2017,21-Aug-17,NCT03404999,Not Applicable,NA,Interventional,5000,Enrolling by invitation,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Peripheral Nerve Blocks for Upper Leg Amputations,1/19/2018,7/31/2019,2/9/2018,9-Feb-18,NCT03404180,Phase 4,NA,Interventional,36,Recruiting,1,FALSE,U.S. Fed,Public,"Procedure, Drug, Procedure, Procedure",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor,1/17/2018,11/30/2019,12/31/2019,Dec-19,NCT03401489,Not Applicable,NA,Interventional,200,Not yet recruiting,3,TRUE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Tailored Drug Titration Through Artificial Intelligence: an Interventional Study,1/12/2018,9/30/2019,10/1/2018,1-Oct-18,NCT03397524,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Industry,Industry,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension,1/4/2018,11/30/2019,5/3/2018,3-May-18,NCT03390426,Phase 4,NA,Interventional,31,Completed,1,FALSE,Other,Other,"Drug, Procedure, Drug",Procedure,Procedure,TRUE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Heart-Related Multiple Chronic Conditions in Primary Care: Behavioral Technology,1/2/2018,1/31/2020,1/1/2018,1-Jan-18,NCT03387735,Not Applicable,NA,Interventional,346,"Active, not recruiting",1,FALSE,NIH,Public,"Other, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2018,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Acute Blood Pressure-lowering Effects of Beetroot Juice in Postmenopausal Women With and Without Hypertension,12/20/2017,10/31/2019,9/12/2014,12-Sep-14,NCT03380000,Phase 2,NA,Interventional,24,"Active, not recruiting",1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Cheese Consumption and Human Microvascular Function,12/18/2017,10/31/2019,3/31/2016,Mar-16,NCT03376555,Phase 1/Phase 2,NA,Interventional,15,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
COmmuNity-engaged SimULation Training for Blood Pressure Control,12/18/2017,9/30/2019,8/13/2018,13-Aug-18,NCT03375918,Not Applicable,NA,Interventional,205,Recruiting,5,TRUE,NIH,Public,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Losartan and ET-1 Mediated Constriction in Postmenopausal Women With High Blood Pressure,12/13/2017,1/31/2020,9/1/2017,1-Sep-17,NCT03371823,Phase 4,NA,Interventional,8,Terminated,1,FALSE,NIH,Public,"Other, Drug",Drug,Pharmaceutical,FALSE,24,TRUE,Non-race specific,Non-race specific,2017,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Blueberry Consumption for Improving Vascular Endothelial Dysfunction in Postmenopausal Women With Elevated Blood Pressure and Stage 1-Hypertension,12/13/2017,1/31/2020,12/2/2017,2-Dec-17,NCT03370991,Phase 2/Phase 3,NA,Interventional,58,Recruiting,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Pre-medication With Alfentanil on Hemodynamics During and Immediately Following Electroconvulsive Therapy (ECT),12/2/2017,6/30/2019,6/4/2018,4-Jun-18,NCT03359395,Phase 4,NA,Interventional,240,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness,11/24/2017,9/30/2019,8/31/2016,Aug-16,NCT03352882,Not Applicable,NA,Interventional,1,Terminated,1,FALSE,NIH,Public,Diagnostic Test,other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Peripheral Laser Iridotomy Placement on Post-operative Visual Function,11/24/2017,11/30/2018,1/1/2018,1-Jan-18,NCT03352492,Not Applicable,NA,Interventional,200,Recruiting,1,FALSE,Other,Other,"Procedure, Procedure",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Personal Mobile and Contextual Precision Health,11/22/2017,3/31/2019,11/6/2017,6-Nov-17,NCT03349918,Not Applicable,NA,Interventional,164,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Combined Diet & Exercise Intervention on Cardiovascular Risk Factors in Volunteer Firefighters & Non-Firefighters,11/17/2017,12/31/2018,11/25/2018,25-Nov-18,NCT03344198,Not Applicable,NA,Interventional,125,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis,11/1/2017,9/30/2019,7/16/2018,16-Jul-18,NCT03327909,Not Applicable,NA,Interventional,500,Enrolling by invitation,2,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
ACtivity Trackers to ImproVe Blood Pressure: a Pilot Study,10/30/2017,12/31/2019,6/1/2017,1-Jun-17,NCT03325426,Not Applicable,NA,Interventional,75,Recruiting,1,FALSE,Other,Other,Device,Device,Device,FALSE,15,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Take a Deep Breath: Randomized Controlled Trial of the Effects of Breathing Exercises on Blood Pressure,10/25/2017,10/31/2017,8/1/2016,1-Aug-16,NCT03320577,Not Applicable,NA,Interventional,103,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Changes in Peripapillary Blood Flow After Use of Anti-glaucoma Medications: A Prospective, Quantitative OCT Angiography Study",10/26/2017,7/31/2019,7/10/2017,10-Jul-17,NCT03323164,Phase 4,NA,Interventional,31,"Active, not recruiting",1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Industry Sponsor,Non-Race Specific
A Pilot Study: Treating Nocturnal Hypertension and Nocturia in African American Men,10/24/2017,1/31/2020,10/25/2017,25-Oct-17,NCT03319823,Phase 4,NA,Interventional,20,"Active, not recruiting",1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,African American,Race-specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Reducing Sedentary Behavior on Blood Pressure,10/11/2017,11/30/2019,1/3/2018,3-Jan-18,NCT03307343,Not Applicable,NA,Interventional,300,Recruiting,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
24-hour Blood Pressure Measurements and Ischemic Conditioning,10/6/2017,10/31/2018,9/12/2017,12-Sep-17,NCT03303404,Not Applicable,NA,Interventional,30,Completed,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Using Intradialytic Systolic Blood Pressure Slopes to Guide Ultrafiltration in Hemodialysis Patients: A Validation Study and Clinical Trial,10/6/2017,9/30/2019,11/1/2017,1-Nov-17,NCT03303391,Not Applicable,NA,Interventional,74,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis,10/4/2017,1/31/2019,3/12/2018,12-Mar-18,NCT03301740,Not Applicable,NA,Interventional,34,Completed,2,TRUE,NIH,Public,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide: a Randomized Clinical Trial,10/2/2017,1/31/2019,11/21/2017,21-Nov-17,NCT03298802,Phase 3,NA,Interventional,612,Recruiting,2,TRUE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension,9/28/2017,11/30/2019,5/29/2018,29-May-18,NCT03295734,Phase 2,NA,Interventional,213,Recruiting,3,TRUE,Other,Other,"Behavioral, Drug, Drug, Drug",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Virtual Hypertension Management Pilot: Randomized Evaluation of Electronic Health Record-connected Blood Pressure Cuffs in a Clinical Pharmacist Panel.,9/25/2017,9/30/2019,7/26/2017,26-Jul-17,NCT03291535,Not Applicable,NA,Interventional,96,Recruiting,2,TRUE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Hypertension Using a Smartphone-Enabled Personal Control Program: The Smart Hypertension Control Study,9/19/2017,9/30/2019,9/21/2017,21-Sep-17,NCT03288142,Not Applicable,NA,Interventional,333,"Active, not recruiting",1,FALSE,Industry,Industry,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of Lasmiditan on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Propranolol,9/1/2017,12/31/2019,8/31/2017,31-Aug-17,NCT03270644,Phase 1,NA,Interventional,44,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function,8/30/2017,5/31/2019,11/25/2017,25-Nov-17,NCT03266510,Not Applicable,NA,Interventional,46,Recruiting,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Mindfulness-Based Blood Pressure Reduction: Stage 2a Randomized Controlled Trial,8/22/2017,10/31/2017,6/13/2017,13-Jun-17,NCT03256890,Not Applicable,NA,Interventional,100,Recruiting,1,FALSE,NIH,Public,"Behavioral, Other",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
HELP-HY: Health Education and sLeep Program in HYpertension,8/21/2017,10/31/2019,4/19/2018,19-Apr-18,NCT03255746,Not Applicable,NA,Interventional,94,Recruiting,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Food Resource Equity and Sustainability for Health,8/16/2017,3/31/2019,8/22/2017,22-Aug-17,NCT03251950,Not Applicable,NA,Interventional,522,Completed,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Influence of Mechanical Ventilation Mode on Arterial Pressure Variations- a Pilot Study,8/11/2017,8/31/2017,9/12/2016,12-Sep-16,NCT03246425,Not Applicable,Recruiting,Interventional,60,Unknown status,1,FALSE,Other,Other,"Other, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Use of Impedance Cardiography to Decrease the Risk of Preeclampsia,8/10/2017,2/28/2019,4/24/2017,24-Apr-17,NCT03245970,Early Phase 1,NA,Interventional,400,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound,8/10/2017,7/31/2019,12/4/2017,4-Dec-17,NCT03245255,Phase 2,NA,Interventional,80,Recruiting,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,10,TRUE,Non-race specific,Non-race specific,2017,1,Drug Intervention,Industry Sponsor,Non-Race Specific
"Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement",8/9/2017,7/31/2019,6/1/2017,1-Jun-17,NCT03243942,Phase 2,NA,Interventional,56,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,10,TRUE,Non-race specific,Non-race specific,2017,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate,7/31/2017,4/30/2019,10/16/2017,16-Oct-17,NCT03234361,Not Applicable,NA,Interventional,114,Recruiting,3,TRUE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,7,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effects of Chia Seed Consumption on Body Composition, Blood Pressure, Blood Glucose, Satiety, Diet Displacement, Joint Pain, Mood and Serotonin Levels in Young, Healthy, Overweight/Obese Females",7/31/2017,5/31/2018,5/20/2017,20-May-17,NCT03233906,Not Applicable,NA,Interventional,60,"Active, not recruiting",1,FALSE,Other,Other,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Diet on Pregnancy Outcome and Child Obesity,7/28/2017,11/30/2019,10/3/2017,3-Oct-17,NCT03232762,Not Applicable,NA,Interventional,303,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Self-management of Blood Pressure Medication for Hypertensive Veterans,7/21/2017,10/31/2019,2/21/2018,21-Feb-18,NCT03224624,Not Applicable,NA,Interventional,400,Recruiting,2,TRUE,U.S. Fed,Public,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Stress Management to Support Women's Health,7/21/2017,8/31/2019,5/7/2018,7-May-18,NCT03223545,Not Applicable,NA,Interventional,132,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Mechanisms of Refractory Hypertension (Reserpine),7/21/2017,6/30/2019,7/23/2015,23-Jul-15,NCT03223272,Phase 2,NA,Interventional,100,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Non-invasive Versus Invasive Blood Pressure Measurement in the Morbidly Obese Parturient (BMI >= 40 kg/m2) With Severe Preeclampsia: A Comparison of Direct Arterial Blood Pressure Measurements With Readings Obtained Using Either Large Cylindrical or Novel Conical Bariatric Upper Arm Blood Pressure Cuffs,7/19/2017,12/31/2019,5/1/2015,1-May-15,NCT03222414,Not Applicable,NA,Interventional,3,Terminated,1,FALSE,Other,Other,"Device, Device, Other",Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
DASH Cloud: Using Digital Health to Improve Adherence to the DASH Diet Among Women at Risk for Cardiovascular Disease,7/12/2017,3/31/2018,7/21/2017,21-Jul-17,NCT03215472,Not Applicable,NA,Interventional,59,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Fit After Baby: A Randomized Controlled Trial of a Mobile Health Intervention to Increase Postpartum Weight Loss in Women at Increased Risk for Cardiometabolic Disease,7/12/2017,1/31/2020,9/1/2017,1-Sep-17,NCT03215173,Not Applicable,NA,Interventional,120,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Assessment of the Clinical Efficacy of a Non-Invasive Measurement of Intracranial Pressure by Magnetic Resonance Phase Contrast Imaging,7/11/2017,10/31/2019,10/26/2017,26-Oct-17,NCT03212976,Not Applicable,NA,Interventional,30,Recruiting,2,TRUE,Other,Other,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
HealthMatters@24/7 Asynchronous Health Promotion eLearning for People Supporting Adults With Intellectual and Developmental Disabilities,7/2/2017,10/31/2019,6/1/2017,1-Jun-17,NCT03206164,Not Applicable,NA,Interventional,60,"Active, not recruiting",1,FALSE,Other,Other,Other,other,other,FALSE,9,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma,7/2/2017,1/8/2020,10/10/2017,10-Oct-17,NCT03206060,Phase 2,NA,Interventional,90,Recruiting,1,FALSE,NIH,Public,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,3,TRUE,Non-race specific,Non-race specific,2017,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 2, Open-Label, Dose-Titrating Safety and Efficacy Study of QGC001 Administered Orally, Twice Daily, Over 8 Weeks in Hypertensive Overweight Subjects of Multiple Ethnic and Racial Groups in the United States",6/26/2017,12/31/2018,10/13/2017,13-Oct-17,NCT03198793,Phase 2,NA,Interventional,256,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Impact of Energy Drink Brands on Heart Rhythm in Healthy Volunteers: A Randomized Controlled Trial,6/23/2017,12/31/2018,7/1/2017,1-Jul-17,NCT03196908,Not Applicable,NA,Interventional,40,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Perioperative Clinical Utilization of Somatic Tissue Oxygen Saturation Monitoring in Pregnant Women,6/22/2017,7/31/2019,10/1/2018,1-Oct-18,NCT03196141,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,Diagnostic Test,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Remote Surveillance of Postpartum Hypertension,6/14/2017,3/31/2019,8/22/2016,22-Aug-16,NCT03185455,Not Applicable,NA,Interventional,206,Completed,1,FALSE,Other,Other,Other,other,other,TRUE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Prospective, Randomized, Open-Label, 13 to 14-week Study of the Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Subjects With Left Ventricular Hypertrophy (LVH)",6/8/2017,4/30/2018,2/7/2017,7-Feb-17,NCT03180593,Phase 4,NA,Interventional,30,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvascular Function and Vessel Remodeling in Hypertensive Humans,6/7/2017,10/31/2019,7/20/2016,20-Jul-16,NCT03179163,Phase 1/Phase 2,NA,Interventional,70,Recruiting,1,FALSE,NIH,Public,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets",6/6/2017,6/30/2017,12/7/2015,7-Dec-15,NCT03178396,Not Applicable,NA,Interventional,31,Completed,1,FALSE,NIH,Public,Dietary Supplement,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Randomized Controlled Trial of Nitric-oxide Donor (NOD) Isosorbide Mononitrate (IMN) Versus Placebo for Induction of Labor in Pregnancies Complicated by Preeclampsia,5/31/2017,4/30/2018,10/30/2017,30-Oct-17,NCT03171480,Not Applicable,NA,Interventional,400,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,6,TRUE,Non-race specific,Non-race specific,2017,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome,5/31/2017,11/30/2019,1/2/2019,2-Jan-19,NCT03170375,Not Applicable,NA,Interventional,130,Recruiting,1,FALSE,U.S. Fed,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Smartphone Delivered Meditation for BP Control Among Prehypertensives,5/30/2017,1/31/2020,10/1/2016,1-Oct-16,NCT03168789,Not Applicable,NA,Interventional,80,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Positive Predictive Value of Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease: A Single Center, Prospective Clinical Trial",5/19/2017,11/30/2018,7/15/2017,15-Jul-17,NCT03161327,Not Applicable,NA,Interventional,238,Completed,1,FALSE,Other,Other,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The MyHEART Study: A Young Adult Hypertension Self-Management Randomized Controlled Trial,5/17/2017,8/31/2019,10/2/2017,2-Oct-17,NCT03158051,Not Applicable,NA,Interventional,310,Recruiting,2,TRUE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,1,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires,5/15/2017,10/3/2019,8/2/2017,2-Aug-17,NCT03152773,Phase 1/Phase 2,NA,Interventional,100,Recruiting,1,FALSE,NIH,Public,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Dialysate Sodium Lowering Trial,5/9/2017,5/31/2019,4/26/2017,26-Apr-17,NCT03144817,Phase 2,NA,Interventional,44,Completed,1,FALSE,Industry,Industry,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Controlling Hypertension in Native American and Other Populations,5/1/2017,5/31/2019,4/11/2017,11-Apr-17,NCT03135405,Not Applicable,NA,Interventional,295,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A 4-week Defined, Raw, Plant-based Diet Improves Anthropometric, Hemodynamic, and Other Cardiovascular Risk Factors",4/28/2017,5/31/2017,1/3/2017,3-Jan-17,NCT03134235,Not Applicable,NA,Interventional,33,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,15,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK),4/26/2017,4/30/2019,5/11/2017,11-May-17,NCT03130257,Not Applicable,NA,Interventional,510,"Active, not recruiting",1,FALSE,Other,Other,Diagnostic Test,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Oral Midodrine Hydrochloride in Early Sepsis: Randomized, Double Blind and Placebo-Controlled Feasibility Study",4/26/2017,10/31/2019,8/30/2017,30-Aug-17,NCT03129542,Phase 1,NA,Interventional,36,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Two-Part Pharmacodynamic Study to Compare VentaProst (Epoprostenol Solution for Inhalation Via Custom Drug Delivery System) Dosing to Conventionally Administered Aerosolized Epoprostenol Dosing in Cardiac Surgery Patients,4/21/2017,5/31/2019,8/23/2017,23-Aug-17,NCT03122730,Phase 2,NA,Interventional,15,Completed,3,TRUE,Industry,Industry,Combination Product,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Should Ambulatory Surgery and Day of Surgery Admission Patients Discontinue Angiotensin Converting Enzyme Inhibitors (ACEI's) and Angiotension Receptor Blockers (ARB's) Preoperatively?,4/19/2017,4/30/2017,5/16/2012,16-May-12,NCT03121092,Not Applicable,NA,Interventional,188,Terminated,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,1,TRUE,Non-race specific,Non-race specific,2017,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Postexercise Central Blood Pressure and Hemodynamic Response After Continuous and Aerobic Interval Exercise,4/18/2017,10/31/2017,3/27/2017,27-Mar-17,NCT03118700,Not Applicable,NA,Interventional,5,Terminated,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Potatoes, Hypertension RIsk and Endothelial Function Study",4/17/2017,1/31/2019,2/15/2018,15-Feb-18,NCT03116919,Not Applicable,NA,Interventional,90,Recruiting,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Feasibility of a Web-based Application to Monitor Home Blood Pressure,4/17/2017,11/30/2018,5/16/2017,16-May-17,NCT03116815,Not Applicable,NA,Interventional,20,"Active, not recruiting",1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function,4/14/2017,7/31/2017,6/30/2009,Jun-09,NCT03115853,Phase 4,NA,Interventional,31,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Remote Patient Monitoring- Telehealth for Management of Women With Postpartum Hypertension,4/12/2017,4/30/2019,4/1/2017,1-Apr-17,NCT03111095,Not Applicable,NA,Interventional,430,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System,4/12/2017,2/28/2019,4/10/2017,10-Apr-17,NCT03109795,Phase 4,NA,Interventional,30,"Active, not recruiting",1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,64,TRUE,Non-race specific,Non-race specific,2017,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Use of Impedance Cardiography to Decrease the Risk of Preeclampsia in Obese Patients,4/10/2017,2/28/2019,4/4/2017,4-Apr-17,NCT03105661,Early Phase 1,NA,Interventional,400,Recruiting,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Communicating Health Information and Improving Coordination With Primary Care - an Ancillary Study of the Childhood Cancer Survivor Study,4/7/2017,4/30/2019,3/1/2017,1-Mar-17,NCT03104543,Not Applicable,NA,Interventional,650,Enrolling by invitation,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Location-based Tailored Messaging to Reduce Sodium Intake in Hypertensive Patients,4/4/2017,6/30/2019,9/21/2017,21-Sep-17,NCT03099343,Not Applicable,NA,Interventional,50,Completed,1,FALSE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluating Raised Intracranial Pressure Using MR Elastography,3/30/2017,5/31/2019,1/10/2017,10-Jan-17,NCT03096743,Not Applicable,NA,Interventional,100,Recruiting,1,FALSE,Other,Other,"Radiation, Radiation, Procedure, Other, Radiation",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 2 Study to Compare the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 2 Dose Regimens of IW-1973 in Patients With Stable Type 2 Diabetes and Hypertension",3/27/2017,4/30/2019,2/28/2017,28-Feb-17,NCT03091920,Phase 2,NA,Interventional,26,Completed,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Industry Sponsor,Non-Race Specific
"Particulate Matter, Blood Pressure, and the Sympathetic Nervous System: Impact of Near-roadway Exposures and N-95 Facemasks",3/15/2017,4/30/2019,4/7/2017,7-Apr-17,NCT03079843,Not Applicable,NA,Interventional,50,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise,3/8/2017,1/31/2018,1/1/2017,1-Jan-17,NCT03073252,Not Applicable,NA,Interventional,31,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Blood Pressure in Blacks and Calcium (BBC) and Vitamin D Study,3/3/2017,4/30/2019,1/8/2018,8-Jan-18,NCT03070483,Phase 2,NA,Interventional,5,Completed,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,1,TRUE,African American,Race-specific,2017,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Racial Differences in the Natriuretic Peptide Response to Exercise and Beta-blockers,3/3/2017,10/31/2019,4/30/2017,30-Apr-17,NCT03070184,Phase 2,NA,Interventional,80,Recruiting,1,FALSE,Other,Other,"Other, Dietary Supplement, Other, Drug",Drug,Pharmaceutical,FALSE,4,TRUE,Non-race specific,Non-race specific,2017,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of a Multi-Pathway Dietary Supplement (Stem Cell 100+) on Indices of Health and Life Expectancy,2/14/2017,2/28/2017,3/12/2016,12-Mar-16,NCT03052491,Not Applicable,NA,Interventional,15,Completed,1,FALSE,Industry,Industry,Dietary Supplement,other,other,FALSE,5,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
OUTPATENT VASODILATOR ASSESSMENT USING ILOPROST IN PULMONARY HYPERTENSION (The OVATION Study),2/7/2017,12/31/2018,7/21/2017,21-Jul-17,NCT03044314,Phase 4,NA,Interventional,50,Recruiting,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Mechanisms Underlying the Blood Pressure Lowering Effect of Sleep Extension,2/6/2017,8/31/2019,2/10/2017,10-Feb-17,NCT03043963,Not Applicable,NA,Interventional,188,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Treating Cognitive Deficits in Traumatic Spinal Cord Injury: A Randomized Clinical Trial,1/31/2017,8/31/2019,4/13/2017,13-Apr-17,NCT03037879,Not Applicable,NA,Interventional,104,Recruiting,1,FALSE,U.S. Fed,Public,"Other, Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent",1/24/2017,1/31/2020,7/27/2017,27-Jul-17,NCT03029247,Phase 2,NA,Interventional,62,Recruiting,11,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Using Values Affirmation to Reduce the Effects of Stereotype Threat on Hypertension Disparities: The Multicenter Randomized HYpertension and VALUEs (HYVALUE) Trial,1/23/2017,9/30/2019,1/31/2017,Jan-17,NCT03028597,Not Applicable,NA,Interventional,1130,Recruiting,3,TRUE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Retrospective Evaluation of Athens Complete Health Improvement Program (CHIP) Database,1/19/2017,10/31/2018,5/31/2011,May-11,NCT03025451,Not Applicable,NA,Interventional,512,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,5,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Prospective Randomized Controlled Trial to Compare and Analyze the Effects of Sound Masking and Reduction Techniques on Heart Rate and Blood Pressure Variability in Critically Ill Patients,1/12/2017,9/30/2019,12/31/2016,Dec-16,NCT03019133,Not Applicable,NA,Interventional,120,Recruiting,1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The PROVIDE Study; Preeclampsia Research on Vitamin D, Inflammation, & Depression",1/11/2017,1/31/2019,4/1/2017,1-Apr-17,NCT03018132,Not Applicable,NA,Interventional,200,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,56,TRUE,Non-race specific,Non-race specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans,1/10/2017,4/30/2019,10/31/2016,Oct-16,NCT03016351,Not Applicable,NA,Interventional,140,Recruiting,1,FALSE,NIH,Public,"Other, Other",other,other,FALSE,13,TRUE,African American,Race-specific,2017,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma,1/10/2017,3/31/2019,3/15/2018,15-Mar-18,NCT03016156,Not Applicable,NA,Interventional,290,Recruiting,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
An Open-Label Pilot Trial of Cognitive Behavioral Therapy in Familial Dysautonomia,1/6/2017,1/31/2019,12/6/2016,6-Dec-16,NCT03013777,Not Applicable,NA,Interventional,15,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study,1/9/2017,11/30/2019,4/1/2017,1-Apr-17,NCT03013907,Not Applicable,NA,Interventional,81,Completed,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Randomized Controlled Trial on the Effects of NSAIDs on Postpartum Blood Pressure in Patients Hypertensive Disorders of Pregnancy,1/5/2017,3/31/2018,1/31/2017,Jan-17,NCT03011567,Not Applicable,NA,Interventional,202,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia",1/2/2017,6/30/2019,4/12/2017,12-Apr-17,NCT03008616,Phase 2/Phase 3,NA,Interventional,200,Recruiting,16,TRUE,Industry,Industry,"Biological, Other",Biological,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2017,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
"Neurocognition, Lifestyle Modification, and Treatment Resistant Hypertension",12/23/2016,1/31/2020,1/31/2016,Jan-16,NCT03001427,Not Applicable,NA,Interventional,120,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,1,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure",12/21/2016,6/30/2018,11/30/2016,Nov-16,NCT02998840,Phase 2,NA,Interventional,132,Completed,10,TRUE,Industry,Industry,"Biological, Biological",Biological,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure,12/19/2016,12/31/2019,11/15/2017,15-Nov-17,NCT02996565,Not Applicable,NA,Interventional,3072,"Active, not recruiting",1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
DASH-Sodium Trial in Adolescents,12/15/2016,12/31/2017,10/31/2016,Oct-16,NCT02993458,Not Applicable,NA,Interventional,79,Terminated,2,TRUE,NIH,Public,"Other, Other, Other, Other",other,other,FALSE,12,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Facilitating Cardiovascular Risk Screening and Risk Reduction in Women Veterans (QUE 15-272),12/13/2016,1/31/2020,11/15/2016,15-Nov-16,NCT02991534,Not Applicable,NA,Interventional,260,Recruiting,4,TRUE,U.S. Fed,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Clinical Evaluation of CATS Tonometer Prism,12/12/2016,8/31/2018,1/31/2017,Jan-17,NCT02989909,Not Applicable,NA,Interventional,86,Completed,1,FALSE,Industry,Industry,"Device, Device",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia-The PROGRESS Pilot Study,12/12/2016,5/31/2019,5/22/2017,22-May-17,NCT02989025,Phase 3,NA,Interventional,60,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Prospective Randomized Controlled Trial Investigating the Use of Genetic Predisposition to Guide Pharmacologic Therapy for Hypertension,12/9/2016,3/31/2019,1/23/2017,23-Jan-17,NCT02988245,Phase 2,NA,Interventional,425,Completed,15,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Piloting Healthcare Coordination in Hypertension,12/9/2016,3/31/2019,12/31/2015,Dec-15,NCT02988193,Not Applicable,NA,Interventional,28,Completed,1,FALSE,Industry,Industry,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Genomic Outcomes of Metformin,12/8/2016,10/31/2019,8/3/2016,3-Aug-16,NCT02986659,Phase 4,NA,Interventional,34,Completed,1,FALSE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Feto-Endoscopic Tracheal Occlusion (FETO) for Left Congenital Diaphragmatic Hernia,12/8/2016,9/30/2017,11/30/2016,Nov-16,NCT02986087,Not Applicable,Recruiting,Interventional,5,Unknown status,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Evaluation and Treatment of Elevated Left-Sided Filling Pressures by Balloon Inflation Within the Interior Vena Cava,12/7/2016,4/30/2018,12/31/2016,Dec-16,NCT02984631,Not Applicable,NA,Interventional,20,Recruiting,1,FALSE,Industry,Industry,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Improving Medication Adherence in Hypertensive Individuals With Bipolar Disorder,12/6/2016,12/31/2019,3/13/2017,13-Mar-17,NCT02983877,Not Applicable,NA,Interventional,38,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Complete Health Improvement Program (CHIP) Risk Reduction/Claims Evaluation Project,11/30/2016,11/30/2019,8/31/2012,Aug-12,NCT02977884,Not Applicable,NA,Interventional,200,Recruiting,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,4,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD,11/29/2016,11/30/2019,2/10/2017,10-Feb-17,NCT02975505,Phase 2,NA,Interventional,200,Recruiting,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
MI-BP: mHealth to Improve Blood Pressure Control in Hypertensive African Americans,11/4/2016,9/30/2019,1/11/2018,11-Jan-18,NCT02955537,Not Applicable,NA,Interventional,304,Recruiting,2,TRUE,Other,Other,Other,other,other,FALSE,NA,FALSE,African American,Race-specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Milrinone in Congenital Diaphragmatic Hernia,11/1/2016,3/31/2019,8/22/2017,22-Aug-17,NCT02951130,Phase 2,NA,Interventional,66,Recruiting,16,TRUE,NIH,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Descriptive Analysis of Near Infrared Spectroscopy in Critically Ill and Injured Pediatric and Neonatal Patients,11/1/2016,4/30/2019,7/29/2014,29-Jul-14,NCT02950181,Not Applicable,NA,Interventional,400,Suspended,1,FALSE,Other,Other,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Evaluation of 3-V Bioscience-2640, a FASN Inhibitor, to Reduce de Novo Lipogenesis in Subjects With Characteristics of the Metabolic Syndrome",10/28/2016,1/31/2018,2/1/2017,1-Feb-17,NCT02948569,Phase 1/Phase 2,NA,Interventional,13,Completed,1,FALSE,Industry,Industry,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease,10/28/2016,11/30/2019,10/31/2016,Oct-16,NCT02947750,Phase 2,NA,Interventional,150,Recruiting,3,TRUE,NIH,Public,"Drug, Other, Dietary Supplement, Other, Other, Dietary Supplement, Other",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Lowering Blood Pressure by Sleep Extension: a Randomized, Controlled Trial",10/11/2016,2/28/2019,10/31/2016,Oct-16,NCT02929810,Not Applicable,NA,Interventional,54,Recruiting,1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Randomized Trial to Evaluate an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care,10/6/2016,8/31/2019,8/14/2017,14-Aug-17,NCT02925962,Not Applicable,NA,Interventional,540,"Active, not recruiting",1,FALSE,Other,Other,"Other, Other",other,other,FALSE,4,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Multi Ethnic Study of Atherosclerosis Individualized Response to Vitamin D Treatment Study,10/5/2016,4/30/2019,1/11/2017,11-Jan-17,NCT02925195,Not Applicable,NA,Interventional,682,Enrolling by invitation,5,TRUE,NIH,Public,"Dietary Supplement, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Management of Uncontrolled Hypertension: Ambulatory Blood Pressure Monitoring and Subsequent Modification of Therapy or Shifting Anti-hypertensive Medication to Night-time Dosing,10/3/2016,1/31/2020,1/31/2017,Jan-17,NCT02922023,Not Applicable,NA,Interventional,25,Recruiting,1,FALSE,Other,Other,"Device, Other",Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy,9/30/2016,10/31/2017,10/31/2016,Oct-16,NCT02920593,Phase 4,Recruiting,Interventional,412,Unknown status,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,17,TRUE,Non-race specific,Non-race specific,2016,0,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Treatment of Post-SCI Hypotension: A Randomized Controlled Study of Usual Care Versus Anti Hypotension Therapy,9/30/2016,2/28/2019,6/1/2017,1-Jun-17,NCT02919917,Phase 2/Phase 3,NA,Interventional,60,Recruiting,2,TRUE,U.S. Fed,Public,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features,9/22/2016,10/31/2017,9/30/2016,Sep-16,NCT02911701,Phase 4,"Active, not recruiting",Interventional,100,Unknown status,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension",9/20/2016,4/30/2019,9/30/2016,Sep-16,NCT02906579,Phase 2,NA,Interventional,11,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Industry Sponsor,Non-Race Specific
NSAID Use in Postpartum Hypertensive Women,9/15/2016,10/31/2018,3/15/2017,15-Mar-17,NCT02902172,Phase 4,NA,Interventional,36,Terminated,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Utilizing Consumer Health Informatics to Support Management of Hypertension by Clinical Pharmacists in Primary Care,9/13/2016,11/30/2019,10/31/2016,Oct-16,NCT02898584,Not Applicable,NA,Interventional,16,"Active, not recruiting",1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Prospective, Randomized, Adaptive, Double-Blind, Sham-Controlled, Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension",9/9/2016,5/31/2019,3/22/2017,22-Mar-17,NCT02895386,Not Applicable,NA,Interventional,30,Terminated,13,TRUE,Industry,Industry,"Device, Other",Device,Device,FALSE,2,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
A Randomized-controlled Trial to Assess the Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy,9/7/2016,5/31/2019,12/1/2016,1-Dec-16,NCT02891174,Phase 4,NA,Interventional,74,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial,8/31/2016,2/28/2019,9/30/2016,Sep-16,NCT02885636,Phase 3,NA,Interventional,30,Completed,1,FALSE,NIH,Public,"Drug, Other",Drug,Pharmaceutical,TRUE,1,TRUE,Non-race specific,Non-race specific,2016,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
L-Arginine For Anti-VEGF Induced Kidney Injury,8/29/2016,5/31/2019,10/23/2018,23-Oct-18,NCT02882373,Phase 2,NA,Interventional,0,Withdrawn,1,FALSE,NIH,Public,"Dietary Supplement, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Adverse Neurogenic Actions of Dietary Salt,8/29/2016,4/30/2019,4/30/2016,Apr-16,NCT02881515,Not Applicable,NA,Interventional,76,Recruiting,1,FALSE,Other,Other,"Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Community Health Workers Using Patient Stories to Support Hypertension,8/22/2016,10/31/2017,4/14/2014,14-Apr-14,NCT02874547,Not Applicable,NA,Interventional,171,Completed,2,TRUE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,5,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Role of Noninvasive Beat-to-Beat ClearSight Blood Pressure Monitoring During Non-cardiac Surgery,8/19/2016,10/31/2018,10/31/2016,Oct-16,NCT02872896,Not Applicable,NA,Interventional,320,Completed,1,FALSE,Other,Other,Procedure,Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Integrating Behavioral Health and Primary Care for Comorbid Behavioral and Medical Problems,8/16/2016,4/30/2019,4/30/2016,Apr-16,NCT02868983,Not Applicable,NA,Interventional,3000,Enrolling by invitation,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Randomized Controlled Trial (RCT) of an Intervention to Combat Postpartum Weight Retention,8/16/2016,5/31/2019,1/31/2014,Jan-14,NCT02867631,Not Applicable,NA,Interventional,175,Completed,1,FALSE,Industry,Industry,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Collaboration to Improve Blood Pressure in the US Black Belt-addressing the Triple Threat,8/15/2016,11/30/2019,5/3/2017,3-May-17,NCT02866669,Not Applicable,NA,Interventional,2000,Recruiting,3,TRUE,Other,Other,"Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,African American,Race-specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluation of Different Frequency Doubling Technology (FDT) Mobile Devices for Visual Field Assessment,8/10/2016,9/30/2019,8/31/2016,Aug-16,NCT02862158,Not Applicable,NA,Interventional,500,Recruiting,1,FALSE,Other,Other,"Device, Device",Device,Device,FALSE,4,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Health Effects of Increasing Muscle Activation While Sitting in Office Workers,8/4/2016,11/30/2018,8/31/2016,Aug-16,NCT02855541,Not Applicable,NA,Interventional,25,Completed,1,FALSE,Other,Other,Device,Device,Device,TRUE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses,8/2/2016,11/30/2019,1/18/2018,18-Jan-18,NCT02852057,Phase 1,NA,Interventional,50,Recruiting,1,FALSE,Other,Other,Drug,Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Pediatric Preventative Health Screenings - Obesity and Family-Centered,7/29/2016,3/31/2019,4/20/2017,20-Apr-17,NCT02850224,Not Applicable,NA,Interventional,703,"Active, not recruiting",1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Overcoming Immunity to Change: A Feasibility Study of a New Method to Promote Medication Adherence Among Older Adults With Hypertension,7/27/2016,2/28/2019,10/31/2016,Oct-16,NCT02846220,Not Applicable,NA,Interventional,36,"Active, not recruiting",1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,1,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
NA,7/22/2016,1/31/2019,7/31/2016,Jul-16,NCT02841280,Phase 2,NA,Interventional,160,Recruiting,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,3,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Northwest Coalition for Primary Care Practice Support,7/21/2016,9/30/2019,5/1/2015,1-May-15,NCT02839382,Not Applicable,NA,Interventional,209,Completed,1,FALSE,Other,Other,"Other, Other, Other",other,other,FALSE,3,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Randomized Trial of Magnesium Sulfate in Obese Preeclamptic Women,7/18/2016,11/30/2019,7/12/2016,12-Jul-16,NCT02835339,Phase 4,NA,Interventional,39,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Pilot Study to Assess Spinal Cord Stimulation To Inhibit Afferent Feedback During Exercise in Hypertension,7/11/2016,7/31/2019,3/22/2017,22-Mar-17,NCT02828436,Not Applicable,NA,Interventional,100,Recruiting,2,TRUE,Other,Other,"Device, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Smart Phone Medication Adherence Saves Kidneys--SMASK,7/11/2016,10/31/2019,5/31/2016,May-16,NCT02827695,Not Applicable,NA,Interventional,160,"Active, not recruiting",1,FALSE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of RMJH-111b in Adult Subjects With Essential Hypertension",7/4/2016,7/31/2016,6/30/2016,Jun-16,NCT02822222,Phase 1/Phase 2,NA,Interventional,22,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Physical Therapist Doctoral Student Stress Levels and Management Through Meditation,7/1/2016,2/28/2019,1/31/2015,Jan-15,NCT02821611,Not Applicable,NA,Interventional,46,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot),6/27/2016,10/31/2018,6/18/2016,18-Jun-16,NCT02814552,Not Applicable,NA,Interventional,47,Completed,3,TRUE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Torsemide for the Prevention of Persistent Postpartum Hypertension in Preeclamptic Women: A Randomized, Placebo-Control Trial",6/27/2016,3/31/2019,8/31/2016,Aug-16,NCT02813551,Phase 2,NA,Interventional,118,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients",6/16/2016,6/30/2019,3/6/2017,6-Mar-17,NCT02802228,Phase 2,NA,Interventional,30,Completed,6,TRUE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Reducing Diagnostic Errors in Primary Care Pediatrics,6/14/2016,12/31/2019,6/1/2015,1-Jun-15,NCT02798354,Not Applicable,NA,Interventional,13853,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,TRUE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Diet Intervention for Hypertension: Adaptation and Dissemination to Native Communities,6/10/2016,10/31/2019,11/17/2017,17-Nov-17,NCT02796313,Not Applicable,NA,Interventional,400,Recruiting,3,TRUE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes,6/10/2016,9/30/2018,3/31/2016,Mar-16,NCT02796170,Phase 4,NA,Interventional,40,Recruiting,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Pharmacodynamic Equivalence Study of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy With the Reference Products AltaceÂ® 10 mg and LipitorÂ® 40 mg,6/7/2016,4/30/2017,3/31/2016,Mar-16,NCT02791958,Phase 2,"Active, not recruiting",Interventional,528,Unknown status,36,TRUE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,1,Drug Intervention,Industry Sponsor,Non-Race Specific
Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus â‰¥ 85 Mmhg,6/2/2016,1/31/2018,1/31/2015,Jan-15,NCT02789150,Early Phase 1,NA,Interventional,18,Completed,1,FALSE,Other,Other,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Hypertension Control Using Bi-directional Texting for Home Blood Pressure Monitoring,5/20/2016,11/30/2017,9/30/2015,Sep-15,NCT02779231,Not Applicable,NA,Interventional,430,Completed,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Physical Activity Program in End-stage Liver Disease: Pilot Study Assessing Changes in Physical Fitness, Sarcopenia, and the Metabolic Profile",5/18/2016,7/31/2019,6/30/2016,Jun-16,NCT02776553,Not Applicable,NA,Interventional,20,"Active, not recruiting",1,FALSE,Other,Other,"Other, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults,5/17/2016,4/30/2018,5/31/2016,May-16,NCT02774668,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Phase 1 Trial Citrulline and Type 2 Diabetes in Pregnancy,5/16/2016,5/31/2019,8/31/2016,Aug-16,NCT02772887,Not Applicable,NA,Interventional,8,Terminated,1,FALSE,Other,Other,"Dietary Supplement, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Families on Track: A Digital Health Behavioral Intervention for Parents Seeking Treatment for Their Child With Obesity,5/10/2016,4/30/2017,6/30/2016,Jun-16,NCT02767440,Not Applicable,NA,Interventional,50,Completed,1,FALSE,Other,Other,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Comparing Different Methods of Patient Education on Preeclampsia: A Randomized Controlled Trial,5/9/2016,8/31/2018,5/31/2016,May-16,NCT02765906,Not Applicable,NA,Interventional,150,Completed,2,TRUE,Other,Other,"Other, Other",other,other,FALSE,11,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
MATCH2: The Multi-clinic Action Trial to Control Hyperglycemia and Hypertension,5/3/2016,5/31/2016,3/31/2015,Mar-15,NCT02759484,Not Applicable,Recruiting,Interventional,240,Unknown status,3,TRUE,Other,Other,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives,5/2/2016,1/31/2020,4/30/2016,Apr-16,NCT02757872,Phase 3,NA,Interventional,2612,"Active, not recruiting",1,FALSE,NIH,Public,"Dietary Supplement, Drug, Dietary Supplement, Dietary Supplement",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects",4/21/2016,8/31/2016,11/30/2015,Nov-15,NCT02746237,Phase 1,NA,Interventional,120,Completed,1,FALSE,Industry,Industry,"Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Industry Sponsor,Non-Race Specific
A Pilot Study of N-of-1 Trials of Blood Pressure Medications in Adults With Hypertension,4/20/2016,3/31/2019,8/1/2014,1-Aug-14,NCT02744456,Early Phase 1,NA,Interventional,10,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZAÂ®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAVÂ®),4/7/2016,5/31/2019,6/24/2016,24-Jun-16,NCT02730871,Phase 4,NA,Interventional,173,Terminated,1,FALSE,Industry,Industry,"Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Industry Sponsor,Non-Race Specific
Medication Adherence Improvement Support App For Engagement - Blood Pressure,4/4/2016,1/31/2017,4/30/2016,Apr-16,NCT02727543,Not Applicable,NA,Interventional,413,Completed,1,FALSE,Industry,Industry,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
Effect of Supplementation With Pumpkin Seed Oil Versus Pumpkin Seeds on Blood Pressure and Menopausal Symptoms in Non-hypertensive Postmenopausal Women,4/4/2016,5/31/2018,8/1/2015,1-Aug-15,NCT02727036,Not Applicable,NA,Interventional,27,Completed,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,2,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Decision Support for Intraoperative Low Blood Pressure,4/4/2016,4/30/2019,1/5/2017,5-Jan-17,NCT02726620,Not Applicable,NA,Interventional,22435,Completed,1,FALSE,Other,Other,"Procedure, Procedure, Procedure, Procedure, Device, Device, Procedure, Device, Procedure, Procedure, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug",Procedure,Procedure,TRUE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Respiratory Strength Training Mitigates Hypertension and Sleep Fragmentation in Obstructive Sleep Apnea,3/16/2016,11/30/2017,3/31/2016,Mar-16,NCT02709941,Not Applicable,NA,Interventional,25,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,3,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Mindfulness-Based Blood Pressure Reduction (MB-BP) Intervention Development: Effects on Self-Regulation Targets, Including Self Awareness, Emotion Regulation and Attention Control",3/8/2016,7/31/2017,2/29/2016,Feb-16,NCT02702258,Not Applicable,"Active, not recruiting",Interventional,48,Unknown status,1,FALSE,NIH,Public,Behavioral,Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"Taxi METERS: Measuring Effectiveness of Technology, Education, Referrals and Support",3/8/2016,9/30/2019,2/29/2016,Feb-16,NCT02701829,Not Applicable,NA,Interventional,244,Enrolling by invitation,1,FALSE,Other,Other,"Other, Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"The Effect of Potatoes on Potassium Retention, Acid Base Balance, and Blood Pressure",3/3/2016,5/31/2018,4/27/2016,27-Apr-16,NCT02697708,Phase 1/Phase 2,NA,Interventional,40,"Active, not recruiting",1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement, Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Vet COACH (Veteran Peer Coaches Optimizing and Advancing Cardiac Health),3/3/2016,12/31/2019,5/30/2017,30-May-17,NCT02697422,Not Applicable,NA,Interventional,400,Recruiting,1,FALSE,U.S. Fed,Public,Other,other,other,FALSE,1,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Prospective Evaluation of Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients Undergoing Invasive ICP Monitoring,3/1/2016,12/31/2016,8/31/2016,Aug-16,NCT02695264,Not Applicable,NA,Interventional,0,Withdrawn,1,FALSE,Industry,Industry,Device,Device,Device,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
An Internet-Assisted Mind-Body-Behavior Program for Blood Pressure Control,2/29/2016,7/31/2018,9/30/2016,Sep-16,NCT02694432,Not Applicable,NA,Interventional,76,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,7,TRUE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period,2/12/2016,1/31/2018,1/31/2013,Jan-13,NCT02681419,Phase 4,NA,Interventional,18,Terminated,1,FALSE,Other,Other,"Procedure, Procedure",Procedure,Procedure,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure,2/11/2016,2/28/2019,2/29/2016,Feb-16,NCT02680704,Not Applicable,NA,Interventional,4,Terminated,1,FALSE,Other,Other,Other,other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
The Effect of the Combination of Whole Body Vibration and External Load Exercise Training on Cardiovascular and Autonomic Function in Obese Individuals,2/11/2016,2/29/2016,9/30/2013,Sep-13,NCT02679898,Not Applicable,NA,Interventional,60,Completed,1,FALSE,Other,Other,"Other, Other",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Comparative Effectiveness of Health System vs. Multilevel Interventions to Reduce Hypertension Disparities,2/4/2016,7/31/2019,9/1/2017,1-Sep-17,NCT02674464,Not Applicable,NA,Interventional,1890,Enrolling by invitation,1,FALSE,NIH,Public,"Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
"A Randomized, ED-based Intervention to Improve Antihypertensive Adherence",2/3/2016,8/31/2018,2/29/2016,Feb-16,NCT02672787,Not Applicable,NA,Interventional,220,Completed,1,FALSE,NIH,Public,"Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate,1/27/2016,4/30/2019,1/31/2015,Jan-15,NCT02665117,Not Applicable,NA,Interventional,60,Recruiting,3,TRUE,Other,Other,"Drug, Drug, Drug",Drug,Pharmaceutical,FALSE,9,TRUE,Non-race specific,Non-race specific,2016,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Proprietary Lipid-Lowering Nutraceutical Supplement in the Management of Hypertension,1/26/2016,1/31/2016,9/30/2015,Sep-15,NCT02663479,Phase 1/Phase 2,Recruiting,Interventional,40,Unknown status,1,FALSE,Industry,Industry,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,1,Non-Drug Intervention,Industry Sponsor,Non-Race Specific
A Nutritional Intervention in Police Officers,1/11/2016,9/30/2019,2/29/2016,Feb-16,NCT02651480,Not Applicable,NA,Interventional,20,Suspended,1,FALSE,Other,Other,"Dietary Supplement, Dietary Supplement",other,other,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension,1/12/2016,6/30/2016,9/30/2012,Sep-12,NCT02653560,Phase 4,NA,Interventional,30,Completed,1,FALSE,Other,Other,"Drug, Drug, Drug, Drug",Drug,Pharmaceutical,TRUE,7,TRUE,Non-race specific,Non-race specific,2016,1,Drug Intervention,Non-Industry Sponsor,Non-Race Specific
Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease,1/5/2016,5/31/2019,8/31/2015,Aug-15,NCT02646488,Not Applicable,NA,Interventional,276,Completed,1,FALSE,U.S. Fed,Public,"Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral, Behavioral",Behavioral,Behavioral,FALSE,NA,FALSE,Non-race specific,Non-race specific,2016,2,Non-Drug Intervention,Non-Industry Sponsor,Non-Race Specific
